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Abstract 
 
Cytochrome P450 reductase (CPR) is a diflavin protein which donates electrons to a 
variety of microsomal cytochrome P450s, heme oxygenase, cytochrome b5, cytochrome c as 
well as therapeutic prodrugs. It plays an indispensable role in the cytochrome P450 
monooxygenase system, which is responsible for the metabolism of myriads of endogenous 
compounds including vitamins, steroids and hormones, as well as exogenous compounds 
including environmental toxins and drugs. In order to understand the electron transfer 
mechanism between CPR and its redox partners and get an better insight into its physiological 
function, it is essential to obtain detailed structural information on the electron transfer 
complexes. The nature of weak interactions between electron transfer proteins poses great 
difficulty to crystallization, while NMR spectroscopy has developed into a powerful tool in 
acquiring high-resolution structural information on the protein complexes. This thesis aims to 
unveil the structures of electron transfer complexes formed between the FMN binding domain 
(FBD) of CPR and its redox partners – cytochrome P450 and cytochrome c, map the binding 
interfaces of the complexes and propose potential electron transfer pathways. A combination of 
solution and solid-state NMR techniques, in conjunction with kinetics studies and molecular 
docking, were utilized for the investigation. Kinetics of electron transfer from FBD to 
cytochrome P450/cytochrome c was characterized and compared with wild-type CPR. The 
results support that conformational gating of CPR plays a key role in the kinetics of interprotein 
electron transfer. Solution NMR experiments were carried out to map the binding interfaces in 
the complexes, from which structural models of the complexes were generated.  
xvii 
 
In addition, high-resolution structures of human calcitonin have been investigated using 
NMR spectroscopy. Calcitonin is a 32-residue peptide hormone known for its hypocalcemic 
effect and its inhibition of bone resorption. While calcitonin has been used in therapy for 
osteoporosis and Paget's disease for decades, human calcitonin (hCT) forms fibrils in aqueous 
solution that limit its therapeutic application. The molecular mechanism of fiber formation by 
calcitonin is not well understood.  In this thesis, by solving the high-resolution structures of hCT 
under two different conditions, we discovered that the peptide undergoes a conformational 
transition in the process of molecular association. The effect of the polyphenol epigallocatechin 
3-gallate (EGCG) on hCT fibrillation was also investigated by NMR and electron microscopy, 
which show that EGCG efficiently inhibits fibril formation of hCT by preventing the initial 
association of hCT before fiber formation. 
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CHAPTER 1 
 Introduction 
 
1.1 NADPH-Cytochrome P450 Reductase 
1.1.1 Background and significance 
NADPH-cytochrome P450 reductase (CPR) is a 78 kDa diflavin microsomal enzyme that 
plays a key role in the “cytochrome P450 monoxygenase system” – an enzyme 
system responsible for the catalysis of a wide variety of oxidative transformations that are 
essential for the livings, including the metabolism of ~75% known pharmaceuticals in humans 
(1). CPR was first isolated from yeast as “FMN-containing cytochrome c reductase” (2); later 
mammal CPR was purified from pig liver (3). CPR was shown to be localized to the cytoplasmic 
surface of the endoplasmic reticulum (4, 5) and responsible for transferring electrons from 
NADPH to cytochrome P450s (cyt P450s), which is an essential step in the catalytic cycle of cyt 
P450s. Microsomal CPR is a multi-domain protein composed of an N-terminal transmembrane 
domain, an FMN binding domain, an FAD/NADPH binding domain and a connecting domain 
which covalently connects the aforementioned two domains (Figure 1.1) (6).  
CPR is a prototype of diflavin reductases – a small family of enzymes which also include 
nitric oxide synthases (7, 8), methionine synthase reductase (9), bacterial cytochrome P450 BM3 
(10), and the reductase subunit of bacterial sulfite reductase (11). It is believed that CPR is the 
result of gene fusion between ancestral FMN- and FAD-containing flavin proteins due to 
evolution (12) for the following reasons: 1. The FMN and FAD/NADPH binding domains of 
CPR have shown structural similarity with bacteria flavodoxin and ferredoxin reductase; 2. The 
genes of the FMN and FAD/NADPH binding domains can be dissected and expressed 
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independently as discrete functional units, and exhibit biological activity as a functional complex 
after reconstitution (13).  
CPR has been discovered in various eukaryotes including yeast, chicken, rat, cow, rabbit 
and human.  High sequence homology was found in CPR from different species, suggesting the 
importance of this enzyme throughout revolution. It has been shown that deficiency and mutation 
of the CPR gene can lead to varies abnormalities and health problems. Knock-out of the gene in 
mice leads to embryonic lethality (14, 15), implying that CPR plays an essential role in the 
normal development of high-level organisms. A post-natal deletion of CPR was carried out in the 
liver of the mice. The hepatic CPR-null mice exhibit a series of metabolic disorders associated 
with the malfunction of the cytochrome P450 (cyt P450) monoxygenase system caused by CPR 
deletion (16). In addition to the major role in the cytochrome P450 enzyme system, CPR is also 
known to reduce cytochrome c (4), cytochrome b5 (17) and heme oxygenase (18). It is also 
shown to be involved in bioactivation of therapeutic prodrugs such as doxorubicin (19) and 
mitomycin c (20).   
1.1.2  Structural characteristics of CPR  
The first high-resolution X-ray crystal structure of CPR soluble domain was solved by 
Wang et al. on rat CPR with the N-terminal transmembrane domain removed (6). It shows that 
the soluble domain of CPR is composed of three domain: an FMN binding domain, the overall 
fold of which highly resembles bacterial flavodoxin, an FAD/NADPH binding domain 
homologous to ferredoxin reductase, and a connecting domain between the aforementioned two 
domains, the functional of which has not yet been fully elucidated.  
The FMN binding domain consists of a typical wound α-β-α fold – five strands of parallel 
β-sheets flanked by five α-helices. The FMN cofactor is located at the C-terminal end of the β-
sheets with its isoalloxazine ring flanked between Tyr-140 and Tyr-178 and forms hydrogen-
bonds with a number of residues at the loop regions (6, 21, 22). The FMN cofactor binds tightly 
to the domain with a dissociation constant of 2.0 × 108 M-1 (22). Removal of Tyr-140 or/and 
Typ-178 has been shown to cause a drastic decrease in the binding affinity between the FMN 
cofactor and the protein (23). This domain has 19 positively and 34 negatively surface charged 
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residues under neutral pH condition, and exhibits a large electrical dipole of 677 Debye pointing 
towards the FMN binding site (22) (Figure 1.2). The significant separation of charges is expected 
to play an important role in orienting the domain in a proper way to interact with its redox 
partners and aid in electron transfer process.  
 
 
Figure 1.1   Domains of microsomal CPR. The structure of the soluble domain is an X-ray crystal 
structure of a rat CPR mutant ΔTGEE (PDB code 3ES9) (24). The transmembrane domain is proposed to 
adopt an α-helical conformation. 
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Figure 1.2   Electrostatic potential surface of the FMN binding domain of rat CPR (PDB code 1AMO) 
calculated using PyMOL (Version 1.1, Schrödinger, LLC) with APBS plugin (25). Panel (a) shows the side of 
FBD where the cofactor FMN is solvent exposed. FMN is indicated in yellow sticks. Panel (b) to (d) are 
the successive 90° clockwise rotations from panel (a) along the axis parallel to the paper plane.  
 
The FAD/NADPH binding domain can be sequentially divided into two parts—the N-
terminal portion composed primarily of antiparallel β-sheets and the C-terminal part which is, 
like FBD, composed of an α-β-α fold. In rat CPR, the isoalloxazine ring of the FAD cofactor 
binds to the intersection of the aforementioned two parts and is stacked between Trp-677 
(parallel to the plane of isoalloxazine ring) and Tyr-456 (~70° tilted with respect to the 
isoalloxazine ring) (Figure 1.3). Deletion/Mutation of these two residues leads to significant 
reduction in the binding affinity of FAD. The FAD cofactor also forms hydrogen bonds with the 
surrounding residues, such as Arg-454, Gly-488, Ala-490, Thr-491, some of which are crucial in 
stabilizing the FAD cofactor by binding to its pyrophosphate group (e.g. Arg-454) (26). The 
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conformation and location of NADP(H) is less defined than the other two cofactors due to the 
spatial disorder of the nicotinamide ring in the crystal structure (6), similar phenomenon of 
which was also observed in the crystal structures of enzymes in the ferredoxin-NADP(+) 
reductase. The lack of electron density of the nicotinamide ring suggests a certain extent of 
mobility in this region of the cofactor. As observed in the crystal structure (6), neither of the 
suggested positions of the nicotinamide ring is spatially close enough to FAD for hydride 
transfer, and the isoalloxazine ring of FAD is “protected” by the aromatic side chain of Trp-677 
from contacting NADP(H) (Figure 1.3). Therefore, it has been proposed that hydride transfer 
from NADPH to FAD would involve Trp-677 flipping away from FAD to make space for 
contacting with NADPH. Mutation of the corresponding Trp in human CPR (Trp-676) leads to a 
slow release of NADP(+) from the active site, implying that Trp-676 serves as a trigger for 
NADP(+) dissociation following hydride transfer (27). The adenosine-ribose and the 
pyrophosphate moieties of NADPH are well defined in the crystal structure, forming hydrogen 
bonds with residue Arg-298, Ile-535, Arg-567, Ser-596, Arg-597, Lys-602, Tyr-604, Gln-606 
and Asp-639. Mutations of residues Arg-597 and Lys-602 in combination with Trp-677 lead to 
reduced inhibition effect by NADP+ on catalysis, which suggests lower binding affinity for 
NADP(H) (28).  
 
The connecting domain sequentially serves as a “bridge” between the FMN binding 
domain and the FAD/NADPH binding domain, and spatially forms direct contact with the two 
Figure 1.3   Arrangement of the FMN and 
FAD cofactors in CPR (PDB code 1AMO).  
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catalytic domains. The interface between the connecting domain and the FMN binding domain is 
mainly hydrophilic, while the interface between the connecting domain and the FAD/NADPH 
binding domain are relatively more hydrophobic. The function of this domain has not been fully 
investigated, although it is suggested that it may be partly responsible for aligning and orienting 
the two catalytic domains to achieve optimal interdomain electron transfer (24, 29, 30). One of 
the interesting discoveries is the important role that a “hinge” (residue 232-242 in rat CPR) plays 
in controlling the domain movement and the efficiency of interflavin electron transfer (24): 
deletion of four residues from the “hinge” resulted in an extended conformation of CPR, which 
impairs electron transfer from FAD to FMN but exposes the FMN cofactor to the solvent 
allowing it to interact with cyt P450. The crystal structure of a chimeric yeast-human CPR 
revealed a fully open conformation in which the interface between the FMN binding domain and 
the connecting domain is completely disrupted and the FMN binding domain is fully solvent 
exposed (29, 30). 
It has been postulated that the transmembrane domain of CPR adopts an α-helical 
conformation (31-34). However, high resolution structure of the transmembrane domain has not 
been revealed experimentally. The major difficulty lies in the hydrophobicity and dynamics of 
the transmembrane domain, preventing it from crystallization with the soluble domain. The 
transmembrane domain of CPR plays a vital role in aiding in electron transfer between CPR and 
cyt P450 (31, 35, 36). Lacking the transmembrane anchor, CPR is still able to reduce cytochrome 
c and other artificial acceptors, but has impaired electron transfer to cyt P450 (6). 
1.1.3  Mechanism of internal electron transfer in CPR 
As an essential component of the “cytochrome P450 monoxygenase system”, CPR plays 
the role of transferring electrons from NADPH to cyt P450 following the pathway NADPH  
FAD  FMN  cyt P450. NADPH is as an obligate two-electron donor while cyt P450 is an 
obligate one-electron acceptor. During the catalytic cycle of cyt P450, the two electrons from 
NADPH need to be shuttled by CPR sequentially to cyt P450 at different steps of the cycle, 
which is a remarkable feature of CPR. This characteristic of CPR is attributed to the fact that one 
electron-reduced semiquinone form of flavin cofactors (FADH• or FMNH•) can be stabilized in 
the protein structure thermodynamically, which serves as a bridge in the electron flow (37-39). 
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It is proposed that the enzyme undergoes the cycle between one electron and three electron-
reduced forms under physiological conditions (Figure 1.4) due to the midpoint redox potentials 
for each flavin couple (Figure 1.5) (40-42). The blue semiquinone form of FMN (FMNH•) is 
both thermodynamically and kinetically stabilized. However, it is incapable of transferring 
electrons to cyt P450 due to its relative high redox potential comparing to that of cyt P450 
(Figure 1.5), while the hydroquinone form of FMN (FMNH2) is more likely to be the electron 
donor of cyt P450 as shown in the cycle (Figure 1.4).  
 
 
 
Figure 1.4   Electron transfer cycle of CPR. It undergoes the cycle between one and three electron-
reduced forms as indicated by the black lines. Two electron- or three electron-reduced CPR is able to 
donate electrons to cyt P450, indicated in red.  
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Figure 1.5   The reduction potentials of flavins in CPR. The reduction potentials of the individual redox 
couples of the FAD and FMN cofactors of rabbit CPR and of cyt P450 (43). Reprinted with permission 
from Iyanagi. Copyright 2005 Elsevier Inc.  
 
Kinetics of internal electron transfer from NADPH via FAD to FMN has been 
investigated using a variety of methods. It has been shown that hydride transfer from NADPH to 
isolated FAD domain is reversible – electron transfer from FADH2 to NADP+ occurs more 
rapidly (8 s-1) than that from NADPH to FAD (3 s-1) (44), which agrees with the redox potentials 
of the NADPH/NADP+ and FAD/FADH2 groups (Figure 1.5). Interflavin electron transfer 
between FAD and FMN is relatively faster, judging from the kinetic studies which showed that 
the accumulation of blue disemiquinone species of CPR (FMNH•/FADH•) takes place at the 
same rate as hydride transfer from NADPH to FAD (44). The rate of interflavin electron transfer 
has been measured by laser flash photolysis for rabbit CPR (45) and temperature-jump relaxation 
kinetic methods for human CPR (46, 47), which appears to be 15 s-1 and 55 s-1 respectively. On 
the other hand, according to the crystal structure of CPR (6), the closest distance between the two 
flavins is 4 Ǻ which would predict an intrinsic electron transfer rate of 1010 s-1 (6, 48). This 
conflict implies that the interflavin electron transfer is gated. Possible gating mechanism includes 
deprotonation of FAD blue semiquinone, interdomain movement between the FMN and 
FAD/NADPH binding domains. The possibility of deprotonation gating was disproved by the 
observation that solvent isotope effect does not affect the reaction rate (47). It was also shown 
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that viscous solvent (75% w/v glycerol) compromises the rate of interflavin electron transfer, 
which implies domain movement could be responsible for gating the reaction (47).  
1.1.4  Domain movement of CPR  
CPR is a multi-domain enzyme, the catalytic function of which requires orchestrated 
intraprotein and interprotein electron transfer. Exquisite control of the association and 
dissociation between the domains or proteins is essential for rapid turnover of the enzyme (49). 
In the “close” conformation of CPR observed in the crystal structure (Figure 1.6A) (6), FMN is 
not solvent exposed and thus cannot transfer electrons to cyt P450. Furthermore, the crucial 
residues suggested by mutagenesis studies for binding cyt P450 were not fully exposed to make 
contact with cyt P450 (50). Therefore, it is proposed that movement of the FMN binding domain 
relative to the rest of the CPR molecule is required during interprotein electron transfer. Similar 
dynamic characteristics of the FMN binding domain were also proposed in other flavin proteins 
(49, 51). For example, in the crystal structure of the reductase subunit of E. Coli sulfite 
reductase, the electron density of the FMN binding module is absent suggesting great flexibility 
of this domain (52).  
Recent observations of domain movement in CPR have been the major breakthroughs in 
understanding the conformational change of the enzyme. A crystal structure of a yeast-human 
chimeric CPR (Figure 1.6B) revealed an open conformation in which there is a large separation 
between the FMN and the FAD/NADPH binding domains compared to the close form of the 
wild-type enzyme (Figure 1.6A) (29). Deletion of four amino acids from a “hinge” that connects 
the FMN binding domain with the rest of the molecule also led to extended formations in the 
crystal structure (Figure 1.6C) (24). The mutation turned out to impair interflavin electron 
transfer, but did not seem to affect electron transfer from FBD to cyt P450. These results suggest 
that the extended conformations observed in the crystal structure may resemble the conformation 
of CPR during interprotein electron transfer. Necessity of domain movement was also 
demonstrated by a mutant with an engineered disulfite bond covalently linking the FAD/NADPH 
and FMN binding domain, which strictly constrained interdomain movement. The mutant 
exhibited drastically decreased rates in both interflavin and interprotein electron transfer, unless 
the disulfite bond was reduced (53).    
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Figure 1.6   Structures of CPR. Different conformations of CPR were observed in crystal structures: (a) a 
closed conformation of wild-type CPR (PDB code 1AMO) (6), (b) an open conformation of yeast-human 
chimeric CPR (PDB code 3FJO) (29), (c) an extended conformation of a CPR mutant with four residues 
deleted from the “hinge” (PBD code 3ES9) (24). Reprinted with permission from Vincent el al. Copyright 
2012 Elsevier Ltd.  
 
Open conformations of CPR have also been identified by other means of investigation. A 
combined NMR and SAXS study concluded that the oxidized CPR exists in equilibrium between 
approximately equal amount of two conformations – a closed conformation and a more extended 
one suitable for interprotein electron transfer. The equilibrium can be shifted by reduction of the 
flavins and coenzyme binding (54). In contrast, a recent NMR study revealed that CPR exists in 
a predominant “close” conformation in the oxidized state by measuring the 15N relaxation 
and 1H-15N residual dipolar couplings (RDC) of the CPR residues (55). The cause of the 
controversy is still to be determined. An electron-electron double resonance (ELDOR) 
spectroscopy study identified several conformations in two electron-reduced CPR and 
demonstrated the significant effect of nucleotide binding, solvent condition and pressure on the 
interflavin distance in the disemiquinone form of the enzyme (56). According to this study, 
nucleotide binding induces more closed conformation which favors interflavin electron transfer, 
while open conformation makes it easier for electron transfer to occur from CPR to its redox 
partners. In addition, evidence was provided showing that reduction of the flavin cofactors in 
CPR induces opening of the enzyme whereas coenzymn binding induces closed structure using 
FRET accompanied by stopped-flow kinetics measurement (57). 
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1.2 Cytochrome P450 
1.2.1 Background and significance 
Cytochrome P450 (cyt P450) is a super family of enzymes that are found in all kingdoms 
of living including bacteria, fungi, insects, plants and animals. In human beings, 57 membrane-
bound cyt P450s are found to distribute in most of the tissues (1, 58, 59). A great proportion of 
the enzymes are found in the liver where they are located in the smooth endoplasmic reticulum 
(ER) membrane of hepatocytes (60). Cyt P450 metabolizes a large number and a wide variety of 
endogenous (e.g. steroids, fatty acids, lipids, etc.) (61) and exogenous substrates (e.g. 
environmental toxins, drugs, etc.). In particular, cyt P450 is responsible for the phase I 
metabolism of approximately 75% of the pharmaceuticals in use today (1). By catalyzing the 
hydroxylation reaction, cyt P450 is able to convert the hydrophobic drugs into more hydrophilic 
products so that they can be eliminated from the body via urine, which reduces the toxicity of the 
drugs. On the other hand, cyt P450 may also activate certain inert compounds or drugs to toxic 
products (1). Therefore, the bioavailability and side effects of drugs are highly dependent on cyt 
P450 metabolism. Understanding the structure and mechanism of various cyt P450s has a 
profound meaning in predicting the metabolism and toxicity of drugs and other chemicals and 
providing basic information for drug designing.   
In addition to its important role in drug metabolism, cyt P450 is involved in many 
pathways of endogenous metabolism, including steroid hormone biosynthesis, prostaglandin and 
fatty acid metabolism, lipid oxidation and vitamin D3 hydrolysis (61). Taken steroid-oxidizing 
P450s as an example, most of these cyt P450 isoforms are critical for human being and the level 
of these enzymes are relatively invariable among individuals, unlike the xenobiotic-metabolizing 
P450s which may vary considerably (62). Deficiency in these cyt P450s usually leads to serious 
diseases, including sex hormone deficiencies and increased risk of prostate cancer (63).  
The most common reaction that cyt P450 catalyzes is the insertion of an atom of 
“activated” oxygen into the C-H bond of a substrate as described in Reaction 1, in which RH is 
the hydrophobic substrate and ROH is the product. Hydroxylation of an inactivated C-H bond is 
a challenge task to achieve synthetically due to the high activation energy. The mechanism of 
this reaction catalyzed by cyt P450 has intrigued chemists for decades both for the desire of 
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understanding the biological oxygen activation and for the development of new and economic 
catalysts. The general accepted catalytic cycle of cyt P450 is shown in Figure 1.7, in which two 
electrons were donated to cyt P450 at different steps by its redox partners – CPR and/or cyt b5. 
While CPR can donate both the first and second electrons, cyt b5 is only involved in delivering 
of the second electron due to its relative high redox potential (≅ 25 mV). Notably, the cycle 
describes a simplified version of the reaction, and in reality the steps do not always follow the 
linear order along the cycle. Dissociation of the substrate can occur in other steps in the cycle as 
well (64, 65). 
RH + O2 + NADPH + H+  ROH + H2O + NADP+     (1) 
 
 
Figure 1.7   Catalytic cycle of cytochrome P450. Two electrons were delivered to cyt P450 sequentially 
by CPR and/or cytochrome b5 indicated in green. 
1.2.2 Structure of cytochrome P450  
Up till now, hundreds of structures on 20 unique cyt P450s have been deposited in the 
Protein Data Bank. These structures revealed that the overall folding of cyt P450s is quite 
conservative across the P450 family and unique among all other proteins. A distinct difference 
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between prokaryotic and eukaryotic cyt P450s lies in their affinities to membrane. Unlike 
prokaryotic cyt P450s, eukaryotic cyt P450s are usually membrane-bound, among which the 
majority are incorporated in the endoplasmic reticulum and a few in mitochondria.  
 
 
Figure 1.8   Structure of cyt P450 2B4. Cyt P450 2B4 consists of a catalytic domain (PDB code 1SUO) and 
a transmembrane domain. The major helices are alphabetically labeled in red.  
 
Figure 1.8 is a structure of cyt p450 2B4 (PDB code 1SUO) – a microsomal cyt P450 
from rabbit hepatocyte (66). It consists of a ~53 kDa catalytic domain and a transmembrane 
anchor. The structure of the catalytic domain has been solved in the presence of different 
substrates/inhibitors (66-74), while the transmembrane domain is proposed to adopt an α-helical 
conformation (75-77). In the catalytic domain of cyt P450 2B4, the heme was axially coordinated 
to Cys-436. The side on which the heme comes closest to the protein surface is called the 
proximal side. It is rich in positive charges (Figure 1.9) and is predicted to bind to the redox 
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partners of cyt P450 – CPR or cyt b5 – driven by electrostatic interaction. Substrates enter the 
catalytic pocket of cyt P450 and lie on the other side of the heme. Although the overall folding of 
cyt P450 is conserved between different isoforms, relative positions of the secondary structural 
elements in the catalytic domain can differ substantially. The most conserved regions are 
generally close to the heme, e.g. helices I and L which form direct contact with the heme, while 
in regions that control substrate specificity, e.g. tbe B' helix, the structures differ most between 
isoforms (62). Even for the same cyt P450, due to the conformational plasticity of the structure, 
the structural features surrounding the active site are prone to large displacement to 
accommodate different substrates (78). In the case of cyt P450 2B4, there are four regions that 
could undergo considerable structural displacement in response to ligands – a loop preceding 
helix A and the N-terminal half of helix A (residue 39-57), helix B' through the C/D loop 
(residue 101-140), the C-terminal half of the helix E (residue 177-188), the C-terminal half of 
helix F through the N-terminal half of helix I (residue 203-298 (73).  
Besides the N-terminus of the protein as a transmembrane anchor, eukaryotic cyt P450s 
have been shown to interact with membrane through additional binding sites. A number of 
microsomal cyt P450s, including cyt P450 1A1, 2B4, 2E1 and c17, were found to be membrane-
bound even with the N-terminal transmembrane anchor (the first ~ 30 residues) removed (79-84). 
Antibody binding studies also revealed that the N-terminal transmembrane domain and the F-G 
and B-C loops of the family 2 P450s are inaccessible to antibodies due to either direct binding or 
in close proximity to the membrane (85). The insertion area of cyt P450 2B4 to the Langmuir-
Blodgett monolayers was determined to be ~ 680 ± 95 Å2 (86), which is greater than what is 
expected for a single transmembrane helix (170-250 Å2). These evidences lead to a proposition 
that a hydrophobic tip of cyt P450 catalytic domain is immersed in the membrane, which could 
facilitate substrate access channel or orient the enzyme for productive interaction with its redox 
partners and aid in electron transfer.   
1.3 Interaction and electron transfer between CPR and cyt P450  
Cyt P450 receives two electrons sequentially from its redox partners at different stages of 
its catalytic cycle (Figure 1.7), the first of which is delivered by CPR and the second can be 
donated either by CPR or cyt b5. Optimal interaction between CPR and cyt P450 is essential for 
efficient electron transfer from the reduced FMN cofactor to the heme of cyt P450. It has long 
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been postulated that the association between CPR and cyt P450 is driven by electrostatic 
interactions between a cluster/clusters of positively charged residues on the proximal surface of 
cyt P450 and negatively charged residues located on the FMN binding domain of CPR (Figure 
1.9). For instance, chemical modification has been used to study the role of lysine and arginine 
residues of cyt P450 in the interaction between the two proteins. Acetylation of lysine residues in 
cyt P450 2B1 and 17α led to significantly reduced activity of the reconstituted cyt P450/CPR 
complex, implying the importance of the positively charged lysine residues in the electrostatic 
coupling with CPR (87, 88). Site-directed mutagenesis studies have indicated specific lysine and 
arginine residues on rat cyt P450 1A1 and 1A2 which may be involved in charge interaction with 
CPR (89, 90). A series of residues on the proximal side of cyt P450 2B4 were identified to be 
crucial for complex formation, the majority of which are positively charged residues including 
Arg-122, Arg-126, Arg-133, Lys-139, Arg-422, Arg-433, Arg-443 (91). Mutation of these 
residues into alanine dramatically decreased the interaction with CPR. On the other hand, 
chemical modification of negatively charged carboxyl groups on CPR was also shown to 
significantly impair the binding between cyt P450 and CPR (92). Mutations on clusters of acidic 
residues on the FMN binding domain of CPR revealed that Asp-208 is essential in interaction 
and electron transfer between the two proteins (21, 50). Asp-113 and Glu-115/Glu-116 also plays 
a critical role in mediating charge-charge interaction (93). Other than electrostatic interaction, it 
has been suggested that that certain hydrophobic residues on the binding interface, e.g. Val-267 
and Leu-270 of cyt P450 2B4, also contributes in stablizing complex formation (13). Interaction 
between these two proteins was also investigated by chemical cross-linking in conjunction with 
mass spectroscopy, the results of which showed the C-helix of cyt P450 2B6 forms contacts with 
residues in the linker region between the FMN and NADPN/FAD binding domains (94). 
Antipeptide binding studies suggested that helices C and L contribute to CPR-binding in multiple 
cyt P450s (95). The results of these studies are summarized in Table 1.1.  
In summary, it is generally accepted that the interaction between cyt p450 and CPR occurs 
between the positively charged proximal surface of cyt P450 and the negatively charged FMN 
binding domain of CPR. However, our knowledge regarding the specific residues involved in the 
interaction merely stems from a limited number of mutagenesis studies. Most of these studies 
measure the changes in the substrate turnover by the reconstituted cyt P450-CPR complex as a 
standard to evaluable whether the mutated residue is involved in complex formation or not. The 
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judgment is based upon the assumption that the mutation does not alter electron transfer pathway 
or the integrity of environment around the redox centers, the effects of which are usually hard to 
distinguish from that of complex formation. A high-resolution structure of the cyt P450-CPR 
complex is lacking due to the difficulty in co-crystallizing the two proteins as a complex, which 
could be attributed to either the transient nature of the complex or a lack of conformational 
rearrangement in CPR required for interacting with cyt P450 under crystallography conditions.  
 
 
Figure 1.9   Electrostatic potential surface of FBD (PDB code 1AMO) and cyt P450 (PDB code 1SUO) 
calculated using PyMOL (Version 1.1, Schrödinger, LLC) with APBS plugin (25). The left panel shows the 
solvent exposed edge of the FMN cofactor indicated by yellow sticks. The right panel is the proximal side 
of cyt P450.  
Cyt P450 is present in the endoplasmic reticulum at an approximately 20-fold molar 
excess over CPR (96, 97). Efficient electron transfer between CPR and different isoforms of cyt 
P450 as well as other redox proteins, e.g. cytochrome b5 (17), heme oxygenase (18), necessitates 
rapid association and dissociation between cyt P450 and CPR. Transient complex is formed upon 
collision while the two proteins diffuse laterally across the membrane surface. What is the role of 
membrane and how the interaction between membrane and the proteins affects complex 
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formation is not yet well understood. It is known that in the absence of the transmembrane 
anchor, CPR is incapable of transferring electrons to cyt P450 (6). And composition of 
phospholipids in the membrane could potentially affect the interaction between CPR and cyt 
P450 (98, 99). The topography of the two proteins was characterized in nanodiscs by AFM, 
revealing that the height of cyt P450 above the membrane surface is approximately 3.5 nm which 
is consistent with an insertion of a hydrophobic tip. A model of the spatial arrangement of the 
complex on the membrane was proposed with both the FMN and NADPH/FAD binding domains 
of CPR lying close to the membrane surface for productive communication with cyt P450 (100). 
A complete understanding of the complex formation in membrane environment requires a 
thorough structural and dynamic characterization of the complex in a lipid membrane 
environment.  
1.4 Interaction and electron transfer between CPR and cytochrome c 
CPR was first isolated and identified as an NADPH-dependent cytochrome c (cyt c)  
reductase in the 1950 (3). In the later studies the true physiological redox partner of CPR was 
revealed to be cyt P450 after successful achievement of hydroxylase activity from a 
reconstitution system composed of cytochrome P450, CPR and phospholipid (101), while cyt c – 
an important component of electron transfer chain in mitochondria – is unlikely to be a 
physiological redox partner of CPR which was found to be localized at endoplasmic reticulum 
(4). Nevertheless, redox reaction between CPR and cyt c has continued to been widely used as a 
standard model to characterize the redox properties and the activities of CPR (21, 53, 93, 102, 
103). Oxidized cyt c can also accept electrons from reductase domains of P450-BM3 and NOS 
which are also in the diflavin reductase family, and it is suggested that electrons flow from the 
FMN of these flavoproteins to the heme of cyt c during electron transfer (104).  
 
Electron transfer between proteins plays an essential role in a number of important 
biological processes including photosynthesis and respiration. It usually requires formation of 
transient protein complexes which are characterized with high association and dissociation rates 
to ensure rapid turnovers. Interaction and complex formation between CPR and cyt c has been 
investigated by cross-linking (105, 106), site-direct mutagenesis studies (21, 50, 93), etc. It has 
been proposed that charge-pairing between the negatively charged CPR and the positively 
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charged cyt c contributes greatly in the complex formation. Methylamidation of the carboxyl 
groups on CPR leads to strong inhibition of cyt c reduction (107), and a decrease on Vmax of the 
reaction (106). Increase in ionic strength also causes disruption in complex formation and 
electron transfer between CPR and cyt c due to masking effect of the charges residues (93). In 
particular, a cluster of acidic residues Glu-213-Glu-214-Asp-215 on the N-terminus of helix α7 
on CPR are potentially located in the CPR – cyt c complex interface suggested by site-directed 
mutagenesis studies (21, 50). It has also been shown that Lys-13 of cyt c can be cross-linked to 
one of the carboxyl groups from the two acidic clusters Asp-207, -208 and -209 and Glu-213-
Glu-214-Asp-215 (105). However, antibody binding studies reveal that an antibody designed to 
bind against Gly-204 to Gly-218 region of CPR fails to show effect on CPR – cyt c interaction 
(108). On the other hand, mutation of another acidic cluster Asp-113 and Glu-115-Glu-116 on 
the β2-α4 coil of CPR improves the cyt c reductase activity, facilitating a more functional 
complex formation (93).  With the controversy in the literature, a high-resolution mapping of the 
binding interface of CPR and cyt c will be necessary to gain a better insight on the interaction 
and electron transfer between the two proteins.  
 
Figure 1.10   Structure of cyt c. The left panel is the cartoon presentation of cyt c (PDB code 1AKK). The 
right panel shows its electrostatic potential surface calculated using PyMOL (Version 1.1, Schrödinger, 
LLC) with APBS plugin (25).  
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Table 1.1 Summary of important residues proposed to be at the binding interface of cyt P450-CPR 
complex. 
CPR Cyt P450 Experiment techniques Critical Residues  reference 
rat 1A1 Site-directed mutagenesis Cyt P450:  
K94, K99, K105, K440, 
K453, R455, K463;  
Less significant: R135, 
R136, R137 
(90) 
 1A1 Site-directed mutagenesis  Cyt P450:  
K271, K279 
(89) 
rat 2B1 Acetylation of lysine residues 
on cyt P450; 
Radiolabeling lysine residues 
followed by trypsin digestion 
Cyt P450: 
K251, K384, K422, K433, 
K473 
(87) 
rat 2B1 Inhibitory peptides binding Cyt P450:  
R125, helices C and L 
(95) 
rabbit 2B4 Site-directed mutagenesis Cyt P450:  
R122, R126, R133, F135, 
M137, K139, K433, R422, 
R443 
(91) 
rat 2B4 Site-directed mutagenesis; 
Fluorescence labeling; 
Stopped-flow spectroscopy 
Cyt P450:  
V267, L270 
(109) 
rabbit 2B4 Site-directed mutagenesis Cyt P450:  
H226, K225, R232, R253, 
F223, F227, F244 
(110) 
 2B6 Cross-linking; MS Cyt P450 :  
C-helix  
CPR:  
connecting domain1 
(94) 
rat 3A4 Chemical modification of 
tyrosine residues;  
Site-directed mutagenesis 
Cyt P450:  
Y430;  
one or more residues 
among Y99, Y347, Y430 
(111) 
porcine 17alpha Chemical modification; 
MS 
Cyt P450:  
K326, K327 
(88) 
rat PB-b Chemical modification of 
carboxyl residues on CPR 
CPR:  
Asp and Glu  
(92) 
Human2 2D6 Site-directed mutagenesis CPR: 
D208 
(21) 
rat  Site-directed mutagenesis CPR: 
D208 
(50) 
rat 2B1 Site-directed mutagenesis CPR: 
D113, E115/E116 
(93) 
1 It may be an artifact caused by cross-linking. 2 Isolated FMN binding domain instead of the intact CPR 
was investigated. 
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1.5 Goal of this research  
The ultimate goal of this project is to understand the interaction and electron transfer 
between CPR and its redox partners – cyt P450 and cyt c, from both structural and kinetic 
perspectives. Isolated FMN binding domain (FBD) of rat CPR, which is the direct electron donor 
to its redox partners, will be expressed, purified and characterized. The kinetics of electron 
transfer between FBD and cyt P450/cyt c will be studied and compared with wild-type CPR. A 
combination of solution and solid-state NMR will be carried out to investigate the interaction 
between FBD and cyt P450/cyt c. In the solution NMR experiments, we will perform chemical 
shift perturbation and line broadening analysis to map out the binding interfaces and to generate 
structural models for the complexes. We will also apply static solid-state NMR approaches to 
study the interaction between FBD and cyt P450 in a native-like environment. By characterizing 
the structure and dynamics of the transmembrane domain of CPR, we will obtain a better 
understanding of its physiological role in the complex formation between CPR and cyt P450.  
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1.6 Experimental methods for studying interaction and electron transfer between proteins 
1.6.1 Solution NMR  
Solution nuclear magnetic resonance (NMR) spectroscopy has developed into a powerful 
tool for high-resolution mapping of protein-protein interactions, especially for studying transient 
protein complexes which are usually difficult to crystallize. NMR detects the magnetic properties 
of certain atomic nuclei, among which the most commonly used isotopes include 1H, 13C 
and 15N. Due to the high nature abundance of 1H (~99.99%) and its common distribution, one-
dimensional 1H-NMR is widely used in characterization of small organic compounds. In studies 
of biomacromolecules, such as proteins, multi-dimensional NMR experiments are necessary to 
achieve higher resolution of the spectra or to assist spectral assignment. In protein NMR 
spectroscopy, one of the most frequently used experiments is the two-dimensional (2D) 
Heteronuclear Single Quantum Coherence (HSQC) experiment. It correlates 13C/15N and 1H 
nuclei and presents in the spectra crosspeaks of 13C-1H or 15N-1H pairs that are directly bonded. 
For example, in 15N-HSQC spectra of a protein, most of the peaks come from the backbone 
amides – each residue corresponds to one N-H crosspeak in the spectra, except for tryptophan, 
asparagine, lysine, arginine and glutamine which have additional peaks from the side-chain N-H 
pairs. 15N-HSQC experiment provide a unique pattern for each protein depending on its overall 
structure, thus this spectrum is usually considered a “fingerprint” of a protein. It is extensively 
used to examine the overall fold of a protein and monitor residue-specific response to variables 
such as ligand/protein binding and environmental changes.  
1.6.1.1  TROSY-HSQC experiments 
Application of solution NMR in studying very large biomacromolecules is limited by 
intrinsic line broadening due to fast transverse relaxation (T2) of the resonances, which is 
associated with long correlation time of large molecules. The development of transverse 
relaxation-optimized spectroscopy (TROSY) experiments increases the size limit of molecules 
that are amendable for solution NMR studies several fold (112). Today, TROSY-based 
experiments are widely used in studying biomacromolecules which are larger than 50 kDa. A 
TROSY-HSQC pulse sequence is shown in Figure 1.11. The TROSY scheme effectively 
increases the resolution of 15N-1H resonances by using the constructive interference between 
dipole-dipole interaction and chemical shift anisotropy. The TROSY effect is more profound in 
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large molecules and high external magnetic field. The theoretical foundation lies in how cross-
correlation between dipolar coupling and chemical shift perturbation affects the relaxation 
process (113).  
 
Figure 1.11   [15N, 1H]-TROSY-HSQC pulse sequence.  
 
1.6.1.2  Chemical shift perturbation and line broadening analysis     
Chemical shift of a resonance is determined by the shielding effect of the electron cloud 
surrounding the nucleus, which is strictly dependent on its chemical environment. Line 
width/peak height indicates the transverse relaxation rate of a resonance, which is affected by the 
dynamics of the nucleus. These two parameters are predominantly analyzed in this project to 
monitor the structural and dynamic changes of a protein as a response to interacting with its 
partner. Chemical shift perturbation analysis is routinely used for mapping the binding interface 
in studies of protein-protein interactions (114). For interactions occurring at different NMR time 
scales, the phenomenon of chemical shift perturbations varies accordingly (assuming a two-site 
exchange): 1. Upon fast exchange (kex ≪ Δν), the resonance of the complex will appear at a 
population-weighted chemical shift of the unbound and bound species; 2. Upon slow exchange 
(kex ≫ Δν), both bound and unbound species will present as separate resonances at individual 
chemical shifts; 3. Upon intermediate exchange (kex ≅ Δν), line broadening occurs which leads 
to low-resolution and poorly defined resonance(s). Chemical shift perturbation is also sensitive 
to allosteric regulation which is usually hard to distinguish from the effect of surface contact 
with protein/ligand. Line broadening of resonances upon protein-protein interaction can attribute 
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to two possible reasons: 1. Increase of overall correlation time upon binding to another protein 
leads to faster transverse relaxation; 2. Chemical exchange in the intermediate time scale. The 
former has a general effect on most of the residues in the proteins, while the latter is more 
specific towards the residues involved in the binding interface or undergoing dynamic changes 
upon interaction. The phenomenon is more profound when the size of the complex is large (115).  
1.6.2 High Ambiguity Driven biomolecular DOCKing (HADDOCK) 
HADDOCK is a data-driven docking program for predicting biomacromolecular 
complexes (116, 117). Since its debut in 2003 (117), it has been applied to generate a number of 
structural models of protein-protein, protein-DNA, protein-RNA and protein-ligand complexes 
with renowned accuracy (118-121). A noted difference of HADDOCK from other rigid body 
docking programs, e.g. GRAMM-X, Z-DOCK, is that it uses ambiguous restraints defined by the 
user – based on experimental data or bioinformatic predictions – to drive the docking process. A 
variety of restraints can be input including NMR experimental data (e.g. chemical shift 
perturbation data, paramagnetic relaxation enhancement, residual dipolar couplings, etc.), site-
directed mutagenesis data and bioinformatics (122).  
In this project, we use chemical shift perturbations/line broadening data as ambiguous 
restraints to drive the docking. Ambiguous Interaction Restraints (AIR) can be generated on the 
HADDOCK website (122), which include “active” and “passive” residues. In the case of NMR 
titration data, the active residues should be chosen to be the residues showing significant 
chemical shift perturbations upon complex formation as well as having high solvent 
accessibilities in the unbound form (>50% relative accessibility as calculated by NACCESS 
(123)) (117). The passive residues correspond to the residues that show a less significant 
chemical shift perturbation and/or that are in close proximity to the active residues and have high 
solvent accessibilities (>50%). An AIR is defined as an ambiguous intermolecular distance 
between any atom of an active residue of protein A and any atom of both active and passive 
residues of protein B with a maximum of 2 Å. This ambiguous definition of AIR allows the 
program to search through all possible configurations around the interacting site defined by the 
user and find the most energy-favorable pairs of interacting residues among the active and 
passive residues (117). The default upper threshold of 2 Å is set as a result of a compromise 
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between hydrogen-hydrogen and heavy atom-heavy atom minimum van de Waals distances, and 
can be modified in the AIR restraint table (122).  
HADDOCK docking algorithm includes three consecutive steps—1. rigid body docking 
in which the two molecules are rotated and translated randomly in turn in order to minimize 
intermolecular energy, 2. Semi-rigid simulated annealing of structures, in which annealing in 
torsion angle space is performed to refine the orientation of the proteins and the side chains 
and/or backbones of the interface residues defined by AIR table, 3. Solvent refinement, in which 
the structures are further refined in explicit solvent layers. The final structures with lowest 
energies are clustered, scored and analyzed as outputs of the docking.  
1.6.3 Electron transfer pathway prediction 
Obtaining direct information of electron transfer pathway between proteins is a 
challenging but beneficial task for a better understanding of the mechanism of many electron-
transfer enzymes, including the cyt P450 system we are investigating. The commonly used 
experimental procedure to determine the electron transfer pathway is through site-directed 
mutagenesis – by mutating the residues which are potentially located on the pathway and 
evaluating how the mutation affects the interprotein electron transfer. However, performing 
mutations is not only time and money consuming but also might introduce perturbations on the 
structure of the proteins or interrupt protein-protein interaction. Alternatively, computational 
tools can be applied to predict electron transfer pathway, given a fair-resolution structure of the 
complex (124-127).  
In this project, we predict electron transfer pathway using HAmiltonian to Research 
LargE Molecules (HARLEM) (128). It employs PATHWAYS analysis of donor/acceptor 
interactions (129) and topological search algorithms to find the shortest pathways between the 
pre-defined electron donor and acceptor. The input file of the program is the structure of the 
complex with the redox centers defined. The PATHWAY model searches for the combination of 
bonded and nonbonded interactions that maximizes the total Donor-Acceptor interaction (TDA) 
(Equation 1.1) mediated by combination of through-bond and through-space coupling in the 
proteins (130). In Equation 1.1, 𝜀C, 𝜀S and 𝜀H present the decay factors for electron tunneling 
through covalent bonds, through-space and through hydrogen bonding, respectively, and are 
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empirically set as shown in Equation 1.2, 1.3, 1.4, in which R represents distances in Å. Since 
electron tunneling is much more efficient through bonded orbitals than through space due to the 
effectively lower potential barrier, the pathway obtained contains mainly bounded interactions 
with limited through-space connections. Electron transfer pathways have been predicted by 
HARLEM for protein complexes, including putidaredoxin/cyt P450 camphor (131), cytochrome 
c/cupredoxin (132), adrenodoxin/cyt P450 11A1 (133)  and cyt b5/cyt P450 2B4 (134) 
complexes. 
 
                                          𝑇DA  ∝  ∏ 𝜀C(𝑖)𝑖 ∏ 𝜀S(𝑗)𝑗  ∏ 𝜀H(𝑘)𝑘       (1.1) 
𝜀C = 0.6   (#)      (1.2) 
𝜀S = 𝜀C2 exp[−1.7(R − 2.8)]    (1.3) 
𝜀H = 0.5 𝜀C exp[−1.7(𝑅 − 1.4)]   (1.4) 
 
1.6.4 Kinetics studies by stopped-flow spectroscopy 
Stopped-flow is a rapid mixing spectroscopic technique used to study chemical kinetics 
of a fast reaction in solution. Reacting reagents are pushed out of the syringes and mixed in a 
mixing chamber, and shortly after mixing the reacting mixture is monitored by a spectrometer 
coupled to the instrument as a function of time (e.g. UV-Vis, fluorescence, etc.) (Figure 1.12). 
The dead time of the technique is between the end of mixing and the start of spectroscopic 
measurement, which is typically on the order of milliseconds. This allows for fast reactions with 
half-lives as short as a few milliseconds or tens of seconds to be accurately measured.  
The kinetics of electron transfer from the FMN binding domain (FBD) of CPR to its 
redox partner cyt c is studied using stopped-flow spectroscopy. Due to a relative slow rate of 
reaction between FBD and cyt P450 upon instant mix (on the order of minutes), the kinetics of 
electron transfer between these two is monitored directly using real-time UV-Vis single-
wavelength detection. In order to fulfill pseudo-first-order conditions, the concentration of cyt 
P450/cyt c is in large excess over FBD. The apparent rates (Kobs, Equation 1.5, 1.6) of electron 
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transfer from FBD are compared with those from wild-type CPR to assess the effect of structural 
integrity on complex formation between CPR and its redox partners.  
 
Figure 1.12   Stopped-flow spectroscopy. 
 
𝑟𝑎𝑡𝑒 = d[FBD]
dt
= 𝑘obs[FBD]      (1.5) 
𝑘obs = 𝑘 [acceptor]      (1.6) 
 
1.6.5 Solid-state NMR experiments  
Solid-state NMR spectroscopy is a powerful approach to probe high-resolution structure 
and dynamics of insoluble, non-crystalline or amorphous biomolecules like membrane proteins – 
systems which usually pose great difficulties for crystallization. One early problem of applying 
solid-state NMR in membrane protein studies comes from severe line broadening of resonances 
due to anisotropic magnetic interactions such as chemical shift anisotropy and dipolar 
interaction, caused by reduced mobility of proteins embedded in the lipid bilayer. This difficulty 
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has been overcome by using aligned samples or magic angle spinning (MAS), which drastically 
improve the spectral resolution and allow for structural and dynamic studies of membrane 
proteins in a native-like membrane environment.  
1.6.5.1 Aligned sample in solid-state NMR 
There are two methods commonly used to make oriented membranes for solid-state NMR 
studies – glass plates and lipid bicelles. In glass plate samples, the lipid-protein mixture fills in 
the space between a stack of glass plates, where the lipids spontaneously form bilayers in the 
orientation parallel to the surface of the plates. Lipid bicelles are assemblies of long-chain lipids 
and detergents at certain molar proportions, which form disk-like bilayer patches shown in 
Figure 1.13. Because of their magnetic susceptibility and geometric property, these assemblies 
spontaneously align in the external magnetic field inside the NMR spectrometer, typically with 
their bilayer normal perpendicular to B0 (Figure 1.13). The properties of bicelles can be adjusted 
by changing the lipid composition. For example, one of the most frequently used bicelles is 
composed of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-
glycero-3-phosphor-choline (DHPC), which aligns at the temperature range between 25 °C and 
45 °C, while substitution of DMPC with DLPC can expand the temperature range required for 
alignment allowing the bicelles to orient at as low as 5 °C (76). The thickness of the bilayer can 
also be adjusted by composing the bicelles using lipids with increased or reduced acyl chain 
length, which can be used to study the effect of hydrophobic mismatch (135). In addition, 
interaction between proteins and charged membrane surface can be investigated by incorporation 
of charged lipids in the bicelles. 
                         
Figure 1.13   Alignment of bicelles in 
an external magnetic field B0. Long 
chain lipids tend to locate at the 
planar region of the bicelles (blue), 
while short chain detergents are more 
concentrated on the rim (green).    
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1.6.5.2 Dynamics of cross polarization  
Cross polarization is generally used to transfer magnetization from protons to low γ 
(gyromagnetic ratio) nuclei such as 13C, 15N and 29Si for sensitivity enhancement. It’s an 
essential element in the conventional multidimensional heteronuclear solid-state NMR 
experiments. In order to allow magnetization transfer to occur, the strength of B1 radio frequency 
field must fulfill the Hartmann-Hahn conditions described in Equation 1.7, in which I and S 
represent proton and low γ nuclei respectively. During cross polarization (CP), the system 
approaches equilibrium under the dynamics governed by dipolar coupling and relaxation in the 
rotating-frame. For CP between dilute (S) and abundant nuclei (I), the peak intensity of S spin 
can be approximated to Equation 1.8 (136). And a typical buildup curve is shown in Figure #. 
Earlier solid-state NMR studies on cyt b5 demonstrated that differences in dynamics between the 
soluble and transmembrane domain of cyt b5 were reflected clearly by the respective CP kinetics 
(34, 137, 138). 
𝛾𝐼𝐵1
𝐼 = 𝛾𝑆𝐵1𝑆     (1.7) 
𝐼(𝑡) = 𝐼(0)
𝑇IS
�
1
𝑇IS
−
1
𝑇1𝜌
I �
−1 (𝑒− 𝑡𝑇1𝜌I − 𝑒− 𝑡𝑇IS)    (1.8) 
               
1.6.5.3 Separated Local Field (SLF) experiment 
Separated Local Field (SLF) experiment correlates 15N chemical shift with 1H-15N dipolar 
couplings in a two-dimensional NMR spectrum. For static aligned protein samples, SLF spectra 
typically show very characteristic features. In particular, α-helices result in circular patterns in 
Figure 1.14   Typical classical CP kinetics. 
Reprinted with permission of Kolodziejski 
et al. Copyright 2002 American Chemical 
Society.  
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the spectra which we call “PISA wheel”. The phenomenon is a result of the fixed geometric 
relationship between the 15N magnetic interaction tensors and peptide plane (Figure 1.15A). The 
shape and position of the “PISA wheel” pattern are sensitive to the tilt angle of the helix with 
respect to the bilayer normal as well as its dynamics in the membrane (Figure 1.15B). By fitting 
the wheel pattern, structural and dynamic information can be extracted even in the absence of 
spectral assignment.  
Different SLF pulse sequences have been developed. The original sequence PISEMA 
sequence is sensitive to the chemical shift and frequency resonance offset, which limits its 
application in high magnetic field where the effect is more pronounced (34). Later on, SAMMY 
(139) and SAMPI4 (140) sequences were developed to reduce the offset dependence of the 
experiment by using a less sensitive homonuclear decoupling scheme. In this project, we utilize a 
HIMSELF sequence (Figure 1.15C) referring to “heteronuclear isotropic mixing by separated 
local field spectroscopy” developed by Dvinskikh et al (141), which uses double channel 
homonuclear decoupling sequences of BLEW or WIM in the indirect dimension. This sequence 
has shown to be less sensitive to the offset effect (141) and thus could be suited to study 
uniformly labeled samples. 
 
 
Figure 1.15   Separated local field spectroscopy. A, Peptide plane NMR interactions that allow for angle 
measurements in static 15N NMR. Dipolar coupling is labeled in red arrow, green arrows indicates two 
principle axis of 15N chemical shift anisotropy. B, PISA wheel patterns of 15N-labeled helix at different tilt 
angles with respect to membrane normal. Reprinted with permission from Dürr et al. Copyright 2007 
Elsevier B.V. C, A two-dimensional HIMSELF sequence. Reprinted with permission from Dvinskikh et al. 
Copyright 2006 American Institute of Physics.  
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CHAPTER 2 
 
Characterization of Interaction and Electron Transfer between the FMN Binding Domain 
of Cytochrome P450 Reductase and Cytochrome c  
 
2.1 Summery 
Cytochrome c reduction has been extensively used as a model reaction to assess the redox 
activity of cytochrome P450 reductase (CPR). In this chapter, electron transfer and complex 
formation between the FMN binding domain (FBD) of cytochrome P450 reductase and 
cytochrome c (cyt c) were investigated. Kinetics of electron transfer between FBD and cyt c 
show distinct rates depending on the redox states of FBD. When compared with wild-type CPR, 
FBD reduces cyt c at a much higher rate in both its semiquinone and hydroquinone state, 
suggesting that conformational gating of CPR plays a key role in the electron transfer process. 
The results of NMR titration experiments reveal the formation of dynamic complexes between 
FBD and cyt c on a fast exchange time scale with a dissociation constant Kd of 0.024 mM. 
Chemical shift mapping identifies the specific residues of FBD involved in the binding interface 
with cyt c, most of which are located around the solvent exposed edge of the FMN cofactor. The 
structure model of the FBD-cyt c complex generated using HADDOCK indicates two probable 
orientations of complex formation. The major structure shows potential salt bridge formation 
between Glu-213/Glu-214 of FBD and Lys-87 of cyt c which may be essential to the stability of 
the complex, and electron transfer pathway mediated by Lys-13 of cyt c was predicted. This 
work provides a structural basis for a better understanding of the interaction between CPR and 
cyt c and allows comparisons to be drawn with other electron transfer complexes involving CPR 
or cyt c.  
 
2.2 Introduction 
Cytochrome P450 reductase (CPR) is a diflavin protein which donates electrons to a 
variety of microsomal cytochrome P450s (1), heme oxygenase (2), cytochrome b5 (3), 
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cytochrome c (4) as well as therapeutic prodrugs (5). It plays an dispensible role in the 
cytochrome P450 monoxygenase system, which is responsible for the metablism of myriads of 
endogenous compounds including vitamins, steroids and hormones, as well as exogenous 
compounds including environmental toxins and drugs. CPR is a ~78 kDa membrane-bound 
protein composed of four distinct domains: the N-terminal transmembrane segment, the FMN 
binding domain (FBD), the connecting domain and the FAD/NADPH binding domain (6). It 
shuttles electrons from its physiological reductant NADPH, via the FAD and FMN cofactors, to 
its acceptor proteins, e.g. cytochrome P450s. The FMN binding domain is the ultimate donor of 
electrons to the acceptor proteins. 
 
CPR was first isolated and identified as an NADPH-dependent cytochrome c (cyt c)  
reductase in the 1950s (7). In later studies, the true physiological redox partner of CPR was 
revealed to be cytochrome P450 after successful achievement of hydroxylase activity from a 
reconstitution system composed of cytochrome P450, CPR and phospholipids (8), while cyt c – 
an important component in the electron transfer chain in mitochondria –is unlikely to be a 
physiological redox partner of CPR which was found to be localized on the endoplasmic 
reticulum (4). Nevertheless, the redox reaction between CPR and cyt c continued to be widely 
used as a standard model to characterize the redox properties and the activities of CPR (9-13). 
Oxidized cyt c can also accept electrons from the reductase domains of both P450-BM3 and 
nitric oxide synthase (NOS) which are also in the diflavin reductase family, and it is suggested 
that electrons flow from the FMN of these flavoproteins to the heme of cyt c during electron 
transfer (14).  
 
Electron transfer between proteins plays an essential role in a number of important 
biological processes including photosynthesis and respiration. It usually requires formation of 
transient protein complexes which are characterized with high association and dissociation rates 
to ensure quick turnovers. Interaction and complex formation between CPR and cyt c has been 
investigated by cross-linking (15, 16), site-direct mutagenesis studies (12, 13, 17), etc. It has 
been proposed that charge-pairing between the negatively-charged CPR and the positively-
charged cyt c contributes greatly in the complex formation and stability. Methylamidation of the 
carboxyl groups on CPR leads to strong inhibition of cyt c reduction (18), and a decrease on Vmax 
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of the reaction (16). Increase in ionic strength also causes disruption in complex formation and 
electron transfer between CPR and cyt c due to masking effect of the charged residues (12). In 
particular, a cluster of acidic residues Glu-213-Glu-214-Asp-215 on the N-terminus of helix α7 
are potentially located on the CPR – cyt c complex interface, as suggested by site-directed 
mutagenesis studies (13, 17). It has also been shown that Lys-13 of cyt c and be cross-linked to 
one of the carboxyl groups from the two acidic clusters Asp-207, -208 and -209 and Glu-213-
Glu-214-Asp-215 (15). However, antibody binding studies reveal that an antibody designed to 
bind against Gly-204 to Gly-218 region of CPR fails to show effect on CPR – cyt c interaction 
(19). On the other hand, mutation of another acidic cluster Asp-113 and Glu-115-Glu-116 on the 
β2-α4 coil of CPR improves the cyt c reductase activity, facilitating a more functional complex 
formation (12).  With the controversy in the literature, a high-resolution mapping of the binding 
interface of CPR and cyt c is necessary to gain insight into the interaction and electron transfer 
between the two proteins. The nature of weak interactions between electron transfer proteins 
makes the complex difficult to crystallize. Meanwhile, solution NMR techniques have been well 
developed to investigate such transient complexes including myoglobin – cyt b5 (20), cyt b5 – 
cyt c (21), cyt c – cyt c peroxidase (22), P450cam – putidaredoxin (23) etc. Therefore in this 
chapter the interaction between CPR and cyt c will be probed by solution NMR.  
CPR-mediated electron transfer from NADPH to cytochrome P450/cyt c is highly 
orchestrated between intraprotein electron transfer (from NADPH to FAD and from FAD to 
FMN) and interprotein electron transfer (from FMN to heme). Internal electron transfer from 
NADPH to FAD is regulated with the side chain movement of Trp-676 of CPR (human) (24), 
and interflavin electron transfer has been suggested to be gated by interdomain movements 
between the FMN binding domain and the rest of the reductase (6, 25). On the other hand, 
interprotein electron transfer between FMN and heme depends on complex formation. In order to 
focus only on complex formation and simplify the electron transfer process, we choose to 
investigate electron transfer and complex formation between cyt c and isolated FMN binding 
domain, which is the direct electron donor to cyt c.  
In this study, we characterized the kinetics of electron transfer from the FMN binding 
domain (FBD) of CPR to cyt c, and compared with that from wild-type CPR to cyt c, 
demonstrating the effect of conformational changes of CPR on interprotein electron transfer. 
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Using solution NMR in combination with molecular docking, we mapped the binding interface 
on the FMN binding domain and proposed a structural model of the FBD – cyt c complex. The 
NMR results imply formation of a dynamic complex and indicate the primary binding sites on 
FBD. The structural models generated by HADDOCK based on NMR restraints suggest 
potential electron pathways that provide strong electronic coupling between the redox centers. 
The details on the FBD – cyt c binding interface also allow comparisons to be drawn with that of 
FBD – P450 complex or other electron transfer complexes involving cyt c.  
 
2.3 Materials and Methods 
2.3.1 Materials 
E. coli C41 cells for protein overexpression were purchased from Lucigen (Middleton, 
MI). Yeast extract, tryptone for unlabeled growth media were purchased from Sigma-Aldrich. 
[15N]ammonium chloride for M9 medium and D2O were purchased from Cambridge Isotope 
Laboratories (Andover, MA). Horse heart cyt c, resins, buffer components, and all the chemicals 
were purchased from Sigma-Aldrich. Glycerol used in NMR experiments was purchased from 
Roche Applied Science.   
2.3.2 Expression and purification of a uniformly 15N-labeled FMN binding domain of rat CPR 
The FMN binding domain (residue 1-239) (FBD) was expressed and purified from E. coli 
C41 cell. E. coli C41 cells were transformed with a pSC-CPR plasmid (26) containing the FBD 
gene and adapted in 100mL Lysogeny Broth (LB) medium for 5 hours before transferred into 
M9 minimal medium (40 mM Na2HPO4, 20 mM KH2PO4, 8.5 mM NaCl, 18 mM 15NH4Cl, 1 
mM MgSO4, 1 µM CaCl2, 16 nM riboflavin, 0.4 % (w/v) glucose). Expression of FBD was 
induced by adding 0.4 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) when the cell growth 
reaches log phase (OD600=0.7). Afterwards, cells were grown for 14 hours at 30°C and with a 
shaking speed of 140 rpm, and harvested. The harvested cells were lysed via treatment with 
lysozyme (30 μg per mL of cell suspension) for 30 min and sonication by alternating 1-min 
pulses for a total of 8 min. The membrane fraction of the cells was recovered by 
ultracentrifugation (105,000 × g, 45 min) and the protein were solubilized from the membrane 
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with 0.3 w/v% TritonX-100 at 4 °C via stirring overnight. Solubilized protein was loaded to 
DEAE Sepharose column equilibrated with loading buffer (50 mM Tris-acetate, 0.1 mM EDTA, 
0.2 mM DTT, 10 % glycerol, 1 µM FMN, pH 6.7). The column was washed with 2 column 
volumns (CV) of loading buffer and 5 CV of washing buffer (loading buffer with additional 0.17 
M NaCl and 0.3 % (w/v) sodium cholate), and gradient-eluted with a total of 4 CV of washing 
buffer and eluting buffer (loading buffer with additional 0.5 M NaCl and 0.3 % (w/v) sodium 
cholate). The eluted protein solution was subjected to hydroxyapatite column to remove the 
detergents. Full-length rat CPR was overexpressed and purified according to published protocol 
(26). Each purified protein exhibited a single band on the SDS-polyacrylamide gel. The 
concentration of the oxidized MFBD and CPR was determined using extinction coefficients of 
12.2 mM-1cm-1 and 21 mM-1cm-1 at 454 nm respectively (27) .  
 
2.3.3 Titration of FBD by dithionite under anaerobic conditions  
FBD and CPR were titrated with sodium dithionite solution under anaerobic conditions 
monitored by UV-Vis spectra. The solution of the FMN binding domain was incubated overnight 
at 4 °C in an anaerobic Belle Technology glove box (Hi-Tech, Salisbury, UK) to remove oxygen. 
The titrant (sodium dithionite solution) was prepared in the glove box in oxygen-free buffer, and 
its concentration was calculated using an extinction coefficient of 8 mM-1 cm-1 at 315 nm. The 
titrand solution of FBD or CPR contains 11.3 µM of the protein, 3 µM of methylviologen, 100 
mM potassium phosphate buffer, 5 % (w/v) of glycerol, pH 7.4. The titration was carried out in a 
home-made anaerobic titration apparatus to minimize contamination of oxygen, and monitored 
by UV-Vis spectrum. 
 
2.3.4 Pre-steady-state kinetics of cyt c reduction by FBD/CPR 
All experiments were performed at 25 °C under anaerobic conditions using a Hi-Tech 
SF61DX2 stopped-flow spectrophotometer housed in an anaerobic Belle Technology glove box. 
The buffer was purged with nitrogen gas for 30 min for deoxygenation prior to being transferred 
to the glove box. The solution of cyt c was incubated overnight at 4 °C in the glove box to 
eliminate oxygen. For measuring the kinetics of cyt c reduction by FBD/CPR, FBD (11.3 µM) 
and wild-type CPR (11.3 µM) were pre-reduced to the intended redox state anaerobically as 
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described above, and then loaded in syringe 1 of the stopped flow, whereas syringe 2 was loaded 
with ferric cyt c. The reaction was started by rapid mixing of an equal volume from both syringes 
and monitored at 550 nm and 630 nm. Traces were fitted using a standard single exponential 
equation (28). The buffer contains 100 mM potassium phosphate, 5 % (w/v) glycerol, pH 7.4. 
 
2.3.5 Kinetics of auto-oxidation of hydroquinone FBD 
Auto-oxidation of hydroquinone FBD was studied using the stopped-flow 
spectrophotometer apparatus descried above. FBD (11.3 µM) was pre-reduced to two electron-
reduced state, and loaded in syringe 1 of the stopped flow, and syringe 2 was loaded with buffer 
saturated with oxygen. The reaction was started by rapid mixing of an equal volume of both 
syringes and monitored at 585 nm and 454 nm. The traces were fitted using a standard single 
exponential equation. 
 
2.3.6 NMR titration experiments  
All NMR experiments were performed on a Bruker Avance 900 MHz NMR spectrometer 
equipped with an x,y,z axis PFG-5mm TCI cryoprobe at 298K. Samples for 2D NMR 
experiments contain 0.3 mM 15N-labeled FBD in 100 mM potassium phosphate buffer with 5% 
(w/v) glycerol at pH 7.4. Titration of unlabeled cyt c into 15N-labeled FBD was carried out by 
addition of concentrated cyt c solution corresponding to 0.3, 0.6, 1 and 5 molar equivalents of 
FBD. 2D 15N, 1H TROSY-HSQC spectra were collected at each titration point with 32 scans and 
144 t1 increments. The average amide chemical shift perturbation (∆δavg) was calculated using 
the equation below 
 
∆𝛿avg = �(∆𝛿N × 𝑆𝑊2 𝑆𝑊1)2 + ∆𝛿H2 
 
where ∆𝛿N and ∆𝛿H are changes in chemical shift observed between the bound and unbound 
states and 𝑆𝑊1  and 𝑆𝑊2  represent spectrum width of the first and second dimension 
respectively. Titration of unlabeled FBD to cyt c was performed by adding aliquots of FBD 
solution to a final concentration of 0.3, 0.6, 0.9, 2 and 3 molar equivalents of cyt c. The 
dissociation constant Kd was determined by fitting the titration data (21).  All NMR spectra were 
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processed using TopSpin 2.0 (Bruker). Resonance assignments and data analysis were performed 
using Sparky (29).  
 
2.3.7 Structural modeling of FBD-cyt c complex 
HADDOCK 2.1 (30) program was utilized to calculate the structural models of FBD-cyt 
c complex based on defined ambiguous restraints. HADDOCK docking algorithm includes three 
consecutive steps—1. rigid body docking in which the two molecules are rotated and translated 
randomly in turn in order to minimize intermolecular energy, 2. simulated annealing of structures 
in which annealing in torsion angle space is performed to refine the orientation of the proteins 
and the side chains and/or backbones of the interface residues, 3. solvent refinement in which the 
structures are further refined in explicit solvent layers. In this docking, the crystal structure of 
FBD (PDB code 1AMO) and the solution NMR structure of the house heart cyt c (PDB code 
1AKK) were used as the starting structures. Ligand and topology files were generated from the 
PRODRG server (31). 1000 structures were generated in the rigid body docking step, followed 
by simulated annealing of the 200 lowest-energy structures from the last step and finally the best 
50 structures were selected for solvent refinement in an 8.0 Ǻ shell of TIP3P water molecules. 
The resulting 50 final structures were analyzed and grouped into clusters based on the backbone 
r.m.s.d. values. Molecular structures of the complexes were viewed and graphed using PYMOL. 
 
2.4 Results 
2.4.1 Characterization of the FMN binding domain 
Isolated FMN binding domain (FBD) was expressed, purified and characterized by SDS-
PAGE analysis and redox titration (Figure 2.1A-B). The spectral properties of FBD during redox 
titration are quite similar to those of the FMN binding domain of human CPR reported (32). 
Reduction of FBD from fully-oxidized state to semiquinone (one electron-reduced) is featured by 
spectral intensity decrease at 454 nm and an increase of a broad band centered at 585 nm – 
characteristic of blue semiquinone formation – with isosbestic points at 502 nm and 361 nm. 
Transition from semiquinone to hydroquinone (two electron-reduced) can be visualized in the 
spectra with further intensity decrease at 454 nm as well as at 585 nm with isosbestic points at 
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327 nm, 386 nm and 432 nm (Figure 2.1B). Auto-oxidation of hydroquinone FBD is 
characterized by rapid mixing of two electron-reduced FBD and oxygen-saturated buffer, and 
monitoring the oxidation of hydroquinone at 454 nm and formation of the air-stable semiquinone 
at 585 nm (Figure 2.1C). The observed rate of blue semiquinone formation (0.746 ± 0.006 s-1) 
(Figure 2.1C-a) is slower than that of hydroquinone oxidation (1.33 ± 0.08 s-1) (Figure 2.1C-b), 
which might attribute to proton diffusion or potential protein side chain rearrangement necessary 
for stabilizing the blue semiquinone.  
 
Figure 2.1 Characterization of FBD. A, SDS-PAGE gel of FBD. The single band reveals the purity of the 
protein. B, spectral changes during a redox titration of FBD with sodium dithionite under anaerobic 
conditions. The titration was performed as described in “Experimental Procedures”. C, Kinetic transients 
of auto-oxidation of two electron-reduced FBD. FBD was reduced to two-electron level by stoichiometric 
titration with dithionite. The reaction was initiated by mixing two electron-reduced FBD and oxygen-
saturated buffer and monitored at 585 nm (a) and 454 nm (b). 
 
2.4.2 Kinetics studies of electron transfer between the FMN binding domain and cytochrome c in 
comparison with wild-type CPR 
In order to gain insight into interactions between cyt c and FBD, we investigated electron 
transfer from reduced FBD to oxidized cyt c under pseudo-first order conditions and compared 
with wild-type CPR. In these experiments, wild-type CPR/FBD were reduced to one and two 
electron-reduced states respectively prior to mixing with cyt c. Lacking the FAD/NADPH 
binding domain, the isolated FMN binding domain cannot be reduced by the physiological 
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reductant of CPR—NADPH (supporting information). Therefore, sodium dithionite was used to 
titrate FBD and wild-type CPR to the intended redox states. Kinetic transients are measured at 
550 nm and 630 nm to monitor cyt c reduction and semiquinone oxidation of the reductases, 
respectively.   
Reduction of cyt c is initiated by rapid mixing of the reduced reductase and a 10-fold 
excess of ferric cyt c. Under this condition, a total of one molar equivalent of cyt c was reduced 
by two electron-reduced CPR with a kobs of 16.8 ± 0.2 s-1 (Figure 2.2A), which is comparable 
with that in human CPR (kobs = 12 ± 0.4 s-1 ) (27), while with one electron-reduced CPR the 
kinetic transient does not show signs of cyt c reduction (Figure 2.2A) which is consistent with 
the literature reports (33). In comparison, mixing one electron-reduced FMN binding domain 
with cyt c leads to reduction of one molar equivalent of cyt c with a kobs of 0.0227 ± 0.0004 s-1 
(Figure 2.2B). As for two electron-reduced FMN binding domain, a total of two molar 
equivalents of cyt c was reduced (Figure 2.2B). The kinetic transient shows an initial increase at 
550 nm within the dead time of the instrument corresponding to one molar equivalent of reduced 
cyt c, followed by a slow phase with a kobs of 0.0225 ± 0.0005 s-1. This implies a two-step 
reaction mechanism as in Scheme 1, in which step 1 occurs at a very high rate (>104 s-1) – mostly 
completed within the dead time, whereas step 2 occurs at a rate of around 0.0225 s-1 agree with 
the rate of cyt c reduction by one electron-reduced FMN binding domain. The hypothesized 
mechanism is also verified by the transients at 630 nm – where the absorbance of cyt c is 
negligible – to indicate the oxidation of FMN semiquinone. For two electron-reduced FMN 
binding domain, mixing with cyt c instantaneously lead to an accumulation of FMN semiquinone 
indicated by the absorbance at 630 nm. This agrees with a rapid reduction of cyt c by the 
hydroquinone FMN suggested in step 1 of the mechanism (Scheme 1-1). The following decay of 
absorbance at 630 nm at a rate of 0.0257 ± 0.0007 s-1 implies the oxidation of semiquinone FMN 
by cyt c in step 2 (Scheme 1-2) coincide with the rate of cyt c reduction. The two step reaction 
can also be observed by the spectra by photodiode array detection (Figure 2.2E). The rate 
constants are summarized in Table 2.1.   
FMNhq + cyt cox            complex          FMNsq + cyt cred                    (1) 
FMNsq + cyt cox            complex          FMNox + cyt cred                    (2) 
k1 
k-1 
k2 
k3
 k-3 
k4 
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Figure 2.2. Electron transfer between the FMN binding domain/wild-type CPR and cyt c. A, CPR (11.3 
µM) was reduced to one electron- and two electron-reduced states by stoichiometric titration with 
dithionite, and rapidly mixed with cytochrome c (100 µM) in the stopped-flow spectroscopy. Reduction 
of cyt c by one electron-reduced (blue) and two electron–reduced (red) CPR was monitored at 550 nm 
respectively. B-E, The FMN binding domain (11.3 µM) was reduced to one electron- and two electron-
reduced states by dithionite, and rapidly mixed with cytochrome c (100 µM). Reduction of cyt c by one 
electron-reduced (blue) and two electron–reduced (red) FMN binding domain was monitored at 550 nm 
(B, C), 630 nm (D). The diode array-detected spectra (E) of the mixture were recorded 0.00074 s (pink), 
28.5 s (black), 56.4 s (green), 125.4 s (purple) and 285 s (red) after rapid mixing. Spectrum of oxidized cyt 
c mixed with buffer is shown in blue.   
 
 
 
 
49 
 
 
 
 
Figure 2.3   Cyt c reduction by pre-reduced wild-type CPR and FMN binding domain. A, CPR (7 µM) was 
reduced to one electron-reduced state (semiquinone) by dithionite and mixed with oxidized cyt c (14 
µM) under anaerobic conditions. Spectrum of the mixture was taken 20 min after mixing (red). NADPH 
(20 µM) was added into the mixture anaerobically and resulted in total reduction of cyt c (purple) 
indicated by arrow 1,  meanwhile CPR rested in one electron-reduced (semiquinone) state indicated by 
arrow 2. B, the FMN binding domain (7 µM) was reduced to one electron-reduced state (semiquinone) 
by dithionite and mixed with oxidized cyt c (14 µM) under anaerobic conditions. Spectrum of the 
mixture was taken 20 min after mixing (red). The reduction and cyt c and oxidation of FMN semiquinone 
are indicated by arrow 1 and 2, respectively. The spectra before mixing were calculated by addition of 
individual spectra of the two components (blue).  
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Table 2.1  Kinetics of cyt c reduction by the FMN binding domain and CPR 
Reductase Wavelength     
(nm) 
k1 obs (s-1) k2 obs (s-1) 
One electron-reduced CPR 550 --  
Two electron-reduced CPR 550 16.8 ± 0.2a -- 
 520 16.2 ± 0.2 -- 
One electron-reduced FBD 550 0.0227 ± 0.004  
 630 0.0239 ± 0.006  
Two electron-reduced FBD 550 > 104 0.0225 ± 0.0005 
 630 > 104 0.0257 ± 0.0007 
a standard deviations were calculated among three kinetic transients monitored at the same 
wavelength.   
 
The distinct abilities of semiquinone FMN binding domain and CPR in reducing cyt c are 
shown in Figure 2.3. Mixing of pre-reduced semiquinone CPR and cyt c did not lead to 
proportional cyt c reduction until NADPH was added into the reaction mixture indicated by 
absorbance at 550 nm (Figure 2.3A). The shoulder at 630 nm, indicating blue semiquinone of 
CPR, remains even after addition of NADPH, showing CPR rests in one electron-reduced state 
(Figure 2.3A). In contrast, one electron-reduced FBD, after mixed with excess cyt c, leads to 
reduction of one molar equivalent of cyt c (550 nm) accompanied by oxidation of semiquinone 
(630 nm) (Figure 2.3B). 
 
2.4.3 Determination of dissociation constant of FBD and cyt c by NMR titrations 
The backbone assignments of the FMN binding domain of CPR have been previously 
reported (34) and utilized in the current study. The two-dimensional 15N, 1H-HSQC spectra were 
recorded to monitor the titration of unlabeled cyt c to 0.3 mM 15N-FBD. Throughout the titration 
only one set of backbone resonances of FBD were observed, implying that the interaction 
between FBD and cyt c occurs in fast-exchange NMR time scale. Figure 2.4 shows 
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Figure 2.4  A, superposition of the 1H-15N HSQC spectra of the FMN binding domain in the free form 
(green) and in complex with unlabeled cyt c (magenta). The FBD : cyt c molar ratio was 1:5 in 100 mM 
potassium phosphate buffer at pH 7.4 containing 5 % (w/v) glycerol. B, expansion of the crowded region 
of the spectra (purple rectangle). C, expansion to show the chemical shift perturbations of certain 
residues (yellow rectangle).  
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Figure 2.5  Titration of 15N-labeled FMN binding domain with cyt c. Changes in weighted average of 
chemical shifts (Δδave) as a function of the molar ratio of cyt c to FBD for backbone amides of S86, E92, 
Y153, E158 and L212. Curves are fitted using the equation 1 under the assumption of 1:1 complex 
formation, with an average Kd of 0.024 ± 0.012 mM.  
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Figure 2.6  Titration of cyt c by the FMN binding domain. A, 1D 1H spectra for the titration of cyt c by 
the FMN binding domain with an increasing ratio of cyt c and the FMN binding domain. Peaks at 35.1 (a) 
and 32.1 ppm (b) are assigned to heme methyl protons. Both peaks show intensity decease with 
increasing amount of FBD, while peak b shows chemical shift perturbation in addition. B, Titration curves 
for the 1H chemical shift of peak b as a function of the molar ratio of FBD : cyt c. The best fit corresponds 
to a Kd of 0.046 mM assuming 1:1 complex formation. 
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superposition of the HSQC spectra of free FBD (green) and FBD in complex with cyt c (red) (the 
molar ratio of FBD : cyt c is 1:5). Chemical shift changes were observed for specific residues of 
FBD upon complex formation with cyt c, clearly shown in Figure 2.4C. Most of the chemical 
shift perturbations occur in a saturable manner throughout the titration.  Figure 2.5 shows 
perturbations of averaged 1H, 15N chemical shift for selected backbone amides as a function of 
increasing molar ratio of cyt c to FBD. Assuming complex formation of 1:1 stoichiometry, the 
dissociation constant of FBD and cyt c was calculated from the chemical shift-monitored 
titration curves, which turned out to be 0.024 ± 0.012 mM, coincide with the apparent Kd (0.021 
mM) measured by rapid-mixing stopped-flow spectroscopy (11). The uncertainty represents the 
standard deviation of Kd values among the examined five residues.  
Titration of FBD to cyt c was also performed by monitoring 1H chemical shift of cyt c. 
The low field resonances at 35.1 and 32.2 ppm are assigned to heme 8-methyl and 3-methyl 
protons, respectively (35) (Figure 2.6A). Upon titration of FBD, both the heme methyl peaks 
showed line broadening while the heme 3-methyl resonance shifts to downfield position (Figure 
2.6A). The chemical shift perturbation of heme 3-methyl resonance as a function of the molar 
ratio of FBD and cyt c was also fitted to calculate the Kd value, which turned out to be 0.046 mM 
(Figure 2.6B). The two sets of measurements confirm that the dissociation constant of the two 
proteins lies at the range of 10-5 ~ 10-4 M, which verifies fast exchange between the bound and 
unbound states. The measured Kd value between FBD and cyt c is similar to that of human CPR-
cyt c complex (3.7×10-5 M) (11) and flavodoxin-cyt c complex (10-5 M) (35). 
 
2.4.4 Chemical shift mapping of binding interface on FBD 
Chemical shift perturbation observed for the backbone amides of FBD upon complex 
formation with cyt c is depicted in Figure 2.7. Upon interacting with molar equivalent of cyt c, 
the residues of FBD (residue 64-239) have an average chemical shift change of 0.007 ppm with a 
standard deviation of 0.008 ppm. The overall relatively small magnitude of chemical shift 
perturbation may be attributed to: (1) low binding affinity between FBD and cyt c; (2) formation 
of “encounter complexes” as have been previously reported for other electron transfer 
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complexes, which is characterized by an ensemble of various orientations in the complex 
formation leading to averaging effect of chemical shift perturbations (20, 21, 36, 37).  
Distribution of chemical shift perturbations was mapped onto the structure of FBD 
(Figure 2.8) according to the color scale in Figure 2.7. The structure of FBD (PDB code 1AMO) 
is composed of five strands of parallel β sheets flanked by six α helices – a typical wound α-β-α 
folding pattern – as shown in Figure 2.8A. The FMN cofactor locates between the loops at the C-
terminus of the β sheets with its isoalloxazine ring sandwiched between Tyr-140 and Tyr-178. 
Among the solvent accessible residues, those whose chemical shift perturbations are above the 
average value (Figure 2.8B-C, orange and red) were found to mainly locate surrounding the 
solvent exposable edge of the FMN cofactor, which is the putative binding interface on FBD for 
efficient electron transfer. These residues (Gln-87, Thr-88, Thr-90, Glu-92, Tyr-140, Asn-175, 
and Leu-212) are mostly neutral, and their chemical shift perturbations are likely due to 
hydrogen bonding and van der Waals interaction with cyt c. There are other solvent exposable 
residues with modest chemical shift perturbations distributed around the surface of FBD distant 
from the cofactor, most of which are charged residues including Lys-72, Glu-116, Arg-104, Lys-
176, Asp-207 and Glu-221.The dispersed distribution of chemical shift mapping (Figure 2.8) is 
another sign of the formation of a dynamic complex between the two proteins. This attributes to 
the fact that FBD is rich in negatively charged residues not only localized in close proximity of 
the FMN cofactor but widely spread out on the surface of FBD. Long-range electrostatic 
interaction between these negatively charged regions on FBD and the positively charged cyt c 
directs collisions on different parts of FBD, leading to small-scale chemical shift changes over a 
large surface area. Despite the variety of orientations that the two proteins may sample during 
complex formation, electron transfer still occurs at a decent rate according to the kinetic results. 
This might attribute to the fact that the two proteins are both small in size and their cofactors are 
both located close to the protein surface.  
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Figure 2.7  Chemical shift perturbation analysis. A histogram presenting the average amide chemical 
shift of FBD upon complex formation with cyt c. The molar ratio of FBD and cyt c is 1:1. The chemical 
shift perturbation is categorized as high (red), medium (orange) and not significant (cyan) presented by 
the vertical color strips and mapped onto the structure of FBD in Figure 8.   
 
 
 
 
Figure 2.8  Chemical shift mapping of FBD upon complex formation with cyt c. A, cartoon 
representation of the FBD. Residues are colored according to the amplitudes of amide chemical shift 
changes on binding cyt c, following the color codes in Figure 7. Red, orange and cyan represent residues 
with high, medium and not significant chemical shift perturbations, respectively. Overlapped and 
unassigned residues are colored gray. B, surface representation of the panel A. C, A 180° rotation view 
of panel B. 
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2.4.5 Structural model of FBD-cyt c complex 
A structural model of FBD-cyt c complex was generated using a data-driven docking 
program HADDOCK (High Ambiguity Driven biomolecular DOCKing) (30). The FMN binding 
domain of a crystal structure of CPR (PDB code 1AMO) and a solution NMR structure of the 
horse heart cyt c (PDB code 1AKK) were used as the starting structures in HADDOCK 
calculations. The docking was driven under defined intermolecular ambiguous restraints 
(supplemental Table 1), including active and passive residues with >40% solvent-accessibility 
from both proteins. As shown in Figure 2.8, solvent-accessible residues on FBD which show 
significant chemical shift perturbation upon complex formation are selected as the active 
ambiguous residues from FBD. Passive restraints were defined by the solvent-accessible residues 
flanking the active ones.  Active ambiguous restraints on cyt c were selected to be the common 
residues in the binding interfaces of several electron-transfer complexes involving cyt c (21, 22, 
38). The restraints were filtered once by carefully examining the results of the docking. Active 
restraints which created violations in more than 45 out of the 50 final structures were removed. 
The refined restraint table was shown in Table 2.2 and applied in the docking program using the 
same protocol.  
Two clusters of complex structures were identified from the 50 lowest energy structures, 
titled cluster I (major) and cluster II (minor). The energy statistics of the clusters are summarized 
in Table 2.3. The average intermolecular energies of the two clusters are -514.7 and -342.4 
kcal/mol, of which the major contribution comes from electrostatic energies.  This implies the 
significance of electrostatic interaction in the complex formation between FBD and cyt c. Two 
lowest energy structures from each cluster were shown in cartoon and surface representations 
(Figure 2.9), which demonstrates two unique but overlapping interfaces on both FBD and cyt c. 
Residues involved in the binding interface largely surround the heme of cyt c and the cofactor 
FMN of FBD, albeit variations in specific residues involved. In cluster I, the interface is mainly 
composed of β1-α3 coil, N-terminus of of α3, N-terminus of β4-α6 coil, β5-α7 coil and the N-
terminus of α7 of FBD and α1 helix, α3-α4 coil, α4-α5 coil of cyt c. In cluster II, β1-α3 coil, β3-
α5 coil, β4-α6 coil and N-terminus of β5-α7 coil of FBD and C-terminus of α1 helix, N-terminus 
of α1-α2 coil and α4-α5 coil of cyt c are predominantly involved in the binding interface. The 
interfacial residues which are common in the two clusters are Gln-87, Thr-88, Thr-90, Tyr-140, 
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Asn-175, Thr-177, Tyr-178, Asp-208 of FBD and Ile-9, Gln-12, Lys-13, Ile-81, Ala-83, Gly-84, 
Ile-85, Lys-86 of cyt c, which are tightly surrounding the redox centers of the two proteins. In the 
two clusters, the dihedral angles between the heme plane and the isoalloxazine ring of FMN are 
60° and 110°. The shortest distances between the edges of heme and FMN are 6.1 and 1.9 Å in 
cluster I and cluster II respectively, which is well within the 14.0 Å limit predicted for efficient 
electron transfer (39).  
Table 2.2 List of restraints used in HADDOCK 
 FBD cyt c 
   
Ambiguous restraints, active Q87, T88, T90, E92, Y140, 
N175, L212, R220  
Q12, K13, Q16, C17, I81, 
A83, I85 
Ambiguous restraints, passive G141, G143, P145, D147, T177, 
Y178, D208, D209, D215, I217 
D2, K5, K8, V11, K79, K86, 
K87, K88, T89 
 
 
Table 2.3 Statistic analysis of the two lowest-energy clusters of the FBD-cyt c complex 
generated from HADDOCK  
Parameters Cluster I Cluster II 
Number of structures  35 7 
Backbone r.m.s.d. (Å)a 2.93 ± 1.98 1.46 ± 0.77 
Total intermolecular energy 
(kcal/mol) 
-514.7 ± 63.8 -342.4 ± 60.1 
van der Waals energy 
(kcal/mol) 
-35.8 ± 7.6 -48.8 ± 6.3 
Electrostatic energy 
(kcal/mol) 
-478.8 ± 67.0 -293.6 ± 65.1 
Buried surface area (Å2) 1299.2 ± 78.2 1312.5 ± 48.7 
a Average r.m.s.d and standard deviation compared with the lowest energy structure within the 
cluster. 
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Figure 2.9  Structure models of the FBD-cyt c complex. A-B, two clusters of the lowest-energy structures 
of the FBD-cyt c complex generated from HADDOCK driven by NMR restraints. PDB 1AMO (cite) and PDB 
1AKK (cite) are used as the initial structures of FBD and cyt c in the docking. Heme molecule and 
cofactor FMN are presented by red and yellow sticks, respectively. C-D, surface representation of the 
two complexes in panel A-B. Interfacial residues involved in protein-protein contacts in the complex 
models are highlighted and color-coded based on properties of the amino acids. Polar neutral, nonpolar, 
positive and negative residues are colored cyan, magenta, orange and green, respectively. Heme and 
cofactor FMN are colored red and yellow, respectively. E-F, from panel C-D, FBD and cyt c are rotated 
around their vertical axes by 90° as indicated, in order to display the binding interfaces. Residues are 
identified with the single-letter amino acid code.  
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Table 2.4 Summary of hydrogen bonds/salt bridges in the FBD-cyt c binding interface 
Cluster I Cluster II 
FBD cyt c FBD cyt c 
Gln-87 Gln-12 Gln-87 Ile-85 
Glu-92 Lys-5 Glu-142 Gln-16 
Glu-93 Lys-86 Asp-147 Lys-13 
Glu-93 Thr-89 Glu-179 Lys-27 
Asp-208 Lys-13 His-180 Gln-16 
Asp-209 Lys-72   
Glu-213 Lys-87   
Glu-214 Lys-87   
 
 
2.5 Discussion 
2.5.1 Electron transfer between FBD and cyt c in comparison with CPR 
Our study reveals that the isolated FMN binding domain both in its one electron- and two 
electron-reduced redox states can reduce cyt c but at distinct rates (Table 2.1). The observation 
that one electron-reduced FMN binding domain is capable of reducing oxidized cyt c has been 
previously reported (11), even though the approach in the reported study of using NADPH to 
reduce the isolated FMN binding domain (11) cannot be achieved under our current experimental 
conditions. And the argument that no electron transfer occurs between two electron-reduced CPR 
and cyt c when CPR is reduced by dithionite (11) was proved otherwise in the present study. 
Considering the large redox potential differences between the semiquinone FBD (-68 mV) (40) 
and oxidized cyt c (250 mV) (41), the slow electron transfer rate between the two proteins (Kobs 
= 0.0227 s-1) implies that the process may be gated. One hypothesis is that hydrogen bonds 
between the semiquinone FMN cofactor and the FMN binding loop Gly-141-Glu-142-Gly-143 
effectively stabilizes the semiquinone form of the FBD, rendering high activation energy for the 
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electron transfer. Previous studies have shown that mutation of the Gly-61 in D. vulgaris 
flavodoxin, which is homologous to Gly-141 in CPR, destabilizes the semiquinone state and 
causes shifts of the midpoint potentials (42). Deletion of Gly-141 and/or Gly-143 leads to red 
semiquinone instead of blue semiquinone formation in one electron-reduced CPR and 
significantly alters the midpoint potentials of each redox state (data not published).  
A comparison of cyt c reduction by wild-type CPR and the isolated FMN binding domain 
(Table 2.1) reveals that FBD reduces cyt c in a rate significantly faster than the wild-type CPR, 
both in its one electron- and two electron-reduce states. Since the midpoint redox potentials of 
the isolated domain has been proved to be near identical to those of the intact CPR (11, 32) and 
the dissociation constants of CPR-cytc and FBD-cyt c are also largely the same, the contrast in 
the reaction rates probably attributes to the distinct accessibility of the FMN cofactor to cyt c. In 
the isolated FMN binding domain the cofactor FMN is partially exposed to the solvent (Figure 
2.8), while in the resting state CPR exists in a predominant “closed conformation” in which the 
FMN cofactor is in close proximity with FAD but buried in the interface between the FMN and 
FAD binding domains making it unfavorable to access cyt c (6, 43). A movement of the FMN 
binding domain relative to the rest of the CPR molecule is essential for electron transfer from 
CPR to its redox partners, the process of which might be regulated by nucleotide binding, redox 
states of the cofactors, solvent condition, et cetera (44-46). Electron transfer between one-
electron reduced CPR and cyt c is probably prohibited due to the “lock-up” of the FMN binding 
domain, while cyt c reduction by two electron-reduced CPR is likely to be gated by domain 
movement of the protein.  
2.5.2 Complex formation between FBD and cyt c 
It has been proposed that weak and transient complexes are commonly formed between 
electron transfer proteins to ensure high turnover rates (47). The relative orientation of two 
proteins in the complex can range from well-fined to highly dynamic (37).The latter is featured 
by an ensemble of various orientations interchanging among themselves in a fast exchange 
timescale. This results in overall averaged intermolecular effects observed in NMR experiments 
(e.g. chemical shift perturbations, Nuclear Overhauser Effects, Paramagnetic Enhancement 
Effects) in the complex and extensive binding sites. As shown in Figure 2.7 and Figure 2.8, the 
relative small scale of overall chemical shift perturbations and distribution of the affected 
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residues distant from the FMN cofactor suggests the existence of an ensemble of dynamic 
complexes. Such type of complexes were observed in a number of other electron transfer 
proteins, including adrenodoxin-cyt c complex (37), myoglobin-cyt b5 complex (20), cyt c-cyt 
b5 complex (21, 36) and plastocyanin-cyt f complex (48). They are usually formed between two 
proteins rich in complimentary charges and dominantly driven by long-range electrostatic 
interactions (47). However, most of the orientations involved in dynamic complexes are not 
optimized to facilitate interprotein electron transfer. Instead, one or more specific complexes 
need to form, which are usually characterized with a higher affinity of the two proteins and 
sufficient proximity of the redox centers, for efficient electron transfer. These complexes are 
represented by the structural models obtained from HADDOCK. 
The structure model of FBD-cyt c complex generated by HADDOCK reveals two 
probable orientations of complex formation between FBD and cyt c. The orientations of cyt c are 
almost perpendicular between the two structures with respect to FBD, resulting in overlapping 
but not identical interfaces. It is evident from the comparison that there is a higher proportion of 
electrostatic interaction involved in the binding interface of cluster I, while in cluster II 
hydrophobic interaction and/or van der Waals contact are predominant in the interface. A close 
look at the interfaces suggests several pairs of hydrogen bond and/or salt bridge formation (Table 
4), which attribute to the stability of the complex and aid in electron transfer. In the previous 
studies, it was reported that mutations on the acidic cluster composed of Glu-213, Glu-214, Asp-
215 leads to significant decrease in catalytic activity of both wild-type CRP and isolated FMN 
binding domain on cyt c reduction (13, 17). In the cluster I of our structural models, we observe 
salt bridge formation between Glu-213 Oε of FBD and Lys-87 N of cyt c as well as Glu-214 Oε 
of FBD and Lys-87 Nζ of cyt c, which probably plays a vital role in the binding and electron 
transfer between the two redox partners. Salt bridges can also form between Asp-208 Oδ of FBD 
and Lys-13 Nζ of cyt c as well as Asp-209 Oδ of FBD and Lys-72 Nζ of cyt c, consistent with the 
previous chemical crosslinking study (15) and prediction from putative docking (6). However, as 
reported, single mutation of Asp-208 or Asp-209 does not affect the cyt c reductase activity 
significantly (13, 17), implying that these salt bridges might not be as essential for the stability of 
the complex as those formed on Glu-213 and Glu-214. Single mutation on other negatively 
charged residues of FBD including Glu-142, Asp-133, Asp-147, Asp-207 and Asp215 also leads 
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to insignificant effect on cyt c reduction (13), which might be due to the abundant/excess 
electrostatic interactions between the two proteins. In addition to the distinguished salt bridges 
and hydrogen bonds, the complex is also stabilized by hydrophobic and van de Waals 
interactions (supplemental Table 2). In cluster II, only two salt bridges are observed – between 
Glu-147 Oδ  of FBD and Lys-13 Nζ of cyt c and between Glu-179 Oε of FBD and Lys-27 Nζ of 
cyt c, although single mutation of Glu-147 does not seem to affect the catalytic activity for cyt c 
reduction significantly (13).  
Cyt c has been widely used as a model redox partner of CPR.  The binding interface of 
CPR in the CPR-cyt c complex has been shown to be overlapping but somehow different from 
that between CPR and its physiological redox partner cytochrome P450 (12, 13, 15, 17, 19). Site-
directed mutagenesis studies reveal that mutation of Asp-208 of CPR significantly affects 
substrate turnover by cyt P450 (13, 17), the residue of which also turned out to be in the FBD-cyt 
c interface in the structural model. Residues 110-119, 118-130 of CPR are suggested to be 
involved in the interaction with cyt P450 by antipeptide antibody studies (19), while none of the 
residues are observed in the binding interface between FBD and cyt c. Mutating Asp-113, Glu-
115, Glu-116 in CPR was reported to influence the catalytic activity towards both cyt c and P450 
and suggested to alter electron transfer pathways between CPR and its redox partners. In our 
structural model, these residues are not involved in the binding interface between FBD and cyt c. 
However, Glu-116 shows significant chemical shift perturbations during titration of cyt c (Figure 
2.8) implying that it may be involved in the formation of nonspecific dynamic complexes which 
do not facilitate electron transfer. The proposed model allows us to draw comparison with CPR-
P450 complex and other electron transfer complexes involving CPR.  
In order to elucidate which residues are crucial for electron transfer, we use the program 
HARLEM (49) to predict the shortest electron transfer pathways between the two proteins. In 
cluster I, the predicted coupling pathway initiates at the C8M atom of the FMN cofactor, and 
continues via the Cα, C(O) and O of Lys-13 of cyt c consecutively until the conjugated heme ring 
(Figure 2.10A). The pathway suggests the importance of Lys-13 in mediating the electron 
transfer process. Lys-13 of cyt c locates in close proximity of the heme and forms a salt bridge 
with Asp-208 of FBD in the complex (cluster I). This residue is mostly conserved in cyt c among 
animals and plants, and has been observed to involve in the binding interfaces between cyt c and 
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other redox proteins including L-galactono-1,4-lactone dehydrogenase in plant mitochondria (38), 
cytochrome b5 (21) and cytochrome c oxidase (50). In cluster II, due to the short edge-to-edge 
distance between FMN and heme (1.9 Å), electron transfer is predicted to occur directly from 
C7M atom of FMN to the heme (Figure 2.10B).  
 
 
 
Figure 2.10  Electron transfer pathway predicted using HARLEM. Black dotted lines show the predicted 
electron transfer pathway for cluster I and II.  
 
2.6 Conclusion  
In summary, we characterized the kinetics of electron transfer from FBD to cyt c by 
stopped-flow spectroscopy and investigated the complex formation using solution NMR 
spectroscopy in conjunction with HADDOCK program. A comparison of cyt c reduction by FBD 
and wild-type CPR supports the key role of conformational gating on electron transfer from CPR 
to its redox partners. Our NMR results not only revealed the formation of dynamic complex 
between FBD and cyt c on a fast exchange time scale (Kd = 0.024 mM), but also identified the 
specific residues of FBD involved in the binding interface with cyt c. A structure model of FBD-
cyt c complex was generated using HADDOCK, unveiling two probable orientations of complex 
formation. The proposed model allows us to identify the potential interactions on the interface 
and to propose electron transfer pathway from FBD to cyt c. Combined kinetic and structural 
information presented in this study provides insights into the interaction between CPR and cyt c, 
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and will facilitate our further understanding of the mechanistic details on how electron transfer 
occurs from CPR to its redox partners. 
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CHAPTER 3 
 
Characterization of Electron Transfer and Interaction between the FMN binding domain 
of Cytochrome P450 Reductase and Cytochrome P450 
 
 
3.1  Summary 
Complex formation and electron transfer from cytochrome P450 reductase to cytochrome 
P450 is an essential step in cytochrome P450 catalysis, which is responsible for the metabolism 
of a dazzling array of endogenous and endogenous substrates. Here we report a study of the 
interaction between cytochrome P450 and the FMN binding domain of cytochrome P450 
reductase by solution NMR. NMR titration experiments reveal that binding of the two proteins 
occurs on a slow-to-intermediate time scale. Chemical shift perturbation and line broadening 
analysis identifies the epitope on the FMN binding domain recognized by cyt P450. 
Subsequently, a structural model was generated by HADDOCK (high ambiguity driven 
biomolecular docking) program based on NMR restraints and previous site-directed mutagenesis 
studies. The model reveals detail information on the binding interface, including the residues 
involved in direct binding and intermolecular interactions. Based on the structural model, a 
potential pathway was predicted involving Met-132 and Arg-133 of cyt P450.  
 
3.2  Introduction  
Cytochromes P450 (cyt P450) are a ubiquitous superfamily of oxygenases that are 
responsible for the metabolism of myriads of endogenous and exogenous compounds, including 
vitamins, steroids, hormones, environmental toxins and ~70% of marketed drugs. Microsomal 
P450s catalyze the oxidation of substrates using two electrons from the redox partners: 
cytochrome P450 reductase and cytochrome b5 (cyt b5). While the second electron can be 
donated by either cytochrome P450 reductase (CPR) or cyt b5, the first electron has to be 
delivered to cyt P450 by CPR due to the high redox potential of cyt b5 (≅ +25 mV) (1).  
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As an indispensable component in the cyt P450 catalysis, CPR is a ~78 kDa microsomal 
diflavin protein composed of multiple domains: an N-terminal transmembrane segment, the 
FMN binding domain (FBD), the connecting domain and the FAD/NADPH binding domain (2). 
It shuttles electrons from its physiological reductant NADPH, via the FAD and FMN cofactors, 
eventually to cyt P450. The FMN binding domain is the ultimate donor of electrons to the 
acceptor proteins. It is indicated that in its resting state CPR exists predominantly in a “closed 
and compact” form (3) resembling the crystalline structure (2), in which the two flavins are in 
van de Waals contact satisfactory for interflavin electron transfer but the solvent inaccessibility 
of FMN prevents inter-protein electron transfer to cyt p450. A large-scale domain movement is 
hypothesized to allow the access of cyt P450 to the reduced FMN cofactor (3), the process of 
which might be regulated by nucleotide binding, redox states of the cofactors, solvent condition, 
et cetera (4-6). Although most of the studies have been devoted to understand the role of CPR in 
cyt P450 catalysis, CPR also donates electrons to heme oxygenase (7), cytochrome b5 (8), 
cytochrome c (9) as well as therapeutic prodrugs (10).   
To get an insight into how CPR interacts with and transfer electrons to cyt P450, studies 
have been carried out using a number of methods including site-direct mutagenesis (11-14), 
enzyme kinetic assays (15-19), fluorescence (20-22), cross-linking (23, 24), FTIR (25), AFM 
(26), optical biosensor (27), chemical modification (28-32), etc. It has been postulated that the 
electrostatic interactions between the basic proximal surface of cyt P450 and the acidic surface of 
the FMN binding domain of CPR plays an crucial role in the formation of the cyt P450-CPR 
complex (11, 12, 17, 22). In particular, positively-charged lysine and arginine residues on cyt 
P450 and negatively-charged aspartic acid and glutamic acid residues on CPR were identified to 
be potentially located on the cyt P450-CPR binding interface by site-directed mutagenesis 
studies (11-13, 33-35). On the other hand, it is suggested that certain hydrophobic residues on the 
binding interface, e.g. Val-267 and Leu-270 of cyt P450 2B4, also contributes in mediating 
complex formation (13). A structural model of cyt P450-CPR has been proposed based on rigid 
docking between cyt P450 2B4 with an extended conformation of CPR with shortened linker 
region (36), which gives insight into some intermolecular interactions on the interface. However, 
to gain a better understanding of the interaction and electron transfer between the two proteins, a 
high-resolution mapping of the binding interface is essential.  
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A high-resolution structure of the cyt P450-CPR complex is lacking due to the difficulty 
in co-crystallizing the two proteins as a complex. This could attribute to either the nature of the 
transient complex or the conformational rearrangement in CPR required for interacting with cyt 
P450. Solution NMR has developed into a powerful tool for high-resolution mapping of protein-
protein interactions. In this study, we investigate the interaction between cyt P450 2B4 and the 
FMN binding domain of CPR, using solution NMR techniques. NMR titration experiments 
reveal that binding of the two proteins occurs on a slow-to-intermediate time scale. The results of 
chemical shift perturbation and line broadening analysis indicate the primary binding site of cyt 
P450 on FBD surrounding the solvent-exposed edge of the FMN cofactor. A structural model 
was generated by HADDOCK using the NMR data and previously published site-directed 
mutagenesis studies. It provides detailed information of the cyt P450-FBD binding interface and 
intermolecular interactions. Based on the structural model, a potential electron pathway was 
predicted involving Met-132 and Arg-133 of cyt P450.  
 
3.3  Materials and Methods  
3.3.1 Materials 
E. coli C41 cells for protein overexpression were purchased from Lucigen (Middleton, 
MI). Yeast extract, tryptone for unlabeled growth media were purchased from Sigma-Aldrich. 
[15N]ammonium chloride for M9 medium and D2O was purchased from Cambridge Isotope 
Laboratories (Andover, MA). Resins, buffer components, and all the chemicals were purchased 
from Sigma-Aldrich. Glycerol used in NMR experiments was purchased from Roche Applied 
Science.   
 
3.3.2  Expression and purification of proteins 
Uniformly 15N-labeled FMN binding domain of CPR (residue 1-239) (FBD), unlabeled 
cyt P450 2B4 (cyt P450) and wild-type cytochrome P450 reductase (CPR) were expressed from 
E. coli C41 cells and purified as described previously (cite FBD-cyt c)(11, 37). Each purified 
protein exhibited a single band on the SDS-polyacrylamide gel. The concentration of the 
oxidized FBD and CPR was determined using extinction coefficients of 12.2 mM-1cm-1 and 21 
mM-1cm-1 at 454 nm respectively (38). Cyt p450 concentration was quantified as described 
previously (39). 
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3.3.3  Pre-steady-state kinetics of cyt P450 reduction by FBD/CPR 
FBD and CPR were titrated with sodium dithionite solution under anaerobic conditions 
monitored by UV-Vis spectra. The stock solutions of FBD and CPR were incubated overnight at 
4 °C in an anaerobic Belle Technology glove box (Hi-Tech, Salisbury, UK) to remove oxygen. 
The titrant (sodium dithionite solution) was prepared in the glove box in oxygen-free buffer, and 
its concentration was calculated using an extinction coefficient of 8 mM-1 cm-1 at 315 nm. The 
titrand solution of FBD or CPR contains 10 µM of the protein, 100 mM potassium phosphate 
buffer, 5 % (w/v) of glycerol, pH 7.4. The titration was carried out in a home-made anaerobic 
titration apparatus to minimize contamination of oxygen, and monitored by UV-Vis spectrum. 
FBD/CPR was first titrated to two electron-reduced state. Oxidized cyt P450 (2 µM) was then 
introduced into the enclosed titration apparatus (isolated from the reductase) anaerobically. The 
apparatus was filled with carbon monoxide. Reaction was started by rapid mixing of FBD/CPR 
and cyt P450 solutions and monitored at 450 nm by UV-Vis absorbance. Traces were fitted using 
a standard single exponential equation (40). The buffer contains 100 mM potassium phosphate, 
5 % (w/v) glycerol, pH 7.4. 
 
3.3.4  NMR titration experiments 
All NMR experiments were performed on a Bruker Avance 900 MHz NMR spectrometer 
equipped with an x,y,z axis PFG-5mm TCI cryoprobe at 298K. Samples for NMR experiments 
contain 0.3 mM 15N-labeled FBD in 100 mM potassium phosphate buffer with 5% (w/v) glycerol 
at pH 7.4. Titration of unlabeled cyt P450 into 15N-labeled FBD was carried out by stepwise 
addition of cyt P450 solution corresponding to 0.3, 0.5, 0.7 and 0.9 molar equivalents of FBD. 
2D 15N TROSY-HSQC spectra were collected at each titration point with 32 scans and 144 t1 
increments. The average amide chemical shift perturbation (∆δavg) was calculated using the 
equation below 
 
∆𝛿avg = �(∆𝛿N × 𝑆𝑊2 𝑆𝑊1)2 + ∆𝛿H2 
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where ∆𝛿N and ∆𝛿H are changes in chemical shift observed between the bound and unbound 
states and 𝑆𝑊1  and 𝑆𝑊2  represent spectrum width of the first and second dimension 
respectively. All NMR spectra were processed using TopSpin 2.0 (Bruker). Resonance 
assignments and data analysis were performed using Sparky (41).  
 
3.3.5 Structural modeling of FBD-P450 complex 
HADDOCK 2.1 (42) program was utilized to calculate the structural models of FBD-
P450 complex based on defined ambiguous restraints. Crystal structure of FBD (PDB code 
1AMO) and cyt P450 2B4 (PDB code 1SUO/2Q6N) were used as the starting structures. Ligand 
and topology files were generated from the PRODRG server (43). 1000 structures were 
generated in the rigid body docking step, followed by simulated annealing of the 200 lowest-
energy structures from the last step and finally the best 50 structures were selected for solvent 
refinement in an 8.0 Ǻ shell of TIP3P water molecules. The resulting 50 final structures were 
analyzed and grouped into clusters based on the backbone r.m.s.d. values. Molecular structures 
of the complexes were viewed and graphed using PYMOL. 
 
3.4  Results 
3.4.1  Kinetics of cyt P450 reduction by FBD 
In order to assess catalytic activity of FBD, we investigated the ability of FBD to reduce 
cyt P450 under single turnover conditions and compared with the wild-type CPR. In this 
experiment, wild-type CPR and FBD were reduced to two electron-reduced states respectively 
prior to mixing with cyt P450. Lacking the FAD/NADPH binding domain, the isolated FMN 
binding domain cannot be reduced by the physiological reductant of CPR—NADPH. 
Alternatively, sodium dithionite was used to titrate FBD and wild-type CPR to the intended 
redox states. The reaction is initiated by rapid mixing of the pre-reduced reductase and and cyt 
P450. Since the binding between the ferrous cyt P450 and carbon monoxide is known to occur 
very fast (44-46), electron transfer from flavin to heme was monitored by the formation of 
Fe(II)-CO specie at 450 nm. As shown in Figure 3.1, mixing of the pre-reduced wild-type CPR 
and cyt P450 leads to the reduction of one molar equivalent of cyt P450 with a kobs of 0.06227 ± 
0.0002 min-1. This slow reaction rate coincides with the previous observation under similar 
conditions (44), and is significantly lower than what was observed in the reconstituted cyt P450 
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systems (44, 47). This is due to the fact the rate-limiting step of this reaction is random collision 
and complex formation between the two proteins driven by diffusion. Electron transfer from 
FBD to cyt P450 occurs three times faster than wild-type CPR, with a kobs of 0.195 ± 0.002 min-
1, implying either a faster diffusion rate due to the relatively smaller size of FBD or more 
productive complex formation between FBD and cyt P450.  
 
 
Figure 3.1 Cyt P450 reduction by the FMN binding domain/wild-type CPR. FBD/CPR (10 µM) was 
reduced to two electron-reduced states by stoichiometric titration with dithionite, and rapidly mixed 
with cytochrome P450 in the environment of carbon monoxide. The formation of Fe(II)-CO specie in cyt 
P450 was monitored at 450 nm.  
 
3.4.2  2D NMR titrations of cyt P450 to FBD 
The 2D 15N-1H HSQC spectrum and the backbone assignments of the FMN binding domain have 
been previously reported (48) and utilized in the current study. In order to gain insight of the 
protein-protein interaction between FBD and cyt P450, a series of two-dimensional 15N, 1H-
TROSY-HSQC spectra were recorded to monitor the titration of unlabeled cyt P450 to 15N-FBD. 
The stepwise addition of cyt P450 leads to significant line broadening of most of the residues in 
the spectrum of FBD (Figure 3.2). After titrating 0.3, 0.5, 0.7, 0.9 molar equivalent of cyt P450, 
the intensities of the resonances decreased averagely to 48%, 31%, 21%, 18% of those in free 
FBD, respectively. This suggests an intermediate-to-slow exchange on the NMR time scale 
between the free FBD and a fast-relaxing FBD-P450 complex (>80 kDa). For each residue, the 
extent of intensity decease highly depends on its mobility in free FBD and in the FBD-P450 
complex. As an example, residues at the N- and C- terminus of soluble domain of FBD (e.g. Val-
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64, Thr-236, Gly-237) exhibit much smaller decrease in peak intensity than those in the well-
structured region (e.g. Phe-83, Met-137 located in the middle of beta sheets), as shown in Figure 
3.3. Modest chemical shift perturbations were also observed for specific residues and analyzed 
for the first titration point.  
 
 
 
Figure 3.2  15N,1H-TROSY-HSQC spectra of FBD upon titration of cyt P450. The representative regions of 
the spectra are shown for free FBD and in the presence of 0.3, 0.5 and 0.7 molar equivalent of cyt P450. 
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Figure 3.3 Intensity decrease of FBD resonances upon titration of cyt P450. A, distinct rates of intensity 
decrease are shown for selected residues. The curves were fitted with a simple exponential decay 
function. B, location of the selected residues in the structure of FBD. Val-64, Thr-236 and Gly-237 are at 
the N- and C-terminus of the soluble FBD, and Phe-83, Cys-136 and Met-137 are in the middle of beta 
sheet structures.  
 
 
3.4.3  Mapping the cyt P450-binding epitope on FBD by NMR 
Chemical shift perturbation and line broadening in the backbone amides of FBD upon complex 
formation with cyt P450 were analyzed to help identify the epitope on FBD for binding cyt P450. 
A histogram (Figure 3.4A) depict the weighted amide chemical shift perturbations of FBD 
resonances in the presence of 0.3 molar equivalent of cyt P450, as compared to the free FBD.  
An average chemical shift change of 0.013 ppm was observed with a standard deviation of 0.007 
ppm (Figure 3.4A). The most significant chemical shift perturbations (Figure 3.4A, above the 
dash line) were observed on the residues mostly located on the loops following the C-terminus of 
the beta sheet structures, including Thr-90, Thr-139, Tyr-140, Gly-141, Gly-143, Thr-146, Lys-
176. These residues are located in close proximity of the FMN cofactor, which could be involved 
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in direct interaction with cyt P450 or affected by a change in FMN positioning upon binding to 
cyt P450. Distribution of chemical shift perturbation was mapped onto the surface representation 
of FBD (Figure 3.5A) according to the color code in Figure 3.4A. Among the solvent accessible 
residues, those which show modest chemical shift perturbations (Figure 3.4A, red, orange and 
pink) were found to mainly locate surrounding the solvent exposable edge of the FMN cofactor, 
which is the putative binding site on FBD for efficient electron transfer. Exceptionally, residues 
Lys-74 and Thr-76 which are distant from the FMN cofactor also show significant chemical shift 
changes, implying a potential non-productive secondary binding site for cyt P450.  
 
 
 
 
Figure 3.4  Chemical shift perturbation and line broadening analysis. Changes of weighted backbone 
amide chemical shifts (A) and percentages of intensity decrease (B) upon interacting with cyt P450 are 
presented. The molar ratio between FBD and cyt c is 1 : 0.3. The solid line represents the mean value of 
all measured residues, and the dash line represents one standard deviation beyond the mean value. The 
color codes are used to categorize the changes and map onto the structure of FBD in Figure 3.5.      
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Figure 3.5 Mapping the effect of cyt P450 interacting with FBD. A, residues of FBD that exhibit chemical 
shift perturbations upon interacting with cyt P450 are color coded according to the categories in Figure 
3.4: red for ≥ 0.02 ppm, orange for ≥ 0.013 ppm, pink for ≥ 0.006 ppm, and blue for < 0.006 ppm. B, 
residues of FBD whose intensity decrease upon complex formation are color-coded according to Figure 
3.4: orange for residues whose intensities decreased more than the average percentage, and blue for 
those less than average. For A and B, the molar ratio between FBD and cyt P450 is 1 to 0.3. C, residues of 
FBD whose resonances are broadened beyond detection upon complex formation with one molar 
equivalent of cyt P450 are colored red. The right panels are 90° rotation views of the left panels.  
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Intensity decrease is plotted as a function of FBD residue number in the presence of 0.3 
molar equivalent of cyt P450 (Figure 3.4B). All the residues with the most significant decrease in 
intensity (Figure 3.4B, above the dash line) are solvent inaccessible, except for Thr-90. This 
suggests that the main cause for the observed line broadening comes from an increase in 
correlation time upon complex formation. In order to assess the distribution of line broadening, 
residues with different extents of intensity decrease was mapped onto the structure of FBD 
(Figure 3.5) according to the color code in Figure 3.4B. Most of the residues on the surface of 
FBD do not show significant line broadening (Figure 3.4, blue) except several residues close to 
the solvent exposed edge of the FMN cofactor (Gln-87, Thr-90, Asp-113, Tyr-140, Gly-141, 
Lys-176, Thr-177) as well as a few residues distant from the FMN cofactor (Thr-76, Asn-79, 
Gly-106, Glu-221). These residues coincide with the ones showing significant chemical shift 
perturbations in Figure 3.4, and are likely involved in the interaction with cyt P450. As the 
titration of cyt P450 proceeds, line broadening for some residues becomes so severe that they 
start to disappear from the spectrum. When the molar ratio between FBD and cyt P450 reaches 1: 
0.9, the intensities of a number of residues decreased to the noise level (Figure 3.5, red). These 
residues cover a fairly large surface area surrounding the solvent exposed edge of FMN with the 
exception of a few residues located at the back side of the protein.  An overall examination of 
Figure 3.5 shows that the effect of complex formation on the chemical shifts and line broadening 
of FBD resonances is most pronounced for residues fringing the solvent exposed edge of FMN 
on the surface, implying the primary binding site of cyt P450 on FBD.  
 
3.4.4  Structural model of FBD-cyt p450 complex 
A structural model of FBD-cyt p450 was generated by a data-driven docking program 
HADDOCK (High Ambiguity Driven biomolecular DOCKing) (42). The FMN binding domain 
of a crystal structure of CPR (PDB code 1AMO) and a crystal structure of cyt P450 (PDB code 
1SUO) were used as the starting structures in HADDOCK calculations. The docking was driven 
under defined intermolecular ambiguous restraints including active and passive residues 
with >40% solvent-accessibility from both proteins. Solvent-accessible residues on FBD which 
show significant chemical shift perturbation upon complex formation are selected as the active 
ambiguous residues from FBD (Figure 3.5A, red and orange). Passive restraints for FBD are 
chosen from the surface residues which show above-average intensity decrease upon binding to 
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cyt P450 (Figure 3.5B, orange) but are not included in the active restraints. Active ambiguous 
restraints on cyt P450 were selected according to a site-directed mutagenesis study in which nine 
residues on cyt P450 are suggested to be involved in the binding interface with cytochrome P450 
reductase (11). No passive restraints were input for cyt P450. Active restraints which created 
violations in more than 45 out of the 50 final structures were removed. The refined restraint table 
was shown in Table 3.1 and applied in the docking program using the same protocol. The 
restraints were filtered once by carefully examining the results of a training run. Active restraints 
which created violations in more than 45 out of the 50 final structures were removed. The refined 
restraint table was shown in Table 3.1 and applied in the docking program. 
 
Table 3.1  List of restraints used in HADDOCK 
 FBD cyt P450 
   
Ambiguous 
restraints, active 
Thr-88, Thr-90, Tyr-140, Gly-141, 
Lys-176, Tyr-178, Glu-214 
Arg-122, Arg-126, Arg-133, Phe-
135, Met-137, Lys-139, Arg-422, 
Lys-433, Arg-443 
Ambiguous 
restraints, passive 
Gln-87, Asp-113, Thr-177, Glu-221  
 
Among 50 lowest-energy structures resulted from the docking, an ensemble of 41 structures 
forms a major cluster with an average backbone r.m.s.d. of 2.54 Å compared to the mean. The 
energy statistics of the cluster are summarized in Table3.2. The average intermolecular energies 
of the clusters is -568.4 kcal/mol, of which the major contribution comes from electrostatic 
energies (-534.8 kcal/mol), implying the importance of electrostatic interaction in the complex 
formation between FBD and cyt p450. A representative structure of the cluster is shown in 
Figure 3.6A. The isoalloxazine ring of the FMN cofactor and the porphyrin ring of heme are 
nearly perpendicular to one another, and the shortest edge-to-edge distance between heme and 
FMN is 12.4 Å, which is within the 14.0 Å limit predicted for efficient electron transfer (49). In 
order to elucidate which residues are essential for electron transfer between the two proteins, we 
use the program HARLEM (50) to predict the shortest electron transfer pathway in the presented 
structure. The result of HARLEM calculation suggests a coupling pathway (Figure 3.6B) 
involving the FMN cofactor, Met-132, Arg-133 and heme of the cyt P450. This pathway reveals 
the crucial role that Met-132 and Arg-133 of cyt P450 play in mediating electron transfer.  
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Figure 3.6  Structure model of the FBD-cyt P450 complex. A, a representative structure of the major 
cluster among the 50 lowest-energy structures generated from HADDOCK. PDB 1AMO and PDB 1SUO 
are used as the initial structures of FBD and cyt P450 in the docking. Heme and the FMN cofactor are 
presented by red and yellow sticks, respectively. B, electron transfer pathway predicted using HARLEM 
(50). Electron transfer initiates at C8 methyl group of the FMN cofactor, via the O, C, Cα, N atom of Arg-
133 and the C, Cα, Cβ, Cγ and Sδ atom of Met-132 on cyt P450 consecutively, and ends at the vinyl group 
of the heme.  Black dash lines show through-space tunneling of electrons.  
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Table 3.2  Statistic analysis of the 50 lowest-energy structures of the FBD-cyt P450 complex 
generated from HADDOCK  
 
Parameters  
Backbone r.m.s.d. (Å)a 2.54 ± 0.91 
Total intermolecular energy (kcal/mol) -568.4 ± 55.7 
van der Waals energy (kcal/mol) -33.6 ± 8.0 
Electrostatic energy (kcal/mol) -534.8 ± 58.5 
Buried surface area (Å2) 1818.5 ± 152.2 
a Average r.m.s.d compared to the lowest energy structure and standard deviation within the 
cluster. 
 
Table 3.3  Summary of hydrogen bonds/salt bridges in the FBD-cyt P450 binding interface 
FBD cyt P450 
Gln-87 (Oε) Arg-343 (Nη) 
Gln-87 (Nε) Glu-439 (Oε) 
Asp-113 (Oδ) Arg-422 (Nη) 
Glu-115 (Oε) Arg-422 (Nε) 
Glu-115 (Oε) Arg-422 (Nη) 
Glu-116 (Oε) Arg-422 (Nη) 
Asp-147 (Oδ) Arg-343 (Nε) 
Asp-147 (Oδ) Arg-343 (Nη) 
Thr-177 (Oγ) Asp-134 (Oδ) 
Thr-177 (O) Met-137 (N) 
Tyr-178 (Oη) Lys-139 (O) 
Asp-208 (Oδ) Arg-133 (Nη) 
Glu-213 (Oε) Arg-126 (Nη) 
Glu-214 (Oε) Arg-126 (Nη) 
FMN (O4’) Arg-133 (Nη) 
 
 
The binding interface in the FBD-cyt P450 complex model is shown in Figure 3.7.  
Residues on FBD which are involved in binding cyt P450 are mostly polar residues with 
negative/no charges. They are mainly located on the loops connecting the C-terminus of the beta 
sheets and N-terminus of the helices, including Gln-87, Thr-88 and Thr-90 on β1-α3 coil, Asp-
113, Glu-115 and Glu-116 on β2-α4 coil, Tyr-140, Gly-141 and Asp-147 on β3-α5 coil, Asn-175, 
Thr-177, Tyr-178 and Glu-179 on β4-α6 coil and Asp-208 and Asn-211 on β5-α7 coil. Other 
residues of FBD located on the helices, including Glu-93 on helix α3, Asn-148 and Gln-150 on 
helix α5, Glu-213 and Glu-214 on helix α7 are also involved in the binding interface according 
to the structural model. On the other hand, interface on cyt P450 is largely composed of 
positively charged and hydrophobic residues, including Arg-126, Leu-129, Ala-130 and Arg-133 
84 
 
on helix αC, Phe-135-Lys-139 on αC-αD loop, Leu-340, Arg-343 and Ala-344 on αJ-αK loop, 
Ala-416, Ala-419, Leu-420, Arg-422, Lys-433 and Leu-437 on αK-αL loop and Gly-440 and 
Arg-443 on helix αL. Polar residues with negative/no charges are also involved in the binding 
interface, including Asp-134 on helix αC, Ser-141 on αC-αD loop, Glu-143 and Glu-144 on 
helix αD, Asp-415 and Asn-417 on αK-αL loop and Glu-439 on helix αL. Salt bridge/hydrogen 
bond formation was observed in the complex model (Table 3.3).  
 
 
 
 
Figure 3.7  Binding interface of the FBD-cyt P50 complex. A, a surface representation of the FBD-cyt 
P450 complex. B, two proteins are rotated by 90° in opposite directions to reveal the interface. 
Interfacial residues involved in protein-protein contacts in the complex model are highlighted and color-
coded based on properties of the amino acids. Polar neutral, nonpolar, positive and negative residues 
are colored cyan, magenta, orange and green, respectively. Heme and cofactor FMN are colored red and 
yellow, respectively. 
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3.5  Discussion 
Our study reveals that the isolated FMN binding domain (FBD) in its two electron-
reduced state is able to transfer electron to cyt P450 at a rate three times higher than the wild-
type CPR. Under the described experimental conditions, productive complex formation by 
random collision is the rate limiting step of the inter-protein electron transfer. A higher rate of 
electron transfer between FBD and cyt P450 can attribute to two possible reasons: 1. FBD 
diffuses faster in solution due to its smaller hydrodynamic radius compared to CPR; 2. lacking 
the FAD/NADPH binding domain makes the FMN cofactor more solvent exposed in FBD, 
improving the chance of FMN to be in close proximity with heme for efficient electron transfer. 
Electron transfer between cyt c and FBD also occurs at a much higher rate than that between cyt 
c and wild-type CPR (see chapter II).  
We investigated complex formation between FBD and cyt P450 using solution NMR 
techniques. In the NMR titration experiments, chemical shift perturbation and line broadening 
were observed and analyzed to probe the potential binding interface (51, 52).  Significant line 
broadening observed on FBD resonances upon complex formation with cyt P450 attributes to a 
combination of increased correlation time due to the large size of cyt P450 and an interaction in 
slow-to-intermediate exchange time scale. Similar phenomenon was also observed in cyt b5-cyt 
P450 complex (51). As illustrated in Figure 3.7, the majority of the residues on FBD which are 
affected by complex formation with cyt P450 are located on the fringe of the solvent-exposed 
edge of FMN, suggesting the primary binding site for cyt P450. Among these residues, single-
site mutations of Thr-88, Asp-113 and Try-178 on FBD into Ala lead to decreased activities of 
the reconstituted cyt P450 system towards benzphetamine metabolism (data not published). 
There are a few other affected residues located in the opposite side of FMN, which may result 
from a potential secondary binding site or conformational perturbation.  
Previous studies have suggested the importance of electrostatic interaction in the complex 
formation between CPR and cyt P450 by chemical modification of charged residues on the two 
proteins and site-directed mutagenesis (11, 28, 33, 53). Increasing ionic strength has been shown 
to disrupt the interaction between CPR and various P450s by masking the charged residues (14).  
The result of our structure model generated by HADDOCK confirmed that the formation of a 
number of salt bridges between the acidic residues on FBD and the basic residues on cyt P450 
(Table 3.3), among which the majority of the intermolecular energy attributes to the charge-
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charge interaction between Asp-113, Glu-115, Asp-147, Asp-208 and Glu-214 from FBD and 
Arg-126, Arg-133, Arg-343, Arg-422 from cyt P450. Asp-113 and Glu-115 are located on 
the β2-α4 coil in FBD, which was proposed to be a potential binding site for cyt P450 by 
chemical modification (53) and antipeptide antibody inhibition studies (29). These two residues 
are conserved through all mammalian and yeast CPRs. Mutations of Asp-113 and Glu-115/116 
affected the stability of the CPR-cyt P450 2B1 complex (14), implying they are important 
contact sites in complex formation. Asp-208 of CPR plays a crucial role in interaction and 
electron transfer between CPR and cyt P450, mutation of which renders significant decrease in 
P450 activity (35, 54). The importance of Asp-147 and Glu-214 of CPR was also investigated by 
previous site-directed mutagenesis study. Mutating Asp-147 in FBD of human CPR into serine 
leads to 20-30% decrease in cyt P450 2D6 activity, while removing the charge of Glu-214 only 
seems to affect cytochrome c reduction but not cyt P450 2D6 activity (35). On the other hand, 
Arg-126, Arg-133 and Arg-422 have shown to be involved in interacting with cyt P450 2B4 by 
mutagenesis studies (11), while mutation of Arg-122 was also found to decrease the ability of cyt 
P450 to bind CPR we do not observe Arg-122 to be on the binding interface in our structural 
model. In addition, hydrogen bonds between Thr-177, Tyr-178 and FMN from FBD and Glu-134, 
Met-137, Lys-139 and Arg-133 from cyt P450 along with hydrophobic and van de Waals 
interactions also contribute to the stability of the FBD-cyt P450 complex. The best electron 
transfer pathway predicted by HARLEM involves Met-132 and Arg-133 of cyt P450. It has been 
reported that mutation of Asp-133, out of nine positively charged residues on the surface of cyt 
P450, leads to the greatest reduction in the affinity with CPR (11). 
 
A previous structural model of the CPR-cyt P450 complex has been reported by Hamdane et al 
(36), generated by rigid body docking between an open conformation of CPR and cyt P450 2B4.  
The binding interfaces on FBD and cyt P450 proposed in this model are largely overlapping with 
what we observed in our NMR results as well as in our structural model. The most notable 
difference between our structural model and the previous proposed one is the relative orientation 
of the two proteins. The orientation of FBD in our structural model is rotated by approximately 
90° around the axis perpendicular to the heme pophyrin ring of cyt P450 with respect to the 
previously proposed model. Therefore, the interactions between specific residues on the binding 
interface in our model, including hydrogen bonds, salt bridges and van de Waals contacts, differ 
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from the reported model, except the salt bridge formed between Asp-208 of FBD and Arg-133 of 
cyt P450. The difference in protein orientation could be a consequence of different starting 
structures utilized in the docking. Hamdane et al generated the model using a partially open 
conformation of CPR in which the FMN cofactor is solvent exposed while the relative 
orientation of the FMN binding domain is restrained with respect to the rest of CPR. Unlike the 
isolated FMN binding domain, the steric hindrance imposed by the FAD/NADPH domain or the 
interaction between the FAD/NADPH domain and cyt P450 (as suggested by the model) might 
alter the orientation of FBD with respect to cyt P450 during the docking process.  
On the other hand, there is a possibility that isolated FMN binding domain interacts with 
cyt P450 in a different orientation compared to the wild-type CPR in vitro, due to its lack of 
restraints from the FAD/NADPH domain. It has been reported that CPR exists in a predominant 
“closed conformation” in the resting state, in which the domains are arranged in a way that the 
FMN cofactor is buried in the interface between the FMN and FAD/NADPH binding domains 
(2, 3). A movement of the FMN binding domain relative to the rest of the CPR molecule is 
essential for electron transfer from CPR to its redox partners (4-6). However, in an extended 
conformation of CPR, it remains unknown whether the FBD tumbles nearly isotropically in 
solution and samples a number of orientations on the surface of cyt P450 searching for an 
optimal contact for electron transfer or the FMN binding domain and FAD/NADPH domain 
collectively interact with cyt P450 restraining the orientations the FBD can adopt for binding cyt 
P450. In the latter case, it may occur that the wild-type CPR interacts with cyt P450 differently 
from the isolated FBD, which also leads to an alternative electron transfer pathway.  
 
3.6  Conclusion 
In this study, we investigated the interaction between the FMN binding domain of CPR 
and cyt P450 by solution NMR. Specific residues of FBD involved in the binding interface with 
cyt P450 were identified by chemical shift perturbation and line broadening analysis. A structural 
model of FBD-cyt P450 complex was generated using HADDOCK based on the NMR data and 
previous site-directed mutagenesis studies. The proposed model allows to identify the potential 
interactions including salt bridges, hydrogen bonds and van de Waals contacts on the interface 
and residues that are important for complex formation. An electron transfer pathway was 
predicted using HARLEM, which involves mediation via Met-132 and Arg-133 of cyt P450.   
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CHAPTER 4 
Interaction between the Transmembrane Domains of Cytochrome P450 and Cytochrome 
P450 Reductase by solid-state NMR 
4.1 Summery  
Structure and dynamics studies of membrane proteins are essential to better understand 
their physiological function. Solid-state NMR spectroscopy is a powerful tool for high-resolution 
structural studies of membrane proteins. In this chapter, we characterized the structure and 
dynamics of the transmembrane domain of cytochrome P450 reductase (CPR) in native 
membrane-like environment by solid-state NMR techniques in conjunction with spectra 
simulation. Our results reveal that the N-terminal transmembrane domain of CPR adopts an α-
helical conformation in the lipid environment. Most notably, we show that the transmembrane 
helix is tilted approximately 13° from the lipid bilayer normal, and exhibits motions on 
submillisecond time scale including rotational diffusion of the whole helix and fluctuation of the 
helical director axis. Using the same approach, we also investigated the interaction between the 
FMN binding domain of CPR and cytochrome P450 (cyt P450) in the lipid environment. Our 
results show clear evidence of the interaction between the soluble domains of the two proteins in 
the lipid bicelles, and suggest transient interplay between their transmembrane helices.  
4.2 Introduction 
Approximately 75% of the pharmaceuticals in use today are metabolized by a group of 
heme-containing monooxygenases known as the cytochrome P450 superfamily. These enzymes 
are responsible for the metabolism of myriads of endogenous compounds including vitamins, 
steroids and hormones, as well as exogenous compounds including environmental toxins and 
drugs. Cyt P450s catalyze a variety of chemical transformations by activating stable carbon-
hydrogen bonds of alkanes using oxygen and electrons from their redox partners. Due to the 
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strong and versatile oxidizing capability of cyt P450, they are referred to as “mother nature’s 
blowtorch”.  
Cytochrome P450 reductase (CPR) is an essential redox partner of microsomal cyt P450s, 
which shuttles electrons from NADPH to cyt P450s. Additionally, CPR plays an indispensable 
role in the development of high-level organisms; it is also able to reduce cytochrome c, 
cytochrome b5 and heme oxygenase as well as a variety of therapeutic prodrugs (1-5). CPR is a 
multi-domain membrane protein composed of a soluble 70 kDa carboxyl terminal catalytic 
domain, a 5 kDa amino terminal transmembrane segment, and a 2 kDa linker connecting these 
two domains. The soluble domain of CPR, the structure of which has been characterized by X-
ray crystallography (6, 7), can be further divided into the FAD/NADPH binding domain and the 
FMN binding domain. However, the structures of the transmembrane and the linker region 
between the soluble and transmembrane domains remain unidentified. Electron transfer pathway 
originates from NADPH, which transfers a hydride ion to the cofactor FAD, which proceeds to 
donate the electrons to the cofactor FMN. The FMN binding domain is the ultimate donor of 
electrons to cyt P450s and other protein acceptors.  
It has long been postulated that the transmembrane domain of CPR plays a vital role in 
aiding electron transfer between CPR and cyt P450 (8-10). Lacking the transmembrane anchor, 
CPR is still able to reduce cytochrome c and other artificial acceptors, but is impaired to transfer 
electrons to cyt P450 (6). Truncation of the N-terminal segment leads to a severe 
decrease/prohibition of substrate turnover in a reconstituted cyt P450 system (8). However, the 
mechanism on how the transmembrane domain affects the cyt P450/CPR interaction and 
catalysis remains under debate. It is generally believed that the transmembrane domain of CPR 
anchors the enzyme on the surface of the membrane constraining the diffusion of the catalytic 
soluble domain and mediating the CPR/cyt P450 interaction in proper orientation (9). Other 
hypothesis has been raised that the N-terminal transmembrane domain of CPR in its free form 
can alter diffusive reduced oxygen species dynamics, thus affect the substrate catalysis (8). A 
complete understanding of the physiological function of the transmembrane domain requires a 
thorough characterization of its structure and dynamics in a lipid membrane environment. 
Despite postulations of its secondary structure (10-13), the atomic-level structure of the 
transmembrane domain has not been revealed experimentally since the first structure of the 
soluble domain of rat CPR was reported in 1997 by X-ray crystallography (6). The major 
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difficulty lies in the hydrophobicity and mobility of the transmembrane domain preventing it 
from co-crystalizing with the soluble domain.  
Interaction between CPR and cyt P450 has been studied with a number of methods 
including site-direct mutagenesis (14-17), enzyme kinetic assays (17-23), fluorescence (24, 25), 
cross-linking (26, 27), FTIR (28), AFM (29), optical biosensor (30), chemical modification (31-
35), etc.; however, detailed structural information on this protein complex, especially in the 
membrane-bound form, is still deficient. In particular, evidence of the interaction between the 
two transmembrane domains and their roles in the formation of the complex is elusive (8, 36, 
37). This is partially due to the fact that studying protein-protein interactions in lipid membrane 
environment remains a challenge, in spite of previous efforts (38-40).  
Solid-state NMR spectroscopy is a powerful approach to probe the structure and 
dynamics of insoluble, non-crystalline or amorphous biomolecules like membrane proteins. It 
has been applied as a unique tool to probe conformation and dynamics of large biomolecular 
complexes in native-like lipid bilayers (41, 42) either under magic angle sample spinning (MAS) 
conditions or in uniformly aligned samples. In this chapter, we first probed the structural and 
dynamic features of the N-terminal FMN binding domain of CPR – including the transmembrane 
domain and linker region – in a native-like membrane environment, using a combination of one-
dimensional cross polarization (CP) and two-dimensional separated local field (SLF) solid-state 
NMR techniques in conjunction with spectral simulations. And later, we investigate the 
interaction of the membrane-bound FMN binding domain (FBD) with cytochrome P450 2B4 (cyt 
P450) in the lipid environment using the same approaches. The results reveal the characteristics 
of the interaction between the soluble domains as well as the transmembrane domains of FBD 
and cyt P450.   
 
4.3 Materials and Methods 
4.3.1 Materials  
E. coli C41 cells for protein overexpression were purchased from Lucigen (Middleton, 
MI). Yeast extract, tryptone for unlabeled growth media were purchased from Sigma-Aldrich. 
[15N]ammonium chloride for M9 medium and D2O was purchased from Cambridge Isotope 
Laboratories (Andover, MA). 1,2-dilauroyl-sn-glycero-3-phosphatidylcholine (DLPC) and 1,2-
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dihexanoyl-sn-glycero-3-phosphatidylcholine (DHPC) were purchased from Avanti Polar Lipids, 
Inc. (Alabaster, AL). 
 
4.3.2 Expression and purification of proteins 
 Expression and purification of a uniformly 15N labeled membrane-bound FMN binding 
domain of rat CPR and unlabeled cytochrome P450 2B4 was carried out as described in Chapter 
3 and Chapter 4.  
 
4.3 3 Preparation of bicelles 
  35.95 mg DLPC, 6.55 mg DHPC and 2.23 mg cholesterol corresponding to a molar ratio 
of [DLPC]:[DHPC]:[cholesterol]=4:1:0.4 were co-solubilized in chlorofosrm. Solvent was 
removed under a stream of N2 gas to produce a lipid film on the walls of a glass vessel, which 
was kept in vacuum overnight to remove any residual solvent. 21.3 μl of 40 mM phosphate 
buffer, pH 7.4, with 5% (w/v) glycerol was added to lipids. The resulting mixture of extreme 
viscosity was homogenized by vortexing, and freeze/heat cycles between 0 °C and room 
temperature for 5-8 times until the bicelles look transparent and homogenous. Protein was added 
in the final step of the preparation. Addition of 2.5 mg or 92.6 nmol protein in 65 µL 40 mM 
phosphate buffer, pH 7.4, with 5% (w/v) glycerol into the bicelle mixture resulted in a protein: 
DLPC molar ratio of 1:625. The homogeneously mixed sample was packed in a flat-bottom glass 
tube and used for subsequent NMR experiments. Prior to NMR measurements, the sample inside 
the probe was treated with a minimum of 3 cooling/heating cycles between 7 and 25 °C to ensure 
homogenous alignment of bicelles (43). Hydrogen-deuterium exchange experiment was carried 
out on a sample with membrane-bound FMN binding domain incorporated in 
DLPC/DHPC/cholesterol bicelles prepared following the protocol descried above. The sample 
was placed under a stream of N2 gas to remove H2O until three fourth of the total sample volume 
remained. Equivalent amount of the D2O (one fourth of the total sample volume) was added into 
the sample and mixed until homogeneous by vortexing. After 10 cycles of H2O evaporation/D2O 
addition, the sample tube was sealed and the sample was transferred to the magnet for 
subsequent NMR experiments. 
 
4.3.4 NMR experiments 
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All one-dimensional 31P and 15N spectra were obtained from a 600 MHz Bruker NMR 
spectrometer using a home-built 5 mm electric-field-free flat-coil probe. 31P spectra were 
obtained using a one pulse sequence with a recycle delay of 3 s and 25 kHz proton decoupling 
during 31P signal acquisition. 15N spectra were obtained using RINEPT and CP pulse sequences 
with a recycle delay of 3.5 s and 55 kHz proton decoupling during 15N signal acquisition. In 
RINEPT experiments, refocusing delays of 1.3 and 0.65 ms were used before and after a pair of 
90° pulses, respectively. In the cross polarization experiments, CP contact time was varied from 
0.05 ms to 2 ms. The two-dimensional Separated Local Field (SLF) spectrum was obtained on a 
720 MHz Varian NMR spectrometer under static conditions using a SAMPI4 sequence with 0.5 
ms cross polarization contact time and 25 kHz SPINAL (Small Phase Incremental Alternation) 
decoupling of protons. The spectrum was acquired with 28 t1 increments, 25 ms acquisition 
time, 2000 scans and a 2.5 s recycle delay, resulting in a total experimental time of 39 hours. A 5 
mm electric-field-free double-resonance static probe (home-built) (44) was used to prevent 
sample heating. All experiments were recorded at 20 °C.   
 
4.3.5 Helical wheel fitting  
A list of resolved peaks from the SLF spectrum was extracted as pairs of 15N chemical 
shift and 15N-1H dipolar coupling values and arranged to fit into the helical wheels by using a 
home-written program in which the helical wheel patterns are predicted by geometrical 
calculations (45). 
 
4.4 Results 
4.4.1 Reconstitution of FBD into bicelles and regional assignment of one-dimensional 15N solid-
state spectra 
In this study, experiments were performed on a uniformly 15N-labeled membrane-bound 
FMN binding domain (FBD) in bicelles composed of DLPC/DHPC/cholesterol, the schematic of 
which is shown in Figure 4.1A. The single band on the SDS-PAGE gel reveals the purity of the 
protein (Figure 4.1B). The bicelles magnetically align with the lipid bilayer normal perpendicular 
to the external magnetic field B0, as confirmed by the static 31P NMR spectrum (Figure 4.1C).  
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Figure 4.1  (A) A schematic of FBD with its N-terminal TM  domain incorporated in lipid bilayers. (B) SDS-
PAGE gel of FBD. (C) Proton-decoupled 31P chemical shift spectra of DLPC/DHPC/cholesterol bicelles 
containing FBD. The narrow peaks for DLPC and DHPC demonstrate a high degree of alignment of 
bicelles. The peaks at 0 ppm and -2.5 ppm are from phosphorous atoms on FMN.  
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One-dimensional 1H-15N cross polarization (CP) experiment gives rise to distinct profiles 
in the 15N spectra of FBD. The resonances distribute in two different chemical shift regions — 
70-100 ppm and 100-140 ppm (Figure 4.2A-C, Figure 4.3B-E). In order to distinguish 
resonances from the soluble and transmembrane domains, we utilize the approach of hydrogen-
deuterium (H/D) exchange to suppress the 15N signals from the solvent-accessible residues. After 
5 hours of H/D exchange, 15N spectra of FBD shows only resonances from 70-100 ppm chemical 
shift region, suggesting resonances from this region correspond to the solvent-inaccessible 
residues which are probably located in the transmembrane domain embedded in the lipid 
bicelles. In comparison, resonances in 100-140 ppm chemical shift region show drastic reduction 
of intensities upon H/D exchange, implying that they might correspond to residues from the 
soluble domain. Similar phenomenon of segmented chemical shift regions for the soluble and 
transmembrane domains of a membrane protein is also observed in cytochrome b5 (42, 46). A 
longer time exposure of the FBD to D2O leads to further reduction of 15N signals (Figure 4.2C) 
in both 100-140 ppm and 70-100 ppm regions possibly due to dynamics of the bicelles.   
 
Figure 4.2  Hydrogen/Deuterium exchange spectra of FBD. 15N NMR spectra were obtained using 
ramped cross-polarization (CP) with a contact time of 0.5 ms before (A) H/D exchange, 5 hours (B) and 
17 hours (C) after H/D exchange. 
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Figure 4.3   15N NMR spectra of FBD were obtained using RINEPT (A) and ramped cross-polarization (CP) 
with a contact time of 2.0 ms (B), 1.0 ms (C), 0.4 ms (D), 0.1 ms (E). The RINEPT spectrum (A) shows 
spectral intensity only in the 100-140 ppm region, indicating the high mobility of the soluble domain. 
Resonances in the 70-100 ppm region in the CP spectra (B-E) are assigned to the immobile TM domain. 
Buildup curves (F) were measured for resonances at 93.5 ppm (black) and 128.4 ppm (red) representing 
the two chemical shift regions corresponding to two different domains. 
101 
 
4.4.2 CP dynamics revealing distinct characteristics of the soluble and transmembrane domains 
of FBD 
In order to achieve optimal intensities of 15N resonances, one-dimensional 15N spectra 
were recorded with different 1H-15N polarization transfer schemes and varied cross polarization 
(CP) contact times. In the series of 15N CP spectra (Figure 4.3B-E), the overall relative intensities 
in the two chemical shift regions —70-100 ppm and 100-140 ppm— change when CP contact 
time is varied to control the extent of magnetization transfer from 1H to 15N nuclei. The 
appearance of peaks in the 70-100 ppm region even for a short CP contact time (Figure 4.3E) 
indicates that these signals arise from immobile residues of the protein, most likely from the 
transmembrane domain. Use of longer CP contact times (Figure 4.3B-D) allows the 
magnetization to transfer not only to the rigid transmembrane  region (70-100 ppm) but also to 
some relatively mobile residues in  the soluble domain of the protein, which gives rise to signals 
in the 100-140 ppm region. These observations support our assignment from the results of the 
H/D exchange experiment. 15N refocused-INEPT (RINEPT) experiment was employed to detect 
the mobile region of the protein (42, 46, 47). In the RINEPT spectrum (Figure 4.3A), peaks in 
the 70-100 ppm region arising from the transmembrane domain are significantly suppressed 
while most peaks from the soluble domain region (100-140 ppm) are present. This difference is 
due to the fast dephasing of the transverse magnetization from the transmembrane domain 
residues during the evolution and refocusing delays in RINEPT, caused by strong 1H-15N and 1H-
1H dipolar couplings. An increase of the CP contact time (Figure 4.3B-C) increases the signal 
intensity for the soluble domain (100-140 ppm) but decreases that for the transmembrane domain 
(70-100 ppm) due to T1ρ relaxation. This observation also indicates that motions in the 
transmembrane domain are more restricted than in the soluble domain.  
Dynamics are crucial for the physiological function of a protein and for protein-protein 
interactions. Parameters characterizing protein dynamics can be extracted from CP build-up 
curves. The buildup rates of peak intensities at 93.5 and 128.4 ppm are different indicating the 
significant difference in the dynamics between the transmembrane and soluble domains (Figure 
4.3F). Typical behavior of CP buildup was observed at 93.5 ppm—intensity build-up during 
short CP contact time dominated by 1H-15N polarization transfer due to dipolar interaction and a 
loss of magnetization after saturation due to T1ρ. Conversely, the peak at 128.4 ppm builds up 
slowly and does not decay with the increasing CP contact time, indicating the effect of a smaller 
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dipolar coupling due to faster dynamics in the soluble domain. Fitting the CP build-up curves 
using Eq. 1 provided a crude measurement of proton spin-lattice relaxation time in the rotating 
frame (T1ρH) and the polarization transfer time-constant (TNH) (48) for the transmembrane  
domain (at 93.5 ppm), which are 1.61 ±0.36 ms and 0.26 ± 0.05 ms, respectively. These two 
relaxation parameters reflect submillisecond timescale motions of the corresponding residues, 
which may include rotational diffusion of the whole helix and fluctuation of the helical director 
axis, and thus can be used to indicate changes in the dynamics of the transmembrane domain 
upon changes in the lipid membrane composition or interaction with other proteins. This is 
demonstrated here by using a lipid composition of DLPC/DHPC. The removal of cholesterol 
from bicelles increases the dynamics of the transmembrane domain as reflected by a longer T1ρH 
value of 2.08 ± 0.57 ms at 93.5 ppm (data not shown). This probably attribute to the effect of 
cholesterol on the rigidity of the lipid membrane, which in turn might affect the rotational 
diffusion of the transmembrane helix.  
      
4.4.3 SLF experiment and simulation of helical wheels reveal the conformation and tilt angle of 
the FBD transmembrane domain 
Two-dimensional (2D) separated local field (SLF) spectra, which correlate 15N chemical 
shift with 1H-15N dipolar coupling, were obtained to characterize the structure and further 
investigate the dynamics of the transmembrane domain (Figure 4.4). In the frequency region 
assigned to the transmembrane domain (70-100 ppm) in 1D 15N spectra, a discernible circular 
wheel-like pattern of resonances was observed, which is unique for proteins with an α-helical 
conformation. This is the first experimental evidence of an α-helical secondary structure for the 
transmembrane domain of CPR, agreeing with some of the postulations in the literature (11-13). 
In the region assigned to the soluble domain (100-140 ppm), we also observed resonances with 
small dipolar coupling values, suggesting a weak alignment of the soluble domain in the bicelle 
environment. 
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Figure 4.4  2D 15N separated-local-field solid-state spectrum of uniformly 15N labeled MFBD 
incorporated in DLPC/DHPC/ cholesterol bicelles. This spectrum was collected with a 0.5 ms CP contact 
time and 25 kHz SPINAL16 decoupling. 
 
In order to further characterize the orientation and dynamics of the transmembrane helix, 
we performed a spectral simulation to fit the observed resonances into a helical wheel pattern. 
Simulations demonstrate the sensitivity of the wheel patterns to the helix tilt angle (with respect 
to membrane normal) and the order parameter (Figure 4.5A-C). The best-fit helical wheel 
(Figure 4.5D-E) indicates an average tilt angle of 13°±2° (49) and the overall order parameter S 
of 0.80. The order parameter reflects a collection of motions that the α-helix exhibits in the lipid 
bilayer, ranging from rotational diffusion to fluctuation of the helical director axis, the schematic 
of which is shown in Figure 4.5F. Similar tilt angle and order parameter have also been observed 
for the transmembrane domain of cytochrome b5 (42, 45). As shown in Figure 4.5D-E, no single 
wheel can fit all the resonances in the circular pattern, implying nonideality of the 
transmembrane helix. Additional experiments using selectively labeled FBD will be carried out 
to assign the spectra and to study FBD-P450 interaction.  
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Figure 4.5  Simulated helical wheels showing the sensitivity of the wheel pattern to the indicated tilt 
angle. (D & E) Fitting of the observed resonances in the SLF spectra of FBD (blue circles) with different 
tilt angles and order parameters. The tilt angle used in (D) is 13° with order parameters S of 0.6 (red), 0.8 
(black), 1.0 (purple). The order parameter used in (E) is 0.8 with varied tilt angles: 11° (orange), 12° 
(purple), 13° (black), 14° (green) and 15° (blue). The best-fitting wheel indicates an average helical tilt 
angle of 13° and an order parameter S of 0.8 (F). 
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4.4.4 One-dimensional 15N solid-state spectra and CP dynamics of FBD-P450 complex  
In order to investigate the interaction between FBD and cyt P450, experiments were 
performed on a uniformly 15N-labeled FBD incorporated in magnetically aligned 
DLPC/DHPC/cholesterol bicelles in the presence of equal molar unlabeled cyt P450. Alignment 
of the bicelles is confirmed by the static 31P spectra shown in Figure 4.6. One-dimensional 15N 
spectra of the complex were recorded with varied cross polarization (CP) contact times (Figure 
4.7, red) and compared with those of free FBD (Figure 4.7, black). In the series of 15N CP 
spectra, the resonances of FBD distribute into two chemical shift regions — 70-100 ppm region 
corresponding to residues from the transmembrane domain and 100-140 ppm region 
corresponding to those from the soluble domain as described above. We observe differences in 
the line shape and intensities of the FBD resonances (Figure 4.7, red and black), implying 
changes in dynamics and/or orientation of FBD due to interaction with cyt P450. In the soluble 
domain region (100-140 ppm), it is evident that the signal intensities of FBD in the presence of 
cyt P450 have a faster buildup and decay rate with respect to CP contact time compared with 
those of free FBD. This observation indicates that motions in the FBD soluble domain are more 
restricted as a consequence of interaction with cyt P450, which leads to stronger dipolar coupling 
and thus more efficient polarization transfer and faster relaxation. In the transmembrane domain 
region (100-140 ppm), differences between the 15N spectra of cyt P450-bound and unbound FBD 
are less pronounced; therefore, CP build-up curves were analyzed and compared between these 
two cases.  
 
Figure 4.6  Proton-decoupled 31P chemical shift spectra of DLPC/DHPC/cholesterol (molar 
ratio=4:1:0.4) bicelles containing 1:1 molar ratio of FBD and cyt P450. The narrow peaks for DLPC and 
DHPC demonstrate a high degree of alignment of bicelles. The peak at around 0 ppm is due to 
phosphate buffer. 
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Figure 4.7  1D 15N NMR spectra of uniformly 15N-labeled FBD of CPR in the presence (red) and absence 
(black) of cyt P450 at molar ratio of 1:1. Spectra were recorded using ramped CP with a contact time of 
0.1 ms (A), 0.4 ms (B), 0.7 ms (C), 1.0 ms (D), 1.5 ms (E), 2.0 ms (F). The differences between the spectra 
of cyt P450-bound FBD (red) and of free FBD (black) reflect changes in structure and dynamics of FBD 
due to cyt P450-FBD interaction. An evidently faster buildup rate of intensities in the 100-140 ppm 
region implies significant increased rigidity in the soluble domain of MFBD when bound to cyt P450.  
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Distinct buildup profiles of the transmembrane domain (Figure 4.8 A-C) and the soluble 
domain (Figure 4.8 D-F) demonstrate marked differences in the dynamics between the two 
domains. The transmembrane domain resonances have apparently faster buildup and decay rates 
than the soluble domain, suggesting higher rigidity of the transmembrane domain. Fitting the CP 
buildup curves using equation (1) provides the proton spin-lattice relaxation time in the rotating 
frame (T1ρH) and polarization transfer time-constant (TNH) (48) where I(0) denotes the initial 
peak intensity.  For the soluble domain resonances (Figure 4.8 D-F), accurate T1ρH and TNH 
values cannot be drawn from the fitting due to insufficient T1ρH relaxation during the 
experimental CP contact times. However, it is clear that intensities build up and decay faster in 
the presence of cyt P450 (Figure 4.8D-E, red) than in its absence (Figure 4.8D-E, black), 
implying an interaction between the soluble domains of MFBD and cyt P450. T1ρH and TNH 
values for the transmembrane domain resonances are summarized in Table 1. In comparison, 
FBD interaction with cyt P450 leads to slight increase in the T1ρH values, suggesting enhanced 
dynamics in the transmembrane domain of FBD on the submillisecond time scale (48).  
 
 
 
Figure 4.8  Build-up curves of resonances in the transmembrane domain region (83.8 ppm (A), 87.4 ppm 
(B), 93.5 ppm (C)) and the soluble domain region (120.7 ppm (D), 123.4 ppm (E), 128.4 ppm (F)) for the 
free MFBD (black) and cyt P450-bound MFBD (red). The intensity scales were set arbitrary but identical 
for all curves. Curves were fit into equation (1) to obtain dynamic parameters T1ρH and TNH.  
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Table 4.1 TNH and T1ρH values for the transmembrane domain resonances of MFBD calculated 
from 1D 15N CP buildup curves of free MFBD and cyt P450-bound MFBD 
 
 
peaks (ppm) 
TNH (ms) T1ρH (ms) 
Free MFBD P450-bound 
MFBD 
Free MFBD P450-bound 
MFBD 
83.8 0.26±0.02 0.18±0.04 1.33±0.12 2.39±0.59 
87.4 0.25±0.05 0.20±0.05 1.58± 0.30 1.84±0.47 
93.5 0.26±0.06 0.23±0.03 1.61±0.36 1.86±0.29 
 
 
4.4.5 SLF experiment on the FBD-P450 complex and simulation of helical wheels  
In order to further investigate the effect of FBD-cyt P450 complex formation on the 
structure and dynamics of the transmembrane domain of FBD, two-dimensional separated local 
field (SLF) spectra were obtained (Figure 4.9). The characteristic α-helical transmembrane 
domain of free FBD gives rise to a discernible circular PISA (Polarity Index Slant Angle)-wheel 
pattern in the transmembrane domain region (70-100 ppm) (Figure 4.9A, red). In the presence of 
cyt P450, the distribution of the FBD resonances is disturbed, resulting in a more dispersed 
wheel pattern and overall reduced dipolar couplings (Figure 4.9A, blue). This observation 
suggests a change in the tilt angle of the FBD transmembrane helix and enhanced dynamics by 
interacting with cyt P450. A spectral simulation was performed to further characterize the 
orientation and dynamics of the transmembrane helix of cyt P450-bound FBD. When compared 
with the 13° tilt angle and an order parameter of 0.4 for the transmembrane helix of free FBD 
(Figure 4.9B), resonances of cyt P450-bound FBD are distributed in a more scattered fashion 
(Figure 4.9C) and cannot be fitted with a single tilt angle. Two PISA wheels simulated with tilt 
angles of 13° and 18° respectively with an order parameter of S=0.35 largely cover the majority 
of the resonances (Figure 4.9C). This simulation implies inhomogeneous tilt angles adopted by 
the FBD transmembrane helix, which are potentially caused by interaction with the 
transmembrane domain of cyt P450. A decreased order parameter for the cyt P450-bound FBD 
(S=0.35) compared with that for the free FBD (S=0.4) suggests higher mobility of the FBD 
transmembrane domain due to complex formation, in agreement with our hypothesis from T1ρ 
analysis.  
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Figure 4.9  2D 15N separated-local-field spectra of uniformly 15N-labeled MFBD in the presence (A, blue) 
and absence (A, red) of equal equivalence of cyt P450 in DLPC/DHPC/cholesterol bicelles. The spectra 
were collected at 720 MHz with a 0.5 ms CP contact time and 25 kHz SPINAL16 decoupling. Best fit of 
the observed resonances (open circles) with simulated helical wheel patterns.  Resonances of the free 
MFBD can be fit with a tilt angle of 13° and an order parameter of 0.8 (B, green), and resonances of cyt 
P450-bound MFBD can be fit into two wheels with tilt angles of 13° (C, green) and 18° (C, blue) with the 
same order parameter of 0.7. A cartoon (D) demonstrates complex formation between the soluble 
domains of MFBD and cyt P450 and a transient interaction between the transmembrane helices.  
 
 
4.5 Discussion  
4.5.1 Secondary structure of the transmembrane domain of CPR in lipid environment 
The criticality of the transmembrane domain of CPR in the complex formation with cyt 
P450 and substrate metabolism mediated by cyt P450 has been predicated through the decades 
(8-10, 50-52). It is general believed that the N-terminal hydrophobic segment of CPR serves as 
an anchor to the endoplasm reticulum and nuclear envelope and aid in interaction and electron 
transfer between CPR and cyt P450 (6). However, the mechanism on how the transmembrane 
domain affects cyt P450/CPR interaction and substrate catalysis remains under debate (8), and 
the experimental evidences to unveil the mist are highly deficient. In order to better understand 
the physiological function of the transmembrane domain of CPR, we decided to carefully 
characterize its structure and dynamics in a lipid membrane environment.  
The transmembrane domain of CPR was predicted to contain a β-sheet structure and 
possibly adopt a “U” shape in the membrane in the early literature (10), while in recent years it 
has been mostly presumed that the transmembrane anchor spans the lipid bilayer in an α-helical 
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conformation (11-13). Our studies present the first experimental evidence of an α-helical 
secondary structure for the transmembrane domain, in line with the previous hypotheses (11-13). 
The overall order parameter of the transmembrane domain coincides with those observed in the 
membrane-spanning transmembrane helices in the literature, further supporting that the 
transmembrane helix of CPR spans the bilayer in the bicelles (53-55). The helix tilt can be 
determined precisely from the range and average of the dipolar couplings, and it can be affected 
by the hydrophobic mismatch between the length of the transmembrane helix and the 
hydrophobic region of the phospholipids (54).  The tilt angle of 13° for the transmembrane helix 
of CPR is comparable with those measured in cytochrome b5 (13°) and cytochrome P450 (17°) 
in bicelles, revealing geometrical similarity in the transmembrane domains of these electron 
transfer partners. The interplay between the transmembrane domains of these proteins and their 
role in affecting electron transfer and complex formation are currently under investigation in our 
laboratory.   
 
4.5.2 Distinct dynamics of the soluble and transmembrane domain of CPR 
    Motions and structural dynamics are essential to the physiological function of 
membrane proteins. In order to gain insight into the role of the transmembrane domain of CPR in 
protein-protein interaction, we first seek to elucidate the dynamic behavior of FBD. In a series of 
CP experiments (Figure 4.3), we observe distinct buildup dynamics between the soluble and 
transmembrane domain. In our immobilized system, the CP dynamics are dominated by dipolar 
interactions, which are sensitive to submillisecond motions. Evidently faster CP buildup and 
decay rates of the transmembrane domain signals (Figure 4.3F) indicate restrained motions of 
this domain compared with the soluble domain. Analysis of CP dynamics also leads to an 
estimation of T1ρH and TNH values, which qualitatively reflect the mobility of the corresponding 
resonances. In the 2D SLF spectrum, difference between the mobility of the two domains is 
clearly presented by the values of the dipolar couplings (Figure 4.4). Heteronuclear dipolar 
coupling reports on the amplitude of local motions occurring on a time scale faster than the 
inverse of interaction. The average dipolar couplings for the transmembrane domain are 
approximately three times larger than those observed for the soluble domain, implying the 
soluble domain undergoes motions of larger amplitude in the submillisecond timescale, in line 
with the result of CP dynamics.  
111 
 
The distinct dynamic characteristics of the two domains are highly correlated with their 
functions. The soluble FMN binding domain is suggested to be able to diffuse rapidly in the 
cytosol in order for fast association and dissociation with cyt P450 to maximize the turnover rate 
of electron transfer. On the other hand, we observe small dipolar couplings of approximately 1 
kHz in the soluble domain (Figure 4.4), implying weak alignment of this domain or transient 
interaction with the lipid bilayer instead of isotropic tumbling/diffusion like a globular protein. 
This may attribute to the anchoring effect of the transmembrane domain, which may constrain 
the diffusion of the soluble domain to the proximity of the membrane surface and meanwhile 
orient the protein properly for interacting with cyt P450. Besides serving as an anchor, the 
transmembrane domain of CPR might also be involved in hetero-recognition with the 
transmembrane domain of cyt P450. These interactions can be reflected by characterizing the 
dynamics of the transmembrane domain in the presence of cyt P450. In lipid bilayer, the motions 
of a single α-helix can be visualized as rotational diffusion around the membrane normal and 
fluctuation of the helix tilt (45). The amplitude of these motions collectively influences the 
magnitude of NMR parameters, in particular chemical shift anisotropies and dipolar couplings 
(56, 57). By measuring the dipolar coupling values and determining the order parameter, we can 
monitor the dynamic changes of the transmembrane domain upon changes of the lipid 
environment or protein-protein interaction. 
In the presence of cyt P450, we observed enhanced dipolar coupling in the soluble 
domain of FBD, indicating complex formation between the two proteins in the DLPC/DHPC 
bicelles. This coincides with the physiological role of FBD in transferring electrons to cyt P450 
in the lipid membrane. On the other hand, the transmembrane helix of MFBD shows 
inhomogeneous tilt angles from 13° to 18° with increased mobility upon interaction with cyt 
P450. This observation might attribute to the transient interaction between the two 
transmembrane domains, which deviates the transmembrane helix of MFBD from its thermal 
equilibrium tilt angle in the free form (13°) towards the tilt angle of cyt P450 transmembrane 
helix (17°) (43). Furthermore, slightly decreased dipolar coupling and order parameter of the 
FBD transmembrane domain suggests a fairly weak interaction between the two transmembrane 
domains where the helix of FBD fluctuates between the bound and unbound states besides its 
axial rotational motion (45), inducing averaging of the dipolar coupling (Figure 4.2D). This 
transient interaction between the transmembrane domains could aid in orienting the soluble 
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domains of the two proteins for proper complex formation without hampering the fast 
dissociation that is required for efficient turnover of the cyt P450 substrates.  
 
4.6 Conclusion 
In this chapter, we have shown the first structural and dynamic study on the FMN binding 
domain of CPR including the transmembrane helix and the linker region in the protein’s native-
like membrane environment using solid-state NMR. We have provided the first experimental 
evidence of an α-helical conformation for the rigid transmembrane anchor of CPR. The focal 
point is the orientation and dynamic information of the transmembrane domain obtained in 
absence of spectral assignment, the knowledge of which is useful to better understand the role of 
the CPR transmembrane domain. We have also investigated the interaction between the FMN 
binding domain and cyt P450 in DLPC/DHPC bicelles. The results not only reveal the 
interaction between the soluble domains of FBD and cyt P450 in the membrane environment, but 
also provide some of the first direct evidences for the transient interplay between the 
transmembrane helices. This information sheds light on the physiological role of the 
transmembrane domains in CPR-cyt P450 interaction and/or catalysis. 
The successful implementation of a combination of 1D CP and 2D SLF spectra provides 
a simple method for further investigating the structural and dynamic properties of full-length 
CPR and its interaction with other membrane proteins in a membrane environment. Compared 
with alternative approaches that determine secondary structures (e.g. circular dichroism 
spectroscopy), our approach allows us not only to obtain conformational information of the 
transmembrane helix but also to investigate the dynamics behavior of the soluble domain and the 
transmembrane domain simultaneously, rendering great convenience in direct comparison of the 
two domains. Along with the resonance assignments, the approaches demonstrated in this work 
can be extended to structural studies of other membrane proteins.  
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CHAPTER 5 
 
NMR Characterization of Monomeric and Oligomeric Conformations of Human 
Calcitonin and Its Interaction with EGCG 
 
5.1 Summary 
Calcitonin is a 32-residue peptide hormone known for its hypocalcemic effect and its 
inhibition of bone resorption. While calcitonin has been used in therapy for osteoporosis and 
Paget's disease for decades, human calcitonin (hCT) forms fibrils in aqueous solution that limit 
its therapeutic application. The molecular mechanism of fiber formation by calcitonin is not well 
understood. Here, high-resolution structures of hCT at concentrations of 0.3 mM and 1 mM have 
been investigated using NMR spectroscopy. Comparing the structures of hCT at different 
concentrations, we discovered that the peptide undergoes a conformational transition from an 
extended to a β-hairpin structure in the process of molecular association. This conformational 
transition locates the aromatic side chains of Tyr-12 and Phe-16 in a favorable way for 
intermolecular π–π stacking, which is proposed to be a crucial interaction for peptide association 
and fibrillation. One-dimensional 1H NMR experiments confirm that oligomerization of hCT 
accompanies the conformational transition at 1 mM concentration. The effect of the polyphenol 
epigallocatechin 3-gallate (EGCG) on hCT fibrillation was also investigated by NMR and 
electron microscopy, which show that EGCG efficiently inhibits fibril formation of hCT by 
preventing the initial association of hCT before fiber formation. The NMR experiments also 
indicate that the interaction between aromatic rings of EGCG and the aromatic side chains of the 
peptide may play an important role in inhibiting fibril formation of hCT. 
 
5.2 Introduction 
Calcitonin is a 32-amino-acid peptide hormone with an N-terminal disulfide bridge 
between Cys-1 and Cys-7 and a C-terminal proline amidated residue (Figure 5.1). Secreted by 
the thyroid in response to elevated serum calcium levels (1, 2), calcitonin acts to reduce blood 
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Ca2+ levels and to reduce bone resorption by inhibiting the activity of osteoclast cells (3–
6). Because of its ability to limit bone resorption, calcitonin has been used as a treatment of 
osteoporosis for more than two decades (7). However, the therapeutic application of human 
calcitonin (hCT) has been limited by its tendency to assemble into inactive, fibril-like aggregates 
inaqueous solution (8–10). Since amyloid fibril formation is also observed in many other 
peptides associated with degenerative disorders, including Alzheimer's disease, Parkinson's 
disease and type II diabetes, a comprehensive understanding of the fibrillation process of 
amyloid peptides and the development of fibril inhibitors are desirable not only for the further 
improvement of medicinal efficiency of calcitonin but also in general for the development of 
treatment for amyloid-related diseases. The structure of calcitonin fibers and other oligomeric 
species have not been determined at high resolution at the molecular level. On a mesoscopic 
scale, electron microscopy studies have shown that hCT fibers are approximately 80 Å in 
diameter with the cross-β-sheet architecture common to amyloid fibers.11 At the molecular level, 
the assembly process of hCT monomers into amyloid fibers has been examined in some detail 
using NMR and other methodologies. Fibrillogenesis of hCT is a pH-dependent process with 
rapid association into antiparallel β-sheets at pH 7.5 and slower association into antiparallel and 
parallel β-sheets at pH 3.3 (12–14), a switch that appears to be controlled by the ionization states 
of Asp-15, Lys-18 and His-20 (13,14). The residues in the central region of hCT are sufficient 
for fiber formation, as a truncated pentapeptide fragment of hCT from Asp-15 to Phe-20 
(DFNKF) forms fibrils similar to those formed by the intact peptide (15,16). Kinetic studies have 
suggested that hCT amyloidogenesis is a multistep process, with non-fibrillar intermediates 
playing a key role in the early stages of amyloidogenesis (12,17,18). A time-dependent solution 
NMR study showed that peaks from residues in the central region (residues 8 to 23) of the 
peptide broaden and disappear much faster than those in the C-terminus during fibril formation, 
suggesting that these residues are involved in the formation of an intermediate before assembly 
of the final amyloid fiber (19).  The existence of an intermediate state of hCT during fiber 
formation is supported by transmission and attenuated total reflection FTIR (Fourier transform 
infrared spectroscopy) experiments that showed the simultaneous increase of α-helix and β-sheet 
components during fibril formation (18). Solid-state NMR studies suggest a localized α-helix 
structure around Gly-10 at pH 3.3, which is slowly converted into a β-sheet structure as the 
fibrils are formed (12,14). However, a high resolution structure of an intermediate conformation 
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has not been reported. 
 
 
Figure 5.1  Amino acid sequence of hCT. 
 
Knowledge on the oligomerization process may be utilized in the design of drugs to stop 
it. Fibrillation of amyloid peptides sometimes can be inhibited by small molecules through 
different pathways: small molecules including dopamide (20), calmidazolium chloride (21), 
hydroxyindole derivatives (22) and sulfated triphenyl methane derivative acid fuchsin (23). (−)-
Epigallocatechin 3-gallate (EGCG), a polyphenol compound obtained from green tea, in 
particular, has raised much interest due to its strongly inhibitory effect on fibrillogenesis and its 
low toxicity. So far, it has been reported that EGCG efficiently inhibits fiber formation of α-
synuclein (24–26), Aβ (26,27), huntingtin (28), IAPP (29),  and MSP2 (30). However, the 
mechanism of the inhibition has not been well established due to the complexity of the 
interaction between EGCG and amyloid peptides, which may involve an initial non-covalent 
interaction, a covalent modification of the peptide (26,30) and auto-oxidation and quinone 
formation of EGCG (31). As EGCG provides a promising lead for further development of 
amyloid fibril inhibitors, a comprehensive understanding of the inhibitory mechanism at the 
atomic level is desirable. 
In this chapter, we have investigated the oligomerization of hCT by examining the 
influence of peptide concentration and amyloid inhibitors on the conformation of hCT by NMR 
spectroscopy. Toward this end, we have solved high-resolution structures of hCT at two different 
concentrations using NMR spectroscopy. Our results indicate a site-specific conformational 
transition of hCT from an extended structure to a β-hairpin in the central region (Phe-12–Phe-19) 
of the peptide upon an increase in hCT concentration from 300 μM to 1 mM, consistent with a 
change in peptide oligomerization state detected by diffusion-ordered NMR. To determine the 
effect of amyloid inhibitors on the oligomericconformation of hCT, we investigated the 
inhibitory effect of EGCG on hCT fibril formation. Our results indicate that EGCG efficiently 
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inhibits fibril formation of hCT by preventing the initial oligomerization step. The interaction 
between EGCG aromatic rings and peptide aromatic side chains may play an important role in 
preventing hCT amyloid fibril formation. 
 
5.3  Material and Methods 
5.3.1 Materials 
EGCG (95% purity) was purchased from Sigma and used without further purification. 
Concentrated (25 mM) stock solutions of EGCG were prepared by dissolving EGCG in N2 
flushed water. hCT was synthesized by Fmoc chemistry using an Applied Biosystems 431A 
peptide synthesizer and Fmoc amino acids purchased from Watanabe Chemical Industries 
(Hiroshima, Japan). An amide resin (Applied Biosystems, Inc., Foster City, CA) was used for the 
formation of the C-terminal amine. After deprotection and cleavage from the resin, the peptides 
were purified by reversed-phase HPLC using a mobile phase of water and acetonitrile containing 
0.05% trifluoroacetic acid. The disulfide bridge between Cys-1 and Cys-7 was formed overnight 
by air oxidation of dilute (0.5 mM) hCT solution in 0.1 M sodium acetate (pH 8.0–8.5) in the 
presence of 6 M urea to prevent fibrillization (61). After an Ellman test confirmed the presence 
of the disulfide bond (62) the oxidation reaction was stopped by adding an acetic acid solution. 
The oxidized product was then repurified by HPLC. After purification, the peptide was 
lyophilized from aqueous solution in 40% acetonitrile (used to maintain the monomeric 
conformation) and  stored at −4 °C. 
 
5.3.2 H/D exchange 
Samples for H/D exchange experiments were prepared by first dissolving lyophilized 
hCT in phosphate buffer [1 mM hCT, 7% D2O and 50 mM NaCl (pH 2.9)] to a concentration of 
1 mM in the absence and presence of 4 molar equivalents of EGCG. Amide proton/deuteron 
exchange was initiated by exchanging the original phosphate buffer into equivalent deuterated 
buffer using a Zeba Spin Desalting Column from Thermo Scientific. We recorded 32 transients 
for each 1H spectrum before H/D exchange and for the indicated time durations after the H/D 
exchange. 
 
5.3.3 Electron microscopy measurements 
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Samples for electron microscopy were prepared by first dissolving lyophilized hCT in 
phosphate buffer (pH 7.3, 20 mM and 100 mM NaCl) at a peptide concentration of 100 μM and 
incubating at 25 °C for 36 h in the absence and presence of 3 molar equivalents of EGCG. 
Aliquots of 10 μL samples were deposited on a 400-mesh copper grid and incubated for 2 min, 
washed with distilled water twice and negatively stained with 10 μL of 2% (w/v) uranyl acetate 
for 1.5 min and dried. Observations were performed on a Philips CM-100 electron microscope.  
 
5.3.4. Sample preparation for NMR experiments  
A few minutes before starting the NMR experiments, samples were prepared by 
dissolving the lyophilized hCT peptide in 20 mM phosphate buffer (pH 7.4 or pH 2.9) containing 
50 mM NaCl to a final concentration of 0.3 or 1 mM. The stability of the sample over the time 
course of the experiment was tested by obtaining a series of 1H chemical shift spectra over a 
period of several days. The high degree of similarity of the spectra confirmed the stability of the 
sample at an acidic pH of 2.9 over the time course of the experiment. However, the sample at pH 
7.4 rapidly aggregated at the concentrations with the solution becoming visibly turbid and with 
the intensity of the signal rapidly diminishing as time progressed, in agreement with previous 
reports (19). Accordingly, all NMR experiments were performed at pH 2.9.  
 
5.3.5 NMR spectroscopy 
All NMR experiments were performed on a Bruker AVANCE 900-MHz spectrometer at 25 °C. 
Samples were prepared by dissolving lyophilized hCT in phosphate buffer (pH 2.9, 7% D2O and 
50 mM NaCl) at peptide concentrations of 0.3 mM and 1 mM. 2D TOCSY and NOESY spectra 
were obtained for structure determination. TOCSY spectra were recorded using 256 t1 
experiments, 80 ms of mixing time and 4 scans, while NOESY spectra were obtained using 512 
t1 experiments, 300 ms of mixing time and 16 scans. The proton frequency for each experiment 
was set on water resonance (4.7 ppm). The spectra were referenced relative to 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS). Spectra were processed using TOPSPIN and analyzed using 
Sparky. The NOE cross peak assignments were obtained by an iterative procedure using a 
combination of manual and automatic approaches. Proton diffusion NMR measurements were 
carried out using the STE (stimulated echo) PFG pulse sequence with squared gradient pulses of 
constant duration (5 ms) and a variable gradient amplitude along the longitudinal axis (63). 
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Typical acquisition parameters used in NMR experiments were as follows: a 90° pulse width of 
23 μs, a spin echo delay of 10 ms, an STE delay of 150 ms, a recycle delay of 5 s, a spectral 
width of 10 kHz and 4048 data points. A saturation pulse centered at the water frequency was 
used for solvent suppression. Radio frequency pulses were phase cycled to remove unwanted 
echoes. All spectra were processed with an exponential multiplication factor equivalent to a 5-Hz 
line broadening prior to Fourier transformation and were referenced relative to DSS. The 
gradient strength was calibrated (G=3.28 T/m) from the known diffusion coefficient of HDO in 
D2O at 25 °C (D0 = 1.9×10− 9 m2/s) (64). The diffusion coefficients were determined from the 
slope of a log plot of the intensity as a function of gradient strength using the Stejskal–Tanner 
equation (65). The hydrodynamic radius was then calculated from the diffusion coefficient using 
the Einstein–Stokes relation and the viscosity of water at 25 °C. To investigate the interaction of 
hCT with EGCG, we added aliquots of the EGCG stock solution to prepare samples with 
different hCT : EGCG molar ratios. For these samples, 1D 1H NMR, 2D NOESY, 2D TOCSY 
and 1H/15N band-selective optimized flip-angle short transient (SOFAST) HMQC spectra were 
recorded in the absence and presence of EGCG. For experiments involving EGCG, NOESY 
spectra were obtained using 512 t1 experiments, 300 ms of mixing time and 8 scans, while 
TOCSY spectra were obtained using 256 t1 experiments, 80 ms of mixing time and 4 scans. The 
SOFAST HMQC spectra were obtained using 128 t1 experiments and 256 scans. 
  
5.3.6  Structure calculations  
Structures were calculated from manually and automatically assigned NOEs in 2D NOESY 
spectra with a 200-ms mixing time using CYANA version 2.0 (66,67). The normalized cross 
peak intensities were qualitatively assigned as strong, medium or weak to assign upper inter-
proton distance restraints of 2.7 Å, 3.3 Å and 5.0 Å, respectively, for both 0.3- mM and 1- mM 
hCT samples (68). An additional 0.5 Å was added to the upper bound for proton pairs involving 
methyl groups. For the 1.0- mM hCT sample, a total of 297 inter-proton distance restraints were 
derived from the NOESY data, including 175 sequential restraints (i−j=1), 19 medium-range 
restraints (2≤i−j≤5) and 2 long-range restraints [(i−j>5) residues]. The combination of chemical 
shift restraints from TALOS and the NOE patterns were used to calculate 23 dihedral angle 
restraints for the 1- mM sample (69). For the 0.3- mM hCT sample, long-range or medium-range 
NOEs were not observed except for 65 intraresidue and 66 sequential NOEs. A total of 100 
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conformers for each sample were initially generated by CYANA based on the dihedral angle and 
NOE restraints obtained, and the bundles of 20 conformers with the lowest target function were 
used to represent the three-dimensional NMR structures. Hydrogen bond constraints were not 
included during the entire structure calculation. The disulfide bridges between C1 and C7 were 
fixed in all structure calculations by constraining the S–S distance to an upper limit of 2.1 Å. 
 
5.4  Results  
5.4.1 Oligomerization of hCT 
To examine the oligomerization state of hCT in solution, we initially acquired one-
dimensional (1D) 1H NMR spectra at two concentrations—0.3mM and 1 mM. A broad peak 
observed at − 0.1 ppm in the 1-mM hCT sample was absent in the 0.3-mM hCT sample (Figure 
5.2a, inset). This peak is commonly found in the spectra of amyloidogenic proteins, and its 
appearance is consistent with a species in which at least some of the aliphatic protons are 
significantly protected from solvent and thus shifted to the highfield region of the spectrum 
(Figure 5.2a) (32–35). However, the relatively narrow dispersion of resonances in other regions 
of the 1H spectra suggests that the peptide is at least partially unfolded at both concentrations 
(Figure 5.2). This difference is consistent with a heterogeneous sample containing at least two 
species, one significantly folded and the other largely unfolded. To confirm this hypothesis, we 
performed pulsed-field gradient (PFG) NMR diffusion experiments to estimate the 
hydrodynamic radius of peaks that likely represent folded and unfolded species (see Figure 5.3). 
A hydrodynamic radius of 1.57 nm was obtained for both samples for peaks between 8.6 and 7.4 
ppm, suggesting that these peaks correspond to a monomeric, significantly unfolded peptide at 
both concentrations. For the peak at −0.1 ppm, the radius of gyration could not be measured 
precisely. However, the insensitivity of the peak intensity to the gradient strength suggests a very 
slowly diffusing oligomeric species at least 50 nm in diameter, in agreement with previous 
studies on other amyloidogenic proteins (34,35). Overall, the 1H spectrum in the 0.3-mM sample 
is consistent with hCT being exclusively in the monomeric state and the monomer coexisting 
with large oligomeric species at 1 mM hCT concentration. However, the only contribution of the 
large oligomeric state to the 1H spectra of the 1-mM sample is the small peak near −0.1 ppm, as 
other resonances originating from the large oligomeric state are apparently broadened beyond 
detection. 
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Figure 5.2  hCT forms oligomers at 1 mM concentration but not at 0.3 mM. (a) 1D 1H NMR spectra of 
hCT at (a) 0.3 mM and (b) 1 mM concentrations showing the characteristic amyloid oligomer peak at 
−0.1 ppm in the 1- mM sample and its absence in the 0.3- mM sample. The peak at 0 ppm is from the 
internal chemical shift reference used (DSS). 
 
 
 
 
 
Figure 5.3  hCT is primarily monomeric at both 0.3 and 1 mM concentrations. The decay of normalized 
STE intensity obtained from STE PFG 1H NMR spectra of 0.3 mM (red circles) and 1 mM (blue squares) 
hCT samples; the intensity was calculated from the integrated volume of the peaks between 8.6 and 7.4 
pm. The similarity of the decays indicates that the peaks within this region correspond to largely 
unfolded  monomeric species of hCT with a hydrodynamic radius of 1.57 nm. 
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5.4.2  Concentration-dependent NOE patterns of hCT 
The partial protection of the amide hydrogen suggests that hCT is at least partially 
structured at pH 2.9. We confirmed this result by recording two-dimensional (2D) 1H/1H total 
correlated spectroscopy (TOCSY) and nuclear Overhauser enhancement spectroscopy (NOESY) 
spectra of samples of hCT at 0.3 mM and 1 mM concentrations. The spectra showed relatively 
good resolution at both concentrations; all intraresidue nuclear Overhauser enhancements 
(NOEs) between backbone amide protons and α protons could be identified except for those 
originating from C1. Figure 5.4 shows the Hα–HN region of the 2D NOESY spectrum at 1 mM 
hCT concentration. Figure 5.5 shows the NOE connectivities obtained for both concentrations. 
Table 1 summarizes the NOE constraints obtained for both concentrations. A far larger 
number of NOEs were observed for the 1-mM concentration compared to the 0.3-mM sample. 
For the 1-mM sample, a total of 291 NOE constraints could be detected, while only 131 could be 
determined for the 0.3-mM sample. This difference persisted even after the signal was 
normalized for the difference in concentration between the two samples. The relative increase in 
the number of NOEs in the 1-mM spectra was not uniform but was largely concentrated in the 
HN–Haliphatic region of the 2D NOESY spectrum. The uneven distribution can be seen in Figure 
5.6, which shows the superposition of the HN–Haliphatic regions of the NOESY spectra at both 
concentrations normalizing for the concentration difference. Normalization is done by reducing 
the contour level of the 0.3-mM spectra by 3.3 times compared with the 1-mM spectra in Sparky. 
Several additional NOEs are particularly prominent, mostly those between side-chain protons of 
residue i and amide protons of residue i or i+1 in the central region of the peptide, for example, 
those between M8Hγ2-HN, L9Hδ-HN, C7HHβ3-M8HN, T11Qγ2-Y12HN, T13Qγ2-Q14HN, 
D15Hβ3-F16HN, F19Hβ3-H20HN, P23Hβ2-Q24HN and Q24Hβ2-T25HN (see Figure 5.6). In 
addition, 1H/1H NOEs dαN(i,i+2) between Ser-5 and Cys-7, between Gly-10 and Tyr-12 and 
continuously from Asp-15 to His-20 were observed in the 1-mM hCT sample. These NOEs are 
absent in the 0.3-mM hCT sample, which suggests a more constrained structure in the central 
region of the peptide at the higher concentration. A dαN(i,i+2) 1H/1H NOE connectivity between 
Asp-15 and Asn-17 is characteristic of a turn structure around these residues (36). The presence 
of a type II β-turn in the 1-mM sample is also well supported by the intense dNN(i,i+1) NOEs 
between Phe-16 and Phe-17 and medium and long-range interresidue NOEs from either side of 
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the turn between residues Thr-13/Asn17, Gln-14/Asn-17 and Thr-13/Phe-19. These medium- and 
long-range NOEs are listed in Table 2. 
 
 
Figure 5.4  Hα–HN region of the 2D NOESY spectrum of 1 mM hCT. The spectrum was recorded from 1 
mM hCT sample in 2 mM sodium phosphate buffer, 7% D2O and 50 mM NaCl (pH 2.9). Only the NOEs 
corresponding to cross peaks of amide protons and α protons are labeled. 
 
 
Figure 5.5  NOE connectivity plots for the 0.3- mM (a) and 1- mM (b) hCT samples. The strengths of 
sequential NOEs are indicated by the height of the bars. 
 
128 
 
 
 
 
 
 
Figure 5.6  Superimposed normalized NOESY spectra of hCT at 0.3 and 1 mM concentrations. The Hside 
chain–HN regions of NOESY spectra at peptide concentration of 0.3 mM (blue) and 1 mM (magenta) are 
superimposed. The 1- mM spectrum was normalized by scaling the contour level down to that of the 
0.3- mM sample, using the diagonal peak intensity as a reference. Additional NOEs were observed in the 
1- mM sample, including intraresidue Hside chain–HN NOEs and interresidue (i−i+1) Hside chain–HN 
NOEs. Samples were prepared in 2 mM sodium phosphate buffer, 7% D2O and 50 mM NaCl (pH 2.9). 
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Table 5.1 Structure statistics for the 20 best structures of hCT 
after energy minimization and structural annealing 
 
 
 
 
 
Table 5.2 Selective medium- and long-range NOEs observed 
from the 2D NOESY spectrum of 1 mM hCT in sodium 
phosphate and 50 mM NaCl (pH 2.9) at 298 K 
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Figure 5.7  Partially folded structures of hCT. (a) A superimposition of five energy-minimized structures 
of hCT at the concentration of 0.3 mM. (b) A superimposition of 20 energyminimized structures of hCT 
at the concentration of 1 mM. The peptide chains are labeled with gradient colors from blue to red 
throughout the sequence from N-terminus to C-terminus. (c) A cartoon plot showing the medium- and 
longrange NOEs (broken lines) that stabilize the formation of the hairpin structure at 1 mM 
concentration. Red broken lines indicate a hydrogen bond. (d) Positions and orientations of three 
aromatic side chains from five randomly chosen energy-minimized structures of the 1- mM sample of 
hCT. 
 
From these NOEs, structural models of hCT could be constructed for both samples (see 
Figure 5.7). For the 0.3-mM sample, hCT is largely unstructured, in agreement with the paucity 
of NOEs detected at this concentration. In the 1-mM sample, on the other hand, a well-defined β-
hairpin structure is present in the central region of the peptide from Tyr-12 to Phe-19. The 
hairpin structure is mainly constrained by 19 medium-range and 2 long-range NOEs observed 
between the two strands (see Figure 5.7c for a cartoon depiction), especially from residues Thr-
13 and Gln-14 on the N-terminal side of the hairpin to residues Asn-17 and Phe-19 on the C-
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terminal side. A β-turn from Gln-14 to Asn-17 separates the strands of the hairpin. The β- turn is 
further stabilized by additional hydrogen bonds originating from side chains within the turn (red 
broken lines in Figure 5.7c). In all the energy minimized structures, the aromatic residues Tyr-12 
and Phe-16 within the turn region are consistently oriented so that the planes of the aromatic 
rings are parallel with the face of the hairpin, presumably favoring peptide stacking through 
intermolecular π–π interaction. While the 20 energy-minimized backbone structures superimpose 
well at the central region of the peptide from Tyr-12 to Phe-19 in the 1-mM sample, the N- and 
C-terminal residues are largely disordered in both samples. 
 
5.4.3  EGCG inhibits the formation of oligomeric species of hCT 
Having characterized a possible oligomeric species of hCT, we next examined the effect 
of EGCG on hCT oligomerization. We first confirmed that EGCG inhibits amyloid fiber 
formation by hCT, similar to what has been observed for other amyloidogenic proteins 
(26,29,30,37–40). To observe the effect of EGCG on hCT fibrillization, we incubated samples of 
100 μM hCT with and without 500 μM EGCG at pH 7.4 for 36 h. In the absence of EGCG, hCT 
aggregates to form a dense network of amyloid fibers (Figure 5.8a). On the other hand, when 
hCT was incubated with a 5-fold excess of EGCG under the same condition, fibers or fiber-like 
aggregates were not observed (Figure 5.8b). The black dots observed in the hCT/ EGCG sample 
match those observed in the control sample containing EGCG only, suggesting that they 
correspond to EGCG aggregates. The absence of amyloid fibers in the hCT/EGCG sample 
therefore implies that the fibrillation of hCT was efficiently inhibited by interaction with EGCG. 
Hydrogen/deuterium (H/D) exchange experiments were carried out to further study the 
effect of EGCG on the oligomerization process of hCT. The time course of H/D exchange of 
hCT amide protons with and without EGCG is shown in Figure 5.9. A comparison of the two 
sets of 1D spectra shows that the H/D exchange rates of amide protons of hCT are much faster in 
the presence of EGCG. In the absence of EGCG, most of the amide peaks could still be observed 
after 48 h of deuterium exchange, although the intensity and resolution of the peaks decreased 
significantly (Figrue 5.9a). In contrast, the peaks from the amide protons were almost 
disappeared within 15 min in the EGCG-treated hCT sample, indicating near complete exchange 
in this sample. Since monomeric hCT is almost completely unstructured (see Figure 5.7a), the 
faster exchange rate is likely to arise from the elimination of oligomeric species of hCT, which 
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have a substantial degree of intermolecular hydrogen bonding (see Figure 5.2b). This conclusion 
is further supported by the absence of the oligomer peak at around −0.1 ppm in the EGCG-
treated hCT sample (Figure 5.9c), which also suggests the inhibition of the growth of large 
oligomer species by EGCG. 
 
 
 
Figure 5.8  Electron microscopy image shows the inhibition of hCT fibrillation by EGCG. Electron 
microscopy image shows the inhibition of hCT fibrillation by EGCG. We incubated 0.3 mM samples of 
hCT for 36 h in the absence (a) and presence (b) of 3 molar equivalents of EGCG at pH 7.4, 298 K. 
 
 
 
Figure 5.9  EGCG inhibits oligomer formation of hCT by NMR. Time course of the amide region of 1D 1H 
NMR spectra of hCT in H/D exchange experiments in the absence (a) and presence (b) of 2 molar 
equivalents of EGCG. (c) 1D 1H NMR spectra of hCT in the presence (a) and absence (b) of 2 molar 
equivalents of EGCG before deuterium exchange. Samples were prepared in 2 mM sodium phosphate 
buffer, 7% D2O and 50 mM NaCl (pH 2.9). 
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5.4.4.  Mechanism of EGCG binding to hCT by NMR experiments  
To elucidate the binding mechanism of EGCG to hCT, we recorded NMR spectra of hCT 
in the absence and presence of a 5-fold molar excess of EGCG. A shifting of the resonances of 
both hCT and EGCG indicated direct binding between EGCG and non-fibrillar forms of the 
peptide (amyloid fibers are not detected in these experiments as the long rotational correlation 
time of the fiber broadens the signal beyond detection). The shifting of the resonances of hCT 
upon the addition of EGCG was investigated in more detail by 2D NMR (see Figure 5.10). A 
superimposition of the 1H/15N heteronuclear multiple quantum coherence (HMQC) spectra of 
hCT with and without 2 molar equivalents of EGCG shows an almost universal shift of the 
resonances upon EGCG binding (Figure 10a), indicating that EGCG binding to the monomer is 
not localized on specific sites within the peptide but is rather largely delocalized, in agreement 
with previous experiments on α-synuclein (26). The chemical shift changes of the amide and α 
protons of hCT occurring upon EGCG binding are summarized in Figure 10b, calculated from 
the 1H/15N HMQC and NOESY spectra, respectively. The amide protons of residues from Leu-9 
to the C-terminus are shifted to high field except for Thr-11 and Asp-15, while the N-terminal 
residues, where there is a disulfide loop from Cys-1 to Cys-7, are shifted to low field only 
slightly. The magnitude of the changes suggests that EGCG largely binds in the central and C-
terminal regions of the peptide. The general high-field shift observed is most likely due to the 
shielding effect of the aromatic rings of EGCG. Interestingly, amide protons of Thr-11, Asp-15 
and Thr-21 show either “abnormal” low-field shifts or a negligible shifts differing from the 
adjacent residues. Although changes are apparent throughout the spectrum when EGCG binds to 
hCT, aromatic side chains appear to play a particular role. The residues with the most significant 
Hα chemical shift differences (δ>20.1 Hz, compared to the mean value of 9.2 Hz) are almost all 
aromatic residues (Tyr-12, Phe-16, Phe-22 and Ala-31), suggesting a close spatial proximity 
between these residues and EGCG. The resonances from protons on aromatic side chains also 
show significant chemical shift perturbations induced by EGCG (Figure 10c), which might be 
due to a π–π stacking interaction between aromatic rings of EGCG and the side chains of these 
residues. Notably, the amide protons showing atypical shifts upon EGCG interaction (Thr-11, 
Asp-15 and Thr-21) directly precede the aromatic residues Tyr-12, Phe-16 and Phe-22. This 
pattern is consistent with parallel stacking of aromatic rings, which should cause a deshielding 
effect on the α protons in the adjacent residues as they lie perpendicular to the aromatic rings.  
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Figure 5.10  NMR analysis of EGCG binding to hCT. NMR spectra of hCT were recorded with and without 
2 molar equivalents of EGCG. (a) 2D 1H/15N SOFAST HMQC spectra of hCT in the absence (blue) and 
presence (red) of EGCG. (b) Chemical shift difference of amide protons and α protons of hCT induced by 
the addition of EGCG. Δδ is calculated by subtracting the chemical shift values of protons of hCT in the 
presence of EGCG from those in the absence of EGCG. Δδ(NH) was calculated from 2D 1H/15N SOFAST 
HMQC spectra. Δδ(αH) was calculated from 2D 1H/1H NOESY spectra. (c) Aromatic region of NOESY 
spectra of hCT in the absence (blue) and presence (red) of EGCG. Samples were prepared in 2 mM 
sodium phosphate buffer, 7% D2O and 50 mM NaCl (pH 2.9). 
 
 
5.5  Discussion  
Our study reveals that a conformational change in hCT accompanies peptide association 
and oligomerization. At a concentration of 0.3 mM, hCT adopts a flexible and extended 
structure. A small degree of structure is present in the form of a loose turn from Asp-15 to Phe-
19 in the central region of the peptide. However, the peptide is almost entirely unstructured at 
this concentration, a fact supported by the PFG results showing a hydrodynamic radius of 1.57 
nm, which is similar to that of completely denatured peptides but is larger than most 
amyloidogenic peptides of this length that are typically partially folded (34,35,41). Both IAPP 
and Aβ1–40, for example, have low-lying helical states that are believed to nucleate amyloid 
formation (42). However, NOEs consistent with a helical structure were not detected for hCT at 
pH 2.9, as has been proposed for hCT oligomers in acidic solution and as a low-lying excited 
state of the monomer at neutral pH (12,14). The absence of a helical structure in the monomer is 
consistent with the finding that metastable secondary structure correlates with amyloidogenicity 
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of the peptide (43–45) as fiber formation is strongly delayed in hCT at an acidic pH compared to 
neutral pH (19). At this concentration, the peptide does not form large oligomers during the 
experimental time period according to the 1H NMR spectra.  
At a higher hCT concentration of 1 mM, many more NOEs could be detected in the 
sample after normalization, particularly in the central region of the peptide from Gly-10 to His-
20. From these additional NOEs, a new structure that is significantly more ordered than the 
monomeric structure obtained for the 0.3-mM sample could be constructed. The loose turn found 
in the 0.3-mM structure is transformed into a well-defined type II β-turn between Gln-14 and 
Asn-17, and the central region of the peptide adopts a well-defined extended conformation from 
Tyr-12 to His-20, which superimposes perfectly among the 20 energy-minimized structures. The 
C- and N-termini, including the disulfide ring, are unstructured at both concentrations. The 
hairpin conformation is similar to that previously obtained for hCT in 85% dimethyl sulfoxide 
and 15% H2O; however, the turn was located in a different position in this study (Asn-17 – His-
20), possibly because of a different ionization state of the peptide (46). The change in the 
conformation of hCT as the concentration is increased implies that the structure obtained at the 
1-mM concentration is of an oligomeric species while the 0.3-mM structure is solely that of a 
monomer. On the other hand, the hydrodynamic radius of hCT in the 1-mM sample calculated 
from most of the peaks in the 1D 1H spectrum nearly exactly matches that of the 0.3-mM sample, 
suggesting that the 1-mM sample still consists largely of monomeric peptide. However, the 
1D 1H and diffusion experiments (Figure 2) also indicate large oligomer species in coexistence 
with the monomer in the samples at 1 mM but not 0.3 mM concentration. Amyloidogenic 
peptides frequently form micellar-type aggregates at intermediate peptide concentrations (47–51) 
which can undergo exchange with the monomeric peptide (34, 52). Such micelles have been 
proposed as intermediates for calcitonin fibrillization (12). Therefore, the most likely explanation 
is that the additional NOEs observed in the 1-mM sample represent transfer NOEs from a large, 
mostly NMR-invisible species in rapid exchange with the monomeric peptide. Under particular 
conditions (koff being fast relative to the T1 relaxation time of the monomer/oligomer complex 
and NOE mixing time), the “memory” of the conformation of the hCT in the oligomer can be 
effectively carried over into the NOESY spectra in the form of additional NOE cross peaks, even 
though the oligomer itself is not visible to NMR (53). Note that transfer NOEs are typically 
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observed when the binding partner (in this case, the oligomer) is in large excess, in agreement 
with the similarity of 1D 1H spectra (53).  
The association of aromatic side chains has been proposed to be a driving force for 
fibrillization of hCT (15,17). For instance, molecular dynamic studies have shown that a five-
residue segment of hCT starting from Asp-15 (DFNKF) forms high-ordered fibrils similar to the 
intact peptide (54). In contrast, the phenylalanine-to-alanine analogue (DANKA) does not form 
amyloid fibrils at all, implying an important role of aromatic interactions in peptide association 
(15). In the hairpin structure of the 1-mM sample, the planes of aromatic rings on the side chains 
of Tyr-12 and Phe-16 are primarily parallel with the hairpin plane (Figure 5.7c and d), which 
potentially favors the association of the peptide along the normal of the hairpin plane by the π–π 
interaction between the phenyl rings from adjacent peptides.  
The apparent importance of aromatic interactions in stabilizing oligomeric conformations 
of hCT is shown by the interaction of hCT with EGCG. EGCG acts as fibril inhibitors of several 
amyloid peptides by stabilizing their oligomers in an off-pathway conformation that prevents 
their conversion to a toxic on-pathway oligomer intermediate (24,26,30) although apparent 
exceptions exist (29,38,55). Our NMR results indicate that EGCG inhibits fibrillation of hCT by 
stabilizing the monomeric form of hCT in a largely unstructured conformation and by preventing 
the oligomerization of hCT. In the 1H NMR spectrum, we did not observe the slowly diffusing 
oligomer peak of EGCG-treated hCT around −0.1 ppm, which suggests the absence of large 
oligomer species in the EGCG-treated sample. In addition, the amide peaks of EGCG-treated 
hCT were quenched before those of the untreated sample in H/D exchange experiments. This 
suggests that EGCG-treated hCT is in a more solvent exposed environment, most likely due to 
stabilization of the unstructured monomeric form of the peptide. While the NMR spectra indicate 
that EGCG affects the chemical shift values of most of the residues (Figrue 5.10), the α protons 
of the aromatic side chains Tyr-12, Phe-16 and Phe-22 show more significant chemical shift 
perturbations by EGCG (Figure 5.10b). In addition, the amide protons of the residues preceding 
the aromatic residues (Thr-11, Asp-15 and Thr-21) show atypical low-field chemical shift 
changes upon interaction with EGCG, suggesting a ring current effect on these residues. From 
these results, it is reasonable to conclude that π–π interactions between EGCG and Tyr-11, Phe-
16 and Phe-22 are involved in the association of EGCG with hCT. If intermolecular π–π 
interactions play an important role in amyloid formation of hCT, it can be expected that the 
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competing interaction of the aromatic rings of EGCG for these side chains blocks potential sites 
for peptide association and prevents oligomer formation.  
It should be noted that, despite apparent superficial similarities with models of β-sheet 
amyloid oligomers, the oligomer structure reported here would require a conformational change 
before it can be incorporated into the hCT amyloid fiber. X-ray crystallography and solid-state 
NMR measurements have suggested that individual protein molecules in amyloid fibers typically 
adopt a common hairpin-type structure with the side chain of residues forming a tight interface 
known as a “steric zipper” between the two β-strands (56–58). Intermolecular association of the 
proteins along the fiber axis is responsible for fiber formation.  
The tight packing of side chains in the steric zipper interface necessarily gives rise to a 
high number of NOEs between the β-strands (59). NOEs of this type were not observed in the 1-
mM oligomer sample except in the immediate vicinity of the type II turn. In addition, the loop 
separating the β-strands in the hairpin is typically ∼10 residues in length (57,58). A smaller loop, 
such as the type II turn observed in the 1-mM oligomer sample, requires either the side chains to 
be pointed away from the plane of the hairpin or the strands to be separated in space. Either 
conformation is not likely to be conducive to the formation of the steric zipper interface essential 
for amyloid formation. For this reason, the oligomer conformation reported here is unlikely to be 
a direct nucleus for amyloid fiber formation. Measurements of the 1D 1H spectra in real-time and 
solid-state NMR spectroscopy suggest that α-helical oligomers instead may be involved as a 
direct intermediate of fiber formation at both low and neutral pH (12,19). Conformational 
changes are often observed in amyloidogenic peptides following peptide association in which 
non-fibrillar oligomers such as those observed here are rapidly formed and then slowly converted 
into amyloid fibers (the nucleated conversion model) (60). Further investigation is needed to 
determine if the oligomer structure determined here is on- or off-pathway for amyloid formation.  
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CHAPTER 6 
 
Conclusions and Future Directions 
 
6.1   Conclusions 
The overall goal of the presented dissertation is to understand the interaction and electron 
transfer between cytochrome P450 reductase and its redox partners from a structural point of 
view. In the preceding chapters, I presented the kinetic and structural characterization of the FBD 
– cyt c and FBD – cyt P450 complexes, proposed structural models of these two complexes 
based on our NMR studies, and predicted potential electron transfer pathways from FBD to cyt 
c/cyt P450. In addition, I showed our approaches to understand the role of the transmembrane 
domains in the complex formation between CPR and its redox partners by probing the structure 
and dynamics of the transmembrane domain of CPR using solid-state NMR techinques. On the 
other hand, I also investigated the structural characteristics of human calcitonin to uncover its 
aggregation pathway and its interaction with an amyloid fibril inhibitor EGCG.  
In chapter 2, we characterized the electron transfer and complex formation between FBD 
and cyt c. From the kinetic studies, we observed distinct rates of electron transfer between FBD 
and cyt c depending on the redox states of FBD. Compared to wild-type CPR, FBD reduces cyt c 
at a much higher rate in both its semiquinone and hydroquinone state, suggesting that 
conformational gating of CPR plays a key role in the electron transfer process. We utilized NMR 
titration experiments to investigate the complex formation and identify the residues on the 
binding interface. The results revealed that the formation of dynamic complexes between FBD 
and cyt c occurs on a fast exchange time scale with a dissociation constant Kd of 0.024 mM. 
Specific residues of FBD involved in the binding interface with cyt c were identified by chemical 
shift perturbation mapping, most of which are located around the solvent exposed edge of the 
FMN cofactor. Finally, we generated the structure model of the FBD-cyt c complex using 
HADDOCK, which includes complexes with two probable orientations. Salt bridge formation 
between Glu-213/Glu-214 of FBD and Lys-87 of cyt c was identified in the major structural 
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model, which could be essential to the stability of the complex. Based on the complex structure, 
we predict electron transfer pathway mediated by Lys-13 of cyt c. This work provides a 
structural basis for a better understanding of the interaction between CPR and cyt c and allows 
comparisons to be drawn with other electron transfer complexes involving CPR or cyt c.  
In chapter 3, we focused on probing the binding interface between FBD and cyt P450 by 
solution NMR techniques. Our NMR titration experiments indicate the residues of FBD 
experienced a slow-to-intermediate exchange upon complex formation with cyt P450. By 
chemical shift perturbation and line broadening analysis, we identified the epitope on FBD 
recognized by cyt P450 which is similar to the binding site of cyt c. Subsequently, a structural 
model was generated using NMR restraints and previous site-directed mutagenesis studies. The 
model revealed detail information on the specific residues involved in interprotein recognition. 
Based on the structural model, a potential pathway was predicted involving Met-132 and Arg-
133 of cyt P450. 
Chapter 4 presents our efforts to understand the role of transmembrane domains in 
complex formation between FBD and its redox partners. We characterized the structure and 
dynamics of the transmembrane domain of CPR in native membrane-like environment by solid-
state NMR techniques in conjunction with spectra simulation. Our results reveal that the N-
terminal transmembrane domain of CPR adopts an α-helical conformation in the lipid 
environment, and is tilted approximately 13° from the lipid bilayer normal. We also investigated 
the interaction between FBD and cyt P450 in the lipid environment. Our results show binding 
between the soluble domains of the two proteins in the lipid bicelles, and suggest transient 
interplay between their transmembrane helices. 
In summary, the work presented in these chapters provides rich structural information on 
the electron transfer complexes between the FMN binding domain of CPR and its redox partners. 
The formation of the two complexes investigated – the FBD-cyt c and FBD-cyt P450 complexes 
– occurs at different time scales based on the observations in the NMR experiments. The 
proposed structural models allow us to zoom in to the binding interfaces and identify the 
intermolecular interactions that contribute to the complex formation. It provides a structural basis 
for further investigations on these electron transfer complexes and helps to elucidate the general 
mechanism of electron transfer from CPR to its redox partners.  
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Chapter 5 is an investigation on understanding the amyloid aggregation pathway of 
human calcitonin and its interaction with an amyloid fibril inhibitor EGCG. We found out that at 
the concentration of 1 mM hCT adopts a β-hairpin conformation, while it is predominantly 
unstructured at 0.3 mM. This implies a conformation transition from an extended to a β-hairpin 
structure in the process of hCT association. In the β-hairpin conformation observed in the 1- mM 
hCT, the aromatic side chains of Tyr-12 and Phe-16 are oriented in a favorable way for 
intermolecular π–π stacking, which is proposed to be a crucial interaction for peptide association 
and fibrillation. We also investigated the effect of the polyphenol epigallocatechin 3-gallate 
(EGCG) on hCT fibrillation by NMR and electron microscopy. The results show that EGCG 
efficiently inhibits fibril formation of hCT by preventing the initial association of hCT before 
fiber formation. The NMR experiments was applied to identify the binding site of EGCG on 
hCT, which revealed that the interaction between aromatic rings of EGCG and the aromatic side 
chains of the peptide may play an important role in inhibiting fibril formation of hCT. 
 
6.2   Future directions 
6.2.1  Refinement of the structure models by paramagnetic labeling approaches 
In this thesis, we use chemical shift perturbation and line broadening analysis as 
ambiguous restraints to generate structural models for the FBD – cyt P450 and FBD – cyt c 
complexes. These models can be improved by using unambiguous distance restraints, which can 
be obtained by paramagnetic labeling approaches. Paramagnetic species affect nuclear magnetic 
resonances in a distance- and geometry-dependent manner, thus can provide powerful restraints 
for the determination of the three-dimensional structure of proteins and analysis of protein-
protein/ligand interactions  (1). The unpaired electron in the paramagnetic label induces extra 
magnetic field at the nuclei of the protein, causing enhanced relaxation for the resonances or 
chemical shift perturbation. Paramagnetic relaxation enhancement (PRE) is proportional to 1/r6 
in which r is the distance between the paramagnetic center to the measured nucleus, therefore it 
can be converted to distance restraints for structural determination. Compared to nuclear 
overhauser effect (NOE) which can indicate spatial proximity up to 5 Å, PRE allows for 
determination of much longer distance restraints (12-30 Å) which makes it particularly useful for 
structural studies for protein complexes. The anisotropic dipolar interaction between the 
paramagnetic center and the measured nucleus also cause chemical shift changes called 
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pseudocontact shift (PCS) which is dependent on the magnetic susceptibility tensor of the 
paramagnetic center and its orientations with respect to the nuclear spins. Strong magnetic 
centers can cause weak molecular alignment with the magnetic field, which provides information 
about the orientation between scalar coupled spin pairs and the molecular alignment tensor. (2). 
Due to high sensitivity of the paramagnetic effects, paramagnetic NMR approaches exhibit great 
advantages in investigating transient intermediates of protein-protein complexes which is a 
common case for electron-transfer protein complexes. 
A variety of paramagnetic labels have been developed to attach to proteins. Based on the 
means of attachment, they can be categorized into terminal metal binding peptide and disulfide-
bond tags. One of the most commonly used labels is MTSL spin label (3) which contains one 
unpaired electron and is attached via a disulfide bond to a cysteine residue. Nevertheless, the 
rotational motion of the MSTL on the protein surface can lead to up to 6 Å of unambiguity in the 
measured distances. Therefore, novel paramagnetic tags are being developed to immobilize the 
paramagnetic center. A double-armed caged lanthanide NMR probe (CLaNP) which attachs to 
two cysteines on the protein surface simultaneously has been developed by Ubbink et al and 
utilized for structure determination of protein-protein complexes and small molecule-protein 
complex (2, 4). The rigidity of the tag enhances pseudocontact shifts of the resonances and RDC 
alignments of the proteins, which aids in generating long-range distance information (2). 
In order to attach the CLaNP tag, we will first introduce double mutations of cycsteines 
on two proximal residues at various sites on the surface of cyt P450/cyt c. Attachment of the 
CLaNP with paramagnetic and diamagnetic metal ions will be performed as described in the 
literature (5). A series of tests will be performed on the CLaNP tagged mutants of cyt P450/cyt c 
to check for their functional viability using metabolism assays as well as measuring the binding 
affinity between the mutants and FBD. Only mutations with similar functional activity and 
binding properties as the wild-type will be utilized for further investigation by NMR studies. The 
second step involves measuring the paramagnetic effect of the tag on the residue of FBD by 
NMR experiments. 15N-labeled FBD and CLaNP-attached cyt P450/cyt c mutants would be 
incorporated together at 1:1 ratio into optimized membrane mimetics (e.g. isotropic bicelles, 
nanodiscs, etc.). 2D 1H- 15N TROSY-HSQC will be recorded to measure the paramagnetic 
effects of the CLaNP on the resonances of FBD. Pseudocontact shifts (PCS) can be calculated by 
taking the differences of the chemical shift values with paramagnetic and diamagnetic probes, 
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and paramagnetic relaxation enhancement (PRE) values can be calculated according to equation 
7.1 (6).  Ip, Id represent the intensities of resonances with paramagnetic and diamagnetic probes 
respectively and R2d represents the transverse relaxation rate with diamagnetic probe. PCS and 
PRE values give information on the distances and angles between a detected nucleus and the 
paramagnetic center in the probe with the relationship depicted in equation 7.2 and 7.3 (1). 
Finally, the structural models of the complexes can be generated by molecular docking. PCS 
values and unambiguous distance restraints derived from PRE values could be implemented into 
docking programs as constraints to drive the formation of complex structures. Available docking 
programs include XPLOR-NIH program with PARArestraints module (7), HADDOCK (8), and 
so on. The lowest energy structures would be analyzed and evaluated by back-calculating the 
PCS and PRE values and comparing with the experimental values. Good agreements between the 
back-calculated and experimental values would be implication of valid complex structures.  
 
                𝐼𝑝
𝐼𝑑
= 𝑅2𝑑e−Γ2𝑡
𝑅2𝑑+Γ2
                    (7.1) 
 
                        𝛥𝛿𝑃𝐶𝑆 = 1
12𝜋𝑟3
[∆𝜒𝑎𝑥(3𝑐𝑜𝑠2𝜃 − 1) + 32 ∆𝜒𝑟ℎ𝑠𝑖𝑛2𝜃 𝑐𝑜𝑠 2𝜑]          (7.2) 
 
                                         𝑟 = �𝛾2𝑔2𝛽2
20Γ2
(4𝜏𝑐 + 3𝜏𝑐1+𝜔ℎ2𝜏𝑐2)6                  (7.3) 
 
6.2.2 Verification of the electron transfer pathways by site-directed mutagenesis and utilization 
of other docking/predicting programs  
Electron transfer pathways were proposed utilizing our structural models of the 
complexes by HARLEM (9). It employs PATHWAY analysis which is based upon single-
tunneling-pathway assumption, while in reality it is possible that the redox centers in the protein 
complex are coupled via a number of pathways with similar coupling values such that modifying 
a single pathway in the network will have hardly any effect on the electron transfer rates. 
Furthermore, the accuracy of the empirical decaying factors input into the program also affects 
the results of pathway prediction. Therefore, in order to verify the predicted electron transfer 
pathway, we can perform site-directed mutagenesis studies on the residues identified by the 
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program in mediating electron transfers. Special caution needs to be taken in conducting these 
studies due to the possible secondary structural changes of the proteins or disruption of the 
binding interface caused by mutations. Activity assays will have to be carried out on the mutants 
to assess the structural integrity of the proteins, and binding affinities between the mutants and 
FBD will be measured to distinguish the effect of the mutation on the interaction of the two 
proteins.  
Utilization of other programs for molecular docking or electron transfer pathway 
prediction also helps to validate our proposed complex models. A dynamic docking tailored to 
the intermolecular ET problem was developed by Liang et al (10). Instead of generating the 
structural models and analyzing electron transfer at two independent and consecutive steps as in 
a conventional way, the novel docking program mathematically combines the electronic coupling 
calculations with estimation of the docking energies in a Monte Carlo (MC) sampling 
framework. By the integrated algorithm, it can apply a direct “electronic coupling” filter for 
functional active complexes in the docking process, and thus is more efficient in sorting out the 
relevant complex orientations than the conventional methods. This enables us to employ more 
computationally expensive and accurate methods to describe the relevant intermolecular 
interaction energies and donor-acceptor coupling upon variations of protein surface and 
environment (10). This approach has been demonstrated on the myoglobin – cyt c complex. 
Mixed quantum mechanics /molecular mechanics (QM/MM) algorithms have also been 
developed to track the electron delocalization. Guallar et al demonstrate this method on the 
cytochrome c – cytochrome c peroxidase complex (11). In this algorithm, the system is divided 
into a quantum region in which the Schrödinger equation is solved to extract electronic 
properties in this region; meanwhile the rest of the protein is treated as charged spheres. By 
shifting the quantum region on to different residues, the electron transfer pathway coupling the 
donor and the accepter can be obtained. By utilizing the aforementioned methosds, we can 
validate the complex models and electron transfer pathway we proposed, and compare the 
outcome and efficiency of different algorithms.  
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Appendix A 
 
Chemical shift assignments of the 15N-1H TROSY-HSQC spectra 
 
 
MGDSHEDTSA    TMPEAVAEEV   SLFSTTDMVL      FSLIVGVLTY       WFIFRKKKEE        IPEFSKIQTT 
APPVKESSFV       EKMKKTGRNI    IVFYGSQTGT       AEEFANRLSK     DAHRYGMRGM   SADPEEYDLA 
DLSSLPEIDK         SLVVFCMATY    GEGDPTDNAQ   DFYDWLQETD   VDLTGVKFAV       FGLGNKTYEH 
FNAMGKYVDQ   RLEQLGAQRI     FELGLGDDDG     NLEEDFITWR     EQFWPAVCEF      FGVEATGEE 
 
Figure A.1  Sequence of FBD. 
 
 
 
 
 
Figure A.2  15N-1H TROSY-HSQC spectrum of 15N-labeled FBD. 
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    Table A.1  Chemical shift of the resonances in 15N-1H TROSY-HSQC spectrum of 15N-labeled FBD. 
 
Residue 15N chemical shift 1H chemical shift 
V64 121.515 8.016 
S67 114.996 8.102 
S68 114.575 8.169 
F69/F181 124.803 7.967 
F69/F181 124.912 7.927 
V70 124.453 7.005 
E71 119.786 7.262 
K72 118.92 7.505 
K74 118.9 8.295 
K75 117.384 8.161 
T76 104.789 7.484 
N79 115.516 8.688 
I80/E214 119.289 7.661 
V82 126.469 8.33 
F83 124.121 8.68 
Y84 114.648 7.306 
G85 111.578 8.988 
S86 115.712 7.805 
T88 109.844 9.639 
G89 108.98 7.57 
T90 126.758 9.724 
A91 125.07 10.676 
E92 114.936 6.422 
E93 121.566 7.565 
F94 119.369 8.11 
N96 118.109 8.242 
L98/V188 118.241 8.424 
S99 111.931 8.292 
K100 121.193 7.692 
D101 121.065 8.227 
A102 117.009 6.893 
H103 114.571 7.231 
R104 119.262 7.511 
Y105 116.66 6.934 
G106 104.244 7.262 
M107 117.938 7.325 
R108 117.168 8.019 
S111 117.985 8.664 
D113/147 123.377 8.622 
E115 119.51 8.22 
E116 114.132 7.431 
Y117 116.633 7.597 
D118 117.771 8.591 
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A120 121.677 7.649 
S123 108.716 7.528 
S124/L192 116.562 7.837 
L125 124.791 7.64 
L132 121.081 8.445 
V134 125.938 8.612 
C136 123.3 9.045 
M137 118.184 8.191 
A138 132.401 9.208 
T139 113.3 6.973 
Y140 129.671 8.589 
G141/G196 106.435 7.74 
G143 105.5 7.629 
D144/D162 121.07 7.879 
T146 107.734 7.396 
N148 117.373 9.226 
A149 120.417 7.59 
Q150/D160 122.783 7.441 
D151 119.254 8.834 
D154 119.31 8.729 
E158 115.864 7.082 
T159 116.057 7.533 
V161 120.299 7.794 
L163 125.414 8.71 
G165 112.405 9.031 
F168 118.998 8.616 
A169/R78 118.852 8.383 
V170 121.44 9.718 
F171 125.834 8.998 
L173 124.91 7.733 
G174 107.799 7.036 
N175 119.896 9.044 
K176 127.179 8.799 
T177 112.433 8.811 
Y178 120.988 7.449 
N182 127.562 9.742 
A183 116.446 6.624 
M184/G172 116.739 8.594 
G185 107.276 8.298 
K186 116.899 7.789 
Y187 120.185 8.068 
D189 115.56 7.628 
E193 117.157 6.368 
L195 117.401 7.562 
A197 122.982 7.85 
Q198 121.557 9.351 
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R199 131.318 8.652 
I200 124.745 8.838 
E202 123.633 5.921 
L203 123.754 8.058 
G204 117.07 8.844 
L205 126.269 8.557 
G206 112.434 8.532 
D207 124.809 9.37 
D208 125.006 10.215 
D209 118.128 8.35 
G210 107.417 7.333 
N211 127.944 9.428 
L212 127.678 8.803 
E213 118.838 8.516 
E214/I80 119.016 7.643 
F216 121.889 8.65 
I217 120.49 8.87 
T218 116.744 8.459 
W219 123.456 7.718 
R220 120.473 8.987 
E221/M110 114.754 7.993 
Q222 115.786 6.951 
F223 126.335 8.122 
W224 115.928 6.767 
A226 120.253 6.671 
V227 122.226 7.852 
C228 117.428 8.331 
E229 118.928 8.019 
G232 111.275 7.859 
V233 116 7.925 
E234/F152 122.285 8.218 
A235 124.645 8.468 
T236 113.928 8.196 
G237 110.878 8.304 
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Appendix B 
 
Solvent accessibility of the FBD residues 
 
The solvent accessibility of FBD residues was assessed using NACCESS (1). The results 
of the solvent accessibility prediction were used to filter the residues input as HADDOCK 
restraints in chapter 2 and 3.  
 
Table B.1  Residues of FBD that are solvent accessible (>35.0% for all-atoms) based on NACCESS. 
Amino 
acid type 
Amino 
acid 
number 
All-atoms, 
Relative %SA 
Total-side, 
Relative %SA 
Main-chain, 
Relative %SA 
Non-polar, 
Relative %SA 
All-polar, 
Relative %SA 
VAL 64 129.1 116.4 168.4 115.6 172.5 
LYS 65 47.9 42.7 70.7 55.9 36.8 
GLU 66 57.9 63 39.4 36.1 69.6 
SER 67 70.3 99.8 10.2 81 62.7 
GLU 71 59.6 74.9 4.8 65 56.7 
LYS 72 38.6 47.1 1.4 40 36.6 
LYS 74 51.4 48.5 63.8 50.9 52.1 
LYS 75 78.5 80.1 71.4 88.7 64.4 
GLY 77 69.9 103.4 47.3 96.1 46.9 
GLN 87 42.2 34.7 70.3 16.3 52.9 
THR 88 80 84.4 67.9 107.3 47.4 
GLY 89 44.8 62.2 33.1 59.1 32.3 
GLU 92 40.5 51.8 0 16 53.8 
GLU 93 59.2 75 2.6 51.4 63.5 
ASN 96 51.1 67.5 4.9 44.4 54.2 
LYS 100 78.9 90 30.5 87.3 67.2 
ARG 104 85.2 89.1 64.1 126.4 65.2 
GLY 106 56.4 30.4 74 30.4 79.3 
ARG 108 45.2 53.6 0.3 36.1 49.6 
GLU 115 49.9 58.3 19.7 38.7 55.9 
GLU 116 43.5 55.6 0 27 52.3 
ASP 118 55.8 74.8 4.1 52.1 57.9 
SER 123 37.8 36.1 41.1 29.1 43.9 
PRO 126 37.9 24.2 139.1 25.2 138.9 
GLU 127 66.8 64.9 73.5 77 61.3 
ASP 129 82.1 99.9 33.7 93.2 76.1 
LYS 130 44.1 49.8 19.1 45 42.9 
GLY 141 60.1 101.7 31.8 90.6 33.1 
GLU 142 82.5 95.7 35.3 79.7 84.1 
ASP 144 50.7 69.3 0 49.3 51.4 
156 
 
ASP 147 76.1 98.1 15.9 72 78.3 
GLN 150 39 49.4 0 69.7 26.3 
ASP 151 62.7 77.4 22.7 54.6 67 
ASP 154 51.9 61.3 26.4 69.3 42.6 
GLN 157 42.5 46.1 28.7 22.8 50.6 
GLU 158 90.2 92.1 83.4 92.3 89.1 
ASP 160 95.3 113 47 94.8 95.6 
ASP 162 70.5 79.5 45.8 86 62.1 
THR 164 63.9 74.3 35.8 82.2 42.1 
GLY 165 41.2 75.3 18.1 65.3 19.9 
LYS 176 61.2 63.9 49.2 66.6 53.7 
THR 177 69.1 64.1 82.6 82.8 52.7 
GLU 179 95.9 99.7 82.4 99 94.3 
HIS 180 46.9 57.7 2.5 55.2 37.4 
LYS 186 40.8 49.8 1.6 39.4 42.8 
GLN 190 57 71.6 2.2 69.8 51.8 
GLU 193 48.9 55.5 25.5 38.6 54.5 
GLN 194 76 75.8 76.8 55.2 84.7 
GLY 196 39.6 56.3 28.2 51.3 29.2 
GLN 198 47.9 60.6 0.5 77.3 35.8 
GLU 202 61.9 75.5 13.1 70.3 57.4 
LEU 205 41.9 38.1 56 38.6 54.5 
ASP 208 45.7 48.3 38.8 10.5 64.8 
ASP 209 58.3 57.3 61.1 11 83.9 
GLY 210 71.5 107.8 47 99.7 46.7 
ASN 211 54.6 69.1 13.5 51.5 56 
GLU 213 37.3 45.9 6.2 70.1 19.6 
GLU 214 56.2 70.3 5.3 72.6 47.4 
ASP 215 35.7 44.8 10.9 35.8 35.7 
THR 218 50.1 68.5 0.3 64.8 32.5 
GLU 221 69.4 83.4 19.2 69.9 69.1 
GLN 222 52.6 64.1 9.3 66 47 
PRO 225 46 49.5 20.1 50.3 11.7 
GLU 229 88.4 99 50.1 92.1 86.4 
PHE 230 54.8 52.1 67.4 51.8 69.6 
GLY 232 50.7 85.9 26.9 86.8 18.9 
VAL 233 37.4 32 54 31.7 55.5 
GLU 234 83.8 93.4 49.4 86.4 82.5 
ALA 235 91.3 36.4 190.2 79.9 113.5 
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Table B.2  Residues of FBD that are solvent inaccessible (<35.0% for all-atoms) based on NACCESS. 
Amino 
acid type 
Amino 
acid 
number 
All-atoms, 
Relative %SA 
Total-side, 
Relative %SA 
Main-chain, 
Relative %SA 
Non-polar, 
Relative %SA 
 
All-polar, 
Relative %SA 
  
REL REL REL REL REL 
SER 68 23.6 24.4 21.9 34.4 15.8 
PHE 69 0 0 0 0 0 
VAL 70 1.9 2.5 0 2.5 0 
MET 73 0 0 0 0 0 
THR 76 24.1 23.6 25.4 37.4 8.2 
ARG 78 20.3 22.5 8.8 6 27.3 
ASN 79 12.2 16.6 0 24.5 6.4 
ILE 80 0.1 0.1 0 0.1 0 
ILE 81 0 0 0 0 0 
VAL 82 0.2 0.2 0 0.2 0 
PHE 83 0 0 0 0 0 
TYR 84 16.2 19.4 0 7.7 31.4 
GLY 85 0.2 0.4 0 0.3 0 
SER 86 13.9 5.8 30.3 9.7 16.8 
THR 90 29 39.7 0 25 33.8 
ALA 91 0 0 0 0 0 
PHE 94 3.3 4 0 4 0 
ALA 95 0 0 0 0 0 
ARG 97 32 37.9 0.7 44.5 26 
LEU 98 0.1 0.1 0 0.1 0 
SER 99 7.4 7.8 6.5 1.7 11.4 
ASP 101 18 23 4.4 15.4 19.4 
ALA 102 0 0 0 0 0 
HIS 103 27 26.8 27.7 22.7 31.7 
TYR 105 32.5 38.5 2.6 36.6 25.1 
MET 107 8.3 8 9.4 8.7 6.4 
GLY 109 5.7 0 9.6 0 10.7 
MET 110 16.9 21 0 20.8 0 
SER 111 25.8 9.1 59.7 0 44.2 
ALA 112 3.5 5.5 0 5.3 0 
ASP 113 19.7 24.9 5.6 6.9 26.7 
PRO 114 2.3 0 19.1 0.3 18.4 
TYR 117 6.4 5.4 11.4 0.7 16.8 
LEU 119 3.5 1.7 10 1.7 10.4 
ALA 120 31.3 43.9 8.6 44.6 5.4 
ASP 121 24.4 33.3 0 2.7 36.1 
LEU 122 0 0 0 0 0 
SER 124 29.5 44.1 0 21.7 35.1 
LEU 125 0 0 0 0 0 
ILE 128 11.4 13.1 5.1 13 5 
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SER 131 2.8 2.7 3.1 0 4.8 
LEU 132 0 0 0 0 0 
VAL 133 0.1 0.1 0 0.1 0 
VAL 134 0.2 0.2 0 0.2 0 
PHE 135 0 0 0 0 0 
CYS 136 0 0 0 0 0 
MET 137 0.1 0.1 0 0.1 0 
ALA 138 0.4 0 1 0 1.1 
THR 139 0 0 0 0.1 0 
TYR 140 15.9 18.3 4.1 22.6 3.9 
GLY 143 18.2 2.1 29 2.3 32.2 
PRO 145 7 0.9 52.7 0.8 56.3 
THR 146 0.7 0.8 0.3 0.9 0.4 
ASN 148 10.8 12.4 6.2 29 2.2 
ALA 149 0.2 0.3 0 0.3 0 
PHE 152 2.7 2.4 4.1 2.4 4.2 
TYR 153 20.8 25 0 10.3 39.7 
TRP 155 22.5 26 3 25.7 12.2 
LEU 156 0 0 0 0 0 
THR 159 16.7 14.1 23.6 12.9 21.2 
VAL 161 25.7 34 0.4 33.6 0.4 
LEU 163 0.3 0.3 0 0.3 0 
VAL 166 0.1 0.1 0 0.1 0 
LYS 167 20.7 25.4 0.2 20.6 20.7 
PHE 168 0 0 0 0 0 
ALA 169 0 0 0 0 0 
VAL 170 0 0 0 0 0 
PHE 171 0.5 0.6 0 0.6 0 
GLY 172 0 0 0 0 0 
LEU 173 0 0 0 0 0 
GLY 174 0 0 0 0 0 
ASN 175 15.3 20.8 0 0 22.6 
TYR 178 36.5 41 13.7 33.9 41.1 
PHE 181 16.2 17.5 10.5 17.4 10.9 
ASN 182 0 0 0 0 0 
ALA 183 27.1 32.9 16.6 33.3 14.9 
MET 184 0.6 0.8 0 0.8 0 
GLY 185 0 0 0 0 0 
TYR 187 27.8 33.2 0.4 39.9 6 
VAL 188 0 0 0 0 0 
ASP 189 2.2 3 0 0.3 3.3 
ARG 191 17.1 20.2 0.7 10.5 20.4 
LEU 192 0.1 0.1 0 0.1 0 
LEU 195 7.9 8.1 7.1 9.9 0 
ALA 197 3.9 0 10.9 0.2 11.2 
ARG 199 27 23.8 43.9 26.4 27.2 
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ILE 200 15.4 2.6 62.9 4 59.5 
PHE 201 13 14.8 4.4 15.7 0 
LEU 203 19.5 13.2 43.3 13.1 44.8 
GLY 204 9.2 22.9 0 19.7 0 
GLY 206 0.1 0 0.1 0 0.1 
ASP 207 10.3 14 0 15.2 7.6 
LEU 212 6 6.1 5.4 6.1 5.6 
PHE 216 0 0 0 0 0 
ILE 217 32.6 41.3 0.3 40.9 0.3 
TRP 219 3.9 4.5 0.8 5 0.5 
ARG 220 31.8 37 3.9 6.9 43.8 
PHE 223 0 0 0 0 0 
TRP 224 1.4 1.6 0 1.8 0 
ALA 226 27.5 36.5 11.4 35.5 12 
VAL 227 0 0 0 0 0 
CYS 228 12.8 15.7 5.3 16.4 3.2 
PHE 231 11.5 7 32.7 9.7 20.3 
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